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Abstract 
Inherited optic neuropathies cause significant visual impairment and this group of 
disorders affect at least 1 in 10,000 people in the United Kingdom. The pathological 
hallmark of inherited optic neuropathies is the preferential loss of retinal ganglion 
cells within the inner retina, which leads to optic nerve degeneration and subsequent 
visual failure. This thesis describes investigations into the underlying disease 
mechanisms of inherited optic neuropathies, including the potential involvement of 
mitochondrial dysfunction in the pathophysiology of Wolfram syndrome. 
A robustly phenotyped cohort of 30 optic atrophy patients with a likely genetic 
cause for their visual failure was screened for possible pathogenic mutations in the 
WFS1 (4p16.1), RTN4IP1 (6q21) and C12orf65 (12q24.31) genes. No pathogenic 
mutations were identified. 
Wolfram syndrome 1 (WFS1) is a rare genetic disease characterised by 
diabetes insipidus, diabetes mellitus, optic atrophy and deafness, and it is primarily 
caused by mutations in the WFS1 gene (4p16.1). A cell culture model consisting of 
fibroblasts derived from five patients harbouring confirmed recessive or dominant 
WFS1 mutations was used to explore the disease mechanisms of Wolfram 
syndrome. WFS1 mutations had a deleterious impact on calcium (Ca2+) transfer from 
the ER to the mitochondria, which was associated with impaired mitochondrial 
oxidative phosphorylation and differential sensitivity to the ER stressor thapsigargin.  
Wolfram syndrome 2 (WFS2) is caused by recessive mutations in the CISD2 
gene (4q24) and shares many of the clinical features of WFS1. In CISD2-mutant 
fibroblasts, mitochondria-ER apposition was increased and there was evidence of 
disturbed Ca2+ homeostasis, including amplified Ca2+ transfer from the ER to 
mitochondria and raised cytosolic Ca2+.  
These results indicate that WFS1 and CISD2 mutations disturb cellular Ca2+ 
homeostasis and alter mitochondrial function supporting the hypothesis that 
mitochondrial dysfunction plays an important role in the neuropathology of Wolfram 
syndrome. 
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Chapter 1. Introduction 
1.1 Mitochondria 
Mitochondria are subcellular organelles found in all nucleated mammalian cells 
(Friedman and Nunnari, 2014). They likely originate from an α-proteobacterial 
progenitor which in an endosymbiotic event was engulfed and subsequently 
assimilated by an ancestral eukaryotic cell (Margulis, 1971; Gray, 2012). The main 
function of mitochondria is the production of adenosine triphosphate (ATP) through 
oxidative phosphorylation (OXPHOS) (Koopman et al., 2013). In addition, 
mitochondria have a crucial role in numerous other metabolic processes, and in 
many cellular processes including the regulation of cellular calcium (Ca2+) 
homeostasis and the propagation of apoptosis (Tuppen et al., 2010; La Rovere et al., 
2016). Mitochondria are essential for cellular integrity and mitochondrial dysfunction 
is increasingly being recognised as a cause of human disease (Friedman and 
Nunnari, 2014). 
1.2 Structure 
Mitochondria have a complex and dynamic ultrastructure that changes according to 
functional demands (Cogliati et al., 2016). They are spherical or tubular shaped 
organelles bound by two distinct membranes termed the outer mitochondrial 
membrane (OMM) and inner mitochondrial membrane (IMM), which differ in 
composition, structure and function (Palade, 1952; Mannella, 2008).  
The arrangement of the two membranes creates three separate internal 
aqueous sub-compartments within mitochondria: (i) the intermembrane space 
between the two membranes, (ii) the intracristal space and (iii) the central IMM  
enclosed protein rich matrix (Figure 1.1) (Pernas and Scorrano, 2016). These serve 
to compartmentalise specific enzymes, metabolites and ions to optimise 
mitochondrial functions. The matrix is the site of multiple metabolic pathways such as 
the β-oxidation of fatty acids and the tricarboxylic acid (TCA) cycle (Pernas and 
Scorrano, 2016).  
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The OMM encloses the whole organelle; it is lipid rich, relatively smooth and 
has the smaller surface area of the two membranes. The OMM is highly permeable to 
ions and small molecules of <5 kDa due to the abundance of pore forming voltage 
dependent anion channels (VDAC) (Dukanovic and Rapaport, 2011), whereas, 
mitochondrial proteins are imported through a dedicated protein import machinery 
(Schmidt et al., 2010). The OMM proteome comprises integral membrane proteins 
and peripheral membrane associated proteins, which as a group facilitate the 
interaction between the mitochondria and the cell (Dukanovic and Rapaport, 2011). 
At least two subdomains of the OMM have been described to mediate interactions 
with other organelles: (i) the mitochondria associated membranes (MAMs), which 
mediate interactions with the endoplasmic reticulum (ER) and (ii) inter-mitochondrial 
junctions (IMJ), which mediate interactions with other mitochondria (Vance, 1990; 
Picard et al., 2015).  
The IMM is composed of two distinct subdomains: the inner boundary 
membrane and the cristae membrane. These two subdomains are contiguous and 
are connected by narrow tubular openings of 20 to 50 nm termed cristae junctions 
(Pernas and Scorrano, 2016). The inner boundary membrane runs parallel to the 
Figure 1.1 The ultrastructure of mitochondria. Transmission electron 
microscopy (TEM) image of a mitochondrion (Image courtesy of Dr Cécile 
Rouzier, Nice Sophia-Antipolis University, France). 
1 µm 
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OMM; the two membranes are closely apposed and functionally interact in certain 
pathways. In contrast, the cristae membrane projects into the interior of the 
mitochondria in tubular or lamellar shaped folds that greatly increase the surface area 
of the IMM (Mannella et al., 2013). Compared to the OMM, the IMM is particularly 
protein rich and largely impermeable, a feature that enables the establishment of a 
transmembrane electrochemical gradient (Vogel et al., 2006). The protein 
composition of the IMM subdomains is distinct but not exclusive; the inner boundary 
membrane contains the mitochondrial carriers which transfer metabolites and ions 
across the IMM, whereas, the cristae membrane is the primary site of the assembled 
complexes of the OXPHOS system (Vogel et al., 2006; Wilkens et al., 2013).    
1.3 Mitochondrial Genetics 
Due to their endosymbiotic origin, mitochondria contain their own DNA (mtDNA) 
(Nass, 1966; van Bruggen et al., 1966; Bogenhagen, 2012). However, mitochondria 
are not autonomous and rely on the import of over 1000 nuclear-encoded proteins for 
the mitochondrial proteome (Calvo et al., 2016). The human mtDNA is a circular, 
double-stranded DNA molecule of 16,569 base pairs (bp) that is packaged into                
DNA-protein complexes termed nucleoids (Andrews et al., 1999b; Bogenhagen, 
2012). Nucleoids are composed of a single copy of mtDNA and a core set of proteins 
involved in mtDNA maintenance (Kukat et al., 2011; Kopek et al., 2012). Multiple 
copies of mtDNA are present in each cell and depending upon bioenergetic demand 
a cell can contain hundreds to thousands of mtDNA molecules (Chinnery and 
Hudson, 2013). 
The human mtDNA is compactly organised and encodes 37 genes: 13 
polypeptides, 22 mitochondrial transfer ribonucleic acids (tRNAs) and 2 mitochondrial 
ribosomal RNAs (rRNAs). The 13 polypeptides are all essential subunits of the 
multisubunit complexes that compose the OXPHOS system. The RNA products are 
components of the mitochondrial translation system and are required for the 
translation of mtDNA-encoded polypeptides (Chinnery and Hudson, 2013). As all 
mtDNA-encoded genes are required for the OXPHOS system, mutations and 
deletions in mtDNA can cause mitochondrial dysfunction and are implicated in human 
disease (Holt et al., 1988; Wallace et al., 1988). Similarly, alterations of mtDNA copy 
number are also associated with human disease (Spiegel et al., 2016).  
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1.4 Mitochondrial OXPHOS 
The primary function of mitochondria is the production of ATP through OXPHOS. 
ATP is an energy rich compound used to meet cellular energy demands and to 
maintain cellular integrity. ATP content is therefore maintained in a strict equilibrium 
between hydrolysis and synthesis (Koopman et al., 2013). The OXPHOS system is 
composed of five multisubunit complexes (I-V) embedded in the IMM and two mobile 
electron carriers: ubiquinone (coenzyme Q10) and cytochrome c (Yu-Wai-Man et al., 
2011a). The five complexes are divided into two functional groups: (i) the electron 
transport chain (ETC) comprising complexes I-IV and (ii) complex V which generates 
ATP (Figure 1.2) (Koopman et al., 2013).  
Electrons extracted from nutrient compounds such as monosaccharides and 
fatty acids are transferred to form nicotinamide adenine dinucleotide (NADH) and 
flavin adenine dinucleotide (FADH2) through glycolysis, β-oxidation and the TCA 
cycle (Fernandez-Vizarra et al., 2009). Electrons from NADH and FADH2 enter the 
ETC at complexes I and II, respectively. These electrons are sequentially transferred 
along the ETC and at complex IV are donated to oxygen (O2), reducing it to form 
water (H2O). The energy released as electrons are transferred along the ETC is used 
to transport protons from the matrix across the IMM into the intermembrane space at 
complexes I, III and IV (Nsiah-Sefaa and McKenzie, 2016). This establishes a proton 
Figure 1.2 The mitochondrial OXPHOS system. (Reproduced from Yu-Wai-
Man et al., 2011a). 
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motive force (PMF) across the IMM consisting of a difference in electrical potential 
(~180 mV, negative inside) and pH gradient (~0.8, alkaline inside). The 
electrochemical gradient of protons is utilized by complex V to drive the production of 
ATP from adenosine diphosphate (ADP) and inorganic phosphate (Pi) (Brand and 
Nicholls, 2011). 
1.4.1 Complex I 
Complex I (NADH:ubiquinone oxidoreductase) is composed of 45 (44 unique) 
subunits and 9 redox cofactors: a flavin mononucleotide (FMN) and eight iron-sulfur 
(Fe/S) clusters (Vinothkumar et al., 2014). Seven complex I subunits are mtDNA-
encoded (ND1, 2, 3, 4, 4L, 5 and 6) and the rest are nuclear-encoded. The core of 
the enzyme is formed by 14 subunits which are surrounded by 31 ‘accessory’ 
subunits that form a shell around the core (Fiedorczuk et al., 2016). Complex I is L 
shaped, comprising a hydrophilic peripheral arm which protrudes into the matrix and 
a lipophilic IMM-embedded arm. The two arms have independent functions; the 
peripheral arm harbors the cofactors which mediate electron transfer from NADH to 
ubiquinone, involving the reduction of the FMN cofactor and transfer along a series of 
Fe/S clusters to the ubiquinone reduction site. In parallel, the membrane arm 
catalyzes proton translocation across the IMM (Sazanov, 2015). Complex I is thought 
to translocate four protons for every two electrons transferred, although how electron 
transfer is coupled to proton translocation is currently unknown (Sazanov, 2015).  
1.4.2 Complex II 
Complex II (succinate:ubiquinone oxidoreductase) functions in both the TCA cycle 
and the OXPHOS system. The oxidation of succinate to fumarate in the TCA cycle is 
coupled to the reduction of ubiquinone (Koopman et al., 2013). Complex II is the only 
respiratory complex that does not contain mtDNA-encoded subunits or pump protons 
across the IMM (Sun et al., 2005; Rutter et al., 2010). The complex consists of four 
nuclear-encoded subunits (SDHA-D); two form the catalytic core and two form an 
integral membrane domain that anchors the complex to the IMM. The catalytic 
domain contains a covalently bound flavin adenine dinucleotide (FAD) cofactor and 
three Fe/S clusters which mediate electron transfer from succinate to ubiquinone. 
The membrane domain contains a heme b moiety, the function of which remains 
unclear (Sun et al., 2005; Rutter et al., 2010).  
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1.4.3 Complex III 
Complex III (ubiquinol:cytochrome c oxidoreductase) is composed of up to 11 
subunits, of which only cytochrome b is mtDNA-encoded (Benit et al., 2009). Three 
subunits contain prosthetic groups and form the catalytic core of the complex: 
cytochrome b with two noncovalently bound heme b groups, cytochrome c1 with a 
covalently bound heme c and the Rieske iron-sulfur protein with a [2Fe-2S] cluster 
(Lange and Hunte, 2002). Complex III couples electron transfer between ubiquinol 
(QH2) and cytochrome c with proton translocation across the IMM in a mechanism 
termed the Q cycle. In total, four protons are released into the intermembrane space 
and two protons are removed from the matrix (Lange and Hunte, 2002).  
1.4.4 Complex IV 
Complex IV (cytochrome c oxidase) is the terminal ETC enzyme and catalyses the 
transfer of electrons from reduced cytochrome c to O2, the final acceptor (Fernandez-
Vizarra et al., 2009). Complex IV consists of 13 subunits; 3 of which are           
mtDNA-encoded (COX1-3) and form the core of the complex. Together, COX1 and 
COX2 contain two heme groups (cytochrome a and cytochrome a3) and thee copper 
ions arranged in two copper centres (CuA and CuB) which mediate electron transfer. 
COX3 is thought to facilitate proton pumping (Kadenbach and Huttemann, 2015). In 
the course of each reaction cycle eight protons are removed from the matrix: four 
protons are taken up by the reduced O2 moiety forming H2O and four protons are 
pumped across the IMM (Popovic, 2013).    
1.4.5 Complex V 
Complex V (FoF1-Atpase) uses the energy stored in the proton gradient across the 
IMM to link the flow of protons back into the matrix with the production of ATP by 
rotary catalysis (Kuhlbrandt, 2015). The complex is composed of 19 subunits, two of 
which are mtDNA-encoded (ATP6 and ATP8). The subunits assemble into two 
functional rotary motors: the F0 module which spans the IMM and contains the proton 
channel and the catalytic F1 module located in the matrix which synthesizes ATP 
from ADP and Pi through a sequence of conformational changes, driven by the rotary 
movement generated during proton translocation (Jonckheere et al., 2012). Each 
ATP molecule produced requires the translocation of 2.7 protons (Watt et al., 2010).  
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1.5 Mitochondrial OXPHOS and ROS 
The OXPHOS system is a major source of intracellular reactive oxygen species 
(ROS), mainly due to electron leak at complexes I and III (Murphy, 2009). At least 10 
other mitochondrial enzymes are also thought to contribute to ROS production, 
including complex II (Quinlan et al., 2013). ROS can be formed by the one-electron 
reduction of O2 producing the free radical superoxide (O2
-), the source of most other 
cellular ROS (Shadel and Horvath, 2015). In the physiological range, ROS production 
has a signalling role and regulates several cellular processes such as development, 
the immune system and maintenance of redox balance (Shadel and Horvath, 2015). 
However, ROS are highly reactive and elevated ROS levels can cause oxidative 
damage to nucleic acids, proteins and lipids, which can lead to the activation of cell 
death processes. The balance between ROS production and their removal by 
antioxidant enzymes is therefore crucial for cellular integrity (Maresca et al., 2013).  
1.6 Apoptosis   
Mitochondria have a central role in the regulation and execution of apoptosis, a form 
of programmed cell death that is important for the development and homeostasis of 
multicellular organisms (Tait and Green, 2010). Mitochondria are primarily involved in 
the intrinsic pathway of apoptosis, which is activated in response to cellular stress  
and regulated by complex interactions between pro- and antiapoptotic proteins 
belonging to the B-cell lymphoma 2 (Bcl-2) family (Galluzzi et al., 2012). The intrinsic 
pathway involves the activation of pro-apoptotic effectors Bcl-2 associated X protein 
(BAX) and Bcl-2 antagonist or killer (BAK), which induce mitochondrial outer 
membrane permeabilization (MOMP) (Tait and Green, 2010). Loss of mitochondrial 
integrity results in the release of pro-apoptotic proteins, such as cytochrome c, from 
the mitochondrial intermembrane space into the cytosol, a key event that results in 
the activation of both caspase-dependent and -independent mechanisms of apoptotic 
cell death (Orrenius et al., 2015). Caspases (cysteine-aspartic proteases) are 
proteolytic enzymes that exist as inactive zymogens and require specific proteolysis 
for their activation. Once activated the proteolytic activity of effector caspases 
(caspase-3, -6 and -7) results in the cleavage of at least 1000 substrates located 
throughout the cell to dismantle the cell contents and create an apoptotic body ready 
to be phagocytosed (Crawford and Wells, 2011). 
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1.7 Mitochondrial dynamics 
Mitochondria are highly dynamic organelles that undergo frequent changes in 
morphology and subcellular distribution through fusion, fission and transport. These 
processes are essential for maintaining a functional mitochondrial population and 
enabling mitochondria to respond the physiological demands of the cell (Mishra and 
Chan, 2016). Not surprisingly, disturbances in mitochondrial dynamics are associated 
with cellular dysfunction and numerous disease states including autosomal dominant 
optic atrophy (DOA), Charcot-Marie-Tooth disease type-2A (CMT-2A) and hereditary 
spastic paraplegia (HSP) (Mishra and Chan, 2016). Despite intensive research, the 
molecular mechanisms and physiological roles of mitochondrial dynamics are still not 
completely understood and the relationship between mitochondrial dynamics and 
disease is often unclear (Roy et al., 2015). 
1.7.1 Fusion 
Mitochondrial fusion is a two-step process coordinated by three dynamin-like 
GTPases: mitofusin-1 (MFN1), mitofusin-2 (MFN2) at the OMM and optic atrophy 1 
(OPA1) at the IMM (Olichon et al., 2002; Eura et al., 2003). The mitofusins form 
homo- and heterotypic oligomers that tether opposing mitochondria and initiate OMM 
fusion in a guanosine triphosphate (GTP) dependent manner (Chen et al., 2003; 
Schrepfer and Scorrano, 2016). Following OMM fusion, IMM fusion occurs in an 
almost simultaneous but distinct event mediated by OPA1 (Liu et al., 2009; Song et 
al., 2009). OPA1 is regulated by alternative splicing and proteolytic processing to give 
rise to long and short isoforms (L-OPA1 and S-OPA1) which are thought to 
coordinate to mediate IMM fusion (Ishihara et al., 2006; Song et al., 2007), although, 
it has recently been suggested that L-OPA1 is sufficient for IMM fusion and that S-
OPA1 is instead associated with IMM fission (Anand et al., 2014).  
1.7.2 Fission 
Mitochondrial fission is performed by a dynamin-like GTPase termed dynamin-related 
protein 1 (DRP1). DRP1 is predominantly located in the cytosol and can be recruited 
to the mitochondria through numerous signalling pathways to induce fission (Chang 
and Blackstone, 2010). DRP1 lacks a lipid-binding pleckstrin homology domain and 
interacts with several integral OMM protein adaptors to mediate fission including: 
mitochondrial fission protein 1 (Fis1), mitochondrial fission factor (MFF) and 
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Figure 1.3 ER-mitochondrial contact in mitochondrial dynamics. The ER 
tubule encircles mitochondria to provide the initial constriction prior to                 
DRP1-dependent mitochondrial fission. (Adapted from Rowland and Voeltz, 
2012). 
mitochondrial dynamics proteins of 49 and 51kDa (MiD49 and MiD51) (Loson et al., 
2013). Once present at the OMM, DRP1 self assembles into oligomeric structures 
that surround mitochondria and conformational changes driven by GTP hydrolysis 
constrict mitochondria ultimately leading to fission (Mears et al., 2011).  
The ER and actin cytoskeleton participate in mitochondrial fission and are 
thought to act upstream of DRP1 recruitment. Mitochondrial fission predominantly 
occurs at sites with ER contact; ER tubules are suggested to encircle mitochondria 
and provide the initial constriction that facilitates subsequent DRP1-mediated fission 
(Figure 1.3) (Friedman et al., 2011). Furthermore, at the mitochondria-ER contact 
site, ER localised inverted formin 2 (INF2) is activated to polymerise actin, a process 
which is suggested to enable force generation to assist mitochondrial constriction 
(Korobova et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7.3 Transport 
The long-range transport of mitochondria is largely dependent on microtubule based 
motor proteins via mechanism which require ATP hydrolysis. Kinesin superfamily 
proteins (KiFs), particularly the Kinesin-1 family, mediate anterograde transport and 
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Figure 1.4 The mitochondrial transport machinery.  (Reproduced from 
Sheng and Cai, 2012). 
dyneins mediate retrograde transport (Pilling et al., 2006). Mitochondria connect to 
motor proteins through motor adaptor proteins and mitochondrial receptor proteins. 
These motor-adaptor-receptor complexes are highly regulated to ensure the selective 
transport and precise distribution of mitochondria (Lin and Sheng, 2015).  
The primary kinesin motor adaptor proteins in mammals are the Milton 
proteins, Trak1 and Trak2, and these proteins are linked to mitochondria through the 
OMM located receptor proteins, Miro1 and Miro2 (Fransson et al., 2006; 
Koutsopoulos et al., 2010). Miro proteins are part of the Rho-GTPase family and 
contain two Ca2+ binding EF hand motifs which coordinate the Ca2+-dependent 
regulation of mitochondrial transport (Saotome et al., 2008; Macaskill et al., 2009; 
Wang and Schwarz, 2009). The molecular mechanisms linking dynein motors to 
mitochondria are not well characterised (Lin and Sheng, 2015). It is suggested that 
specific binding of kinesin or dynein to Trak1/2 may coordinate the bidirectional 
transport of mitochondria. This model is based on the observation that Trak1 binds 
both kinesins and dyneins, whereas, Trak2 predominantly binds dyneins (van 
Spronsen et al., 2013).  In addition to long-range transport, mitochondrial distribution 
is dependent on short-range transport mediated by myosin motors on actin filaments 
and the docking of stationary mitochondria, primarily via interactions with the protein 
syntaphilin (Figure 1.4) (Lin and Sheng, 2015).     
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1.7.4 The functions of mitochondrial dynamics 
The balance between fusion and fission events maintains mitochondria within a 
dynamic network. Mitochondrial morphology varies according to the cell type and 
physiological context, ranging from small distinct organelles to tubular interconnected 
filaments (Scorrano, 2013). Mitochondrial fusion is required for the exchange of 
contents between mitochondria, including metabolites, proteins and mtDNA, and the 
absence of mitochondrial fusion is associated with OXPHOS dysfunction, mtDNA 
depletion and increased ROS production (Chen et al., 2010; Westermann, 2012). A 
fused mitochondrial network positively correlates with high OXPHOS activity and a 
shift towards fusion has been shown to occur in response to cellular energy demand, 
nutrient availability and cellular stress (Tondera et al., 2009; Gomes et al., 2011; 
Rambold et al., 2011). Mitochondrial fission is equally important and is required for 
the segregation of mitochondria into daughter cells during cell division and the 
elimination of dysfunctional mitochondria via mitophagy (the specific degradation of 
mitochondria) through fission and selective fusion events (Taguchi et al., 2007; Twig 
et al., 2008). In addition, mitochondrial fission is associated with the intrinsic pathway 
of apoptosis and DRP1-dependent fissions is thought to be essential for cristae 
remodelling and cytochrome c release during the early phase of apoptosis (Otera et 
al., 2016). 
Transport mechanisms are required to distribute mitochondria throughout the 
cell to satisfy the local demand for ATP, Ca2+ buffering and other mitochondrial 
functions. Regulation of mitochondrial transport is particularly important in neurones 
due to their unique structure and is essential for the function of synapses and 
maintenance of dendrites and axons (Sheng and Cai, 2012). Two signalling 
pathways that control mitochondrial transport are sensing ATP and ADP levels and 
alterations of cytosolic [Ca2+] (Mironov, 2007; Macaskill et al., 2009). Mitochondrial 
velocity appears to increase in areas with high ATP levels and decrease in areas with 
local ATP depletion, thus ensuring mitochondria respond to cellular energy demand 
(Mironov, 2007). Similarly, elevated cytosolic [Ca2+] is suggested to arrest 
mitochondrial movement, as Ca2+ influx largely occurs at sites of high energy 
demand, such as neuronal synapses, this mechanism ensures mitochondria are 
positioned to both buffer Ca2+ and supply ATP (Macaskill et al., 2009; Wang and 
Schwarz, 2009). 
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1.8 The Mitochondria Associated Membrane 
Mitochondria interact with the ER at specialised interfaces termed MAMs (Vance, 
1990). These contact sites are defined as regions where the two organelles are 
closely apposed and functionally interact, but remain as distinct organelles (Rowland 
and Voeltz, 2012). The best characterised functions of the MAM are phospholipid 
synthesis and the transfer of Ca2+ from the ER to mitochondria, which serves to 
regulate cytosolic Ca2+ signalling, mitochondrial bioenergetics and                      
mitochondrial-mediated apoptosis (van Vliet et al., 2014).    
1.8.1 The Endoplasmic Reticulum 
The ER is a large membrane bound intracellular organelle that is continuous with the 
nuclear envelope and extends into to the periphery of the cell in a dynamic network 
of interconnected sheets and tubules (Schwarz and Blower, 2016). The ER has 
functional subdomains including the nuclear, transitional, rough and smooth ER that 
together perform the numerous cellular functions of the ER (Figure 1.5) (Schwarz 
and Blower, 2016). Both the smooth and rough ER have been shown to mediate ER 
interactions with mitochondria at the MAMs, although whether these interactions 
have distinct functions is unclear (Csordas et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Schematic of the ER. The structure and functional 
subdomains of the ER (Reproduced from Park and Blackstone, 2010) 
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One function of the ER is the synthesis and maturation of proteins. Protein synthesis 
occurs at the ribosomes which coat the rough ER and further processing is facilitated 
by ER-resident protein chaperones (Park and Blackstone, 2010). The ER is also 
involved in the synthesis of phospholipids, cholesterol and steroids (Schwarz and 
Blower, 2016). Importantly, the ER is the main intracellular Ca2+ store and has a role 
in cellular Ca2+ signalling, a feature that is central to the functional interaction 
between the ER and mitochondria at the MAM (Kaufman and Malhotra, 2014).  
1.8.2 ER Ca2+ homeostasis 
In the cell, Ca2+ ions are utilized as second messengers and a rise in intracellular 
[Ca2+] regulates numerous physiological functions such as metabolism, gene 
expression, hormone secretion, synaptic transmission and cell death (Kaufman and 
Malhotra, 2014). An increase in cytosolic [Ca2+] (~100 nM resting) can be produced 
through two mechanisms: (i) the entry of Ca2+ from the extracellular milieu (~1 mM) 
or (ii) the release from intracellular Ca2+ stores, primarily the ER (total ~1 mM) 
(Bononi et al., 2012).  
The ER Ca2+ store is regulated by: (i) Ca2+ binding proteins in the ER lumen, 
(ii) Ca2+ uptake through the sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) and 
(iii) Ca2+ release through channels including the inositol-1, 4, 5-triphosphate receptor 
(IP3R) and the ryanodine receptor (RyR) (Szabadkai et al., 2006; Zatyka et al., 2015). 
The ER luminal Ca2+ binding proteins have a low affinity but a high capacity for Ca2+ 
buffering and maintain free ER [Ca2+] at ~200 µM (Prins and Michalak, 2011). The 
SERCA couples ATP hydrolysis to the transport of Ca2+ into the ER against the ion 
gradient, with a stoichiometry of 2:1 Ca2+/ATP. There are three genes encoding 
SERCAs, with alternate splicing producing additional isoforms and each has a 
different activity, expression level and tissue distribution (Krebs et al., 2015). The 
IP3R is the most ubiquitously expressed ER Ca
2+ channel and is activated in 
response to inositol 1, 4, 5-triposphate (IP3) production. Three genes encode IP3Rs, 
with further splice isoforms and these form homo- or heterotetrameric Ca2+ channels 
(Kiviluoto et al., 2013). Regulation of IP3R activity primarily occurs through: (i) the 
local environment, (ii) phosphorylation and dephosphorylation by many kinases and 
phosphatases and (iii) direct interactions with regulatory proteins which can stimulate 
or inhibit IP3R activity (Kiviluoto et al., 2013). One role of the IP3R is the transfer of 
Ca2+ from the ER to mitochondria at the MAM (Figure 1.6) (Bononi et al., 2012).    
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Figure 1.6 Schematic model of intracellular Ca2+ homeostasis. Cellular Ca2+ signals are tightly 
regulated by the coordinated action of Ca2+ channels, pumps, exchangers and binding proteins mainly 
located at the plasma membrane, ER and mitochondria. Activation of plasma membrane G protein coupled 
receptors results in the production of IP3 which stimulates IP3R dependent ER Ca
2+ release. The MAM 
domain facilitates the efficient transfer of Ca2+ from the ER to mitochondria (Reproduced from Bononi et 
al., 2012).    
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Figure 1.7 The MAM. A TEM image showing the apposition between a 
mitochondrion and the ER at the MAM (Image courtesy of Dr Cécile Rouzier, 
Nice Sophia-Antipolis University, France). 
1.8.3 Structural composition of the MAM 
The MAM interface is essential for coordinating the function of the mitochondria and 
the ER, including processes that involve both organelles (Paillusson et al., 2016). 
Approximately 1000 proteins are thought to be enriched at the MAM (Zhang et al., 
2011; Poston et al., 2013). A core set of proteins comprise the basic MAM proteome 
to mediate key MAM functions, and the MAM is able to recruit a diverse range of 
proteins to perform further functions according to cellular demands (Van Vliet et al., 
2014). 
The MAM is highly dynamic and the length and width of organelle apposition 
are regulated by the cell. In HeLa cells, the total surface of the OMM apposed to the 
ER was estimated to range from 5 to 20 %, whereas, in mouse liver cells the 
percentage of OMM in contact with the ER varied from 4.7% to 11.2%, dependent 
upon the metabolic state of the cell (Rizzuto et al., 1998; Sood et al., 2014). In 
addition, the width of the MAM is thought to range from ~10 to 30 nm (Csordas et al., 
2006). These parameters shape the properties of the MAM and are modulated by the 
cell to control fundamental MAM functions. However, the mechanisms which mediate 
formation and regulation of the MAMs are not well characterised (Giacomello and 
Pellegrini, 2016).   
 
 
 
 
 
 
 
 
 
 
 
 
1 µm 
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1.8.4 Protein tethers at the MAM  
Protein complexes that may contribute to ER-mitochondrial tethering at the MAM 
have been observed by electron tomography. The length of the tethers connecting 
the OMM and the smooth ER were ~9 to 16 nm, whereas, the tethers connecting the 
OMM and the rough ER were ~19 to 30 nm in length (Csordas et al., 2006). 
One protein tether identified in mammalian cells is a complex formed by the 
IP3R on the ER and the VDAC on the OMM which are physically tethered by the 
chaperone glucose regulated protein 75 (GRP75) (Szabadkai et al., 2006). However, 
studies describing overexpression of GRP75 or complete loss of the IP3Rs 
demonstrate that neither disturbs ER-mitochondrial apposition, indicating that this 
complex does not represent a structural tether and can instead be considered a 
functional tether which promotes ER-mitochondrial Ca2+ transfer (Csordas et al., 
2006; Szabadkai et al., 2006).  
Another candidate protein tether at the MAM is homo- or heterocomplexes of 
MFN2 on the ER with MFN1 or MFN2 on the OMM. Ablation of MFN2 was reported 
to decrease MAM apposition and disturb MAM functions including ER-mitochondrial 
Ca2+ transfer and amplification of apoptosis (de Brito and Scorrano, 2008). However, 
recent studies have suggested that MFN2 ablation increases the structural and 
functional interaction between the ER and mitochondria, indicating that the model 
regarding MAM tethering by MFN2 needs to be revised (Cosson et al., 2012; Filadi et 
al., 2015).  
A final protein tether at the MAM is an interaction between the ER localised 
vesicle-associated membrane protein associated protein B (VAPB) and the OMM 
localised protein tyrosine phosphatase interacting protein 51 (PTPIP51). 
Overexpression of VAPB and/or PTPIP51 increases ER-mitochondria contact, 
whereas, siRNA-mediated knockdown of VAPB and/or PTPIP51 reduces organelle 
contact, suggesting that this tether is required for the structure of the MAM. Notably, 
dysfunction of the VAPB-PTPIP51 protein tether is implicated in amyotrophic lateral 
sclerosis (ALS) (De Vos et al., 2012; Stoica et al., 2014).  
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1.8.5 Functions of the MAM  
Two fundamental processes occurring at the MAM are phospholipid synthesis and 
ER-mitochondrial Ca2+ transfer (van Vliet et al., 2014). 
The MAM is enriched with enzymes associated with phospholipid synthesis 
allowing the ER and mitochondria to coordinate the biosynthesis of three abundant 
cellular phospholipids: phosphatidylserine (PS), phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC) (Stone and Vance, 2000). Phospholipid synthesis is 
dependent on close apposition between the two organelles. PS is first synthesized on 
the ER and then translocated to the IMM where decarboxylation of PS produces PE. 
In turn, PE is translocated back to the ER where it is converted into PC (Osman et 
al., 2011). An increase or decrease in the MAM interface area is known to correlate 
with a corresponding increase or decrease in phospholipid synthesis, highlighting 
how modulation of organelle apposition relates to MAM function  (Giacomello and 
Pellegrini, 2016).  
Another function of the MAM is the transfer of Ca2+ from the ER to the 
mitochondria, predominantly occurring through the IP3R-GRP75-VDAC complex 
Figure 1.8 The MAM protein tethers. (A) IP3R interacts with VDAC through 
GRP75, (B) MFN2 on the ER has been proposed to interact with MFN1 or 
MFN2 on the OMM, and (C) VAPB interacts with PTPIP51 (Reproduced from 
Paillusson et al., 2016).  
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(Rizzuto et al., 1998; Szabadkai et al., 2006). Once across the OMM, the 
mitochondrial Ca2+ uniporter (MCU) complex (the MCU and regulatory elements) 
mediates Ca2+ uptake across the IMM into the mitochondrial matrix, dependent upon 
the mitochondrial membrane potential (Baughman et al., 2011; De Stefani et al., 
2011). The MCU has a low affinity for Ca2+ uptake and the microdomain theory 
suggests that close apposition between the ER and mitochondria exposes the 
mitochondria to high cytosolic [Ca2+] domains, 5 to 10 fold greater than the overall 
cytosol, thus enabling efficient mitochondrial Ca2+ uptake (Rizzuto et al., 1998; 
Giacomello et al., 2010). These Ca2+ microdomains are facilitated by: (i) the close 
apposition of the ER and mitochondria, (ii) the enrichment of Ca2+ handling 
machinery at MAMs and (iii) the tethering of the IP3R and VDAC by GRP75 (Krols et 
al., 2016). Consequently, factors which decrease or increase MAM apposition 
modulate ER-mitochondrial Ca2+ flux in parallel (Csordas et al., 2006). Numerous 
studies support this concept, for example overexpression of presenelin 2 or                             
α-synuclein have been shown to increase ER-mitochondria Ca2+ flux dependent on 
increased ER-mitochondria apposition (Zampese et al., 2011; Cali et al., 2012).  
 One function of ER-mitochondrial Ca2+ transfer is the regulation of OXPHOS. 
Consistent low level Ca2+ transfer to mitochondria via the IP3R is required to 
stimulate ATP production under basal conditions and loss of this function 
compromises mitochondrial bioenergetics (Cardenas et al., 2010). Furthermore, Ca2+ 
dependent OXPHOS stimulation is utilized to upregulate OXPHOS function in 
response to activity-dependent rises in cellular ATP demand, for example during 
neuronal activity (Rangaraju et al., 2014). There are several mechanisms by which 
Ca2+ regulates OXPHOS. A rise in mitochondrial matrix Ca2+ stimulates the activity of 
the TCA cycle directly at isocitrate dehydrogenase (ICDH) and α-ketoglutarate 
dehydrogenase (KDH), and indirectly at pyruvate dehydrogenase (PDH) through a 
Ca2+-dependent phosphatase, thus increasing the production of NADH and electron 
entry into the ETC (Denton, 2009). Mitochondrial Ca2+ uptake also stimulates the 
activity of complex V, directly increasing ATP synthesis, through an unknown 
mechanism that likely involves a post-translational modification of the complex. In 
addition, complexes III and IV are potentially regulated by mitochondrial Ca2+ levels 
(Glancy and Balaban, 2012), and the activity of several mitochondrial carriers are                        
Ca2+-dependent (Figure 1.9) (Llorente-Folch et al., 2015). 
 19 
 On the contrary, excessive ER-mitochondrial Ca2+ transfer is associated with 
the induction of cell death (Mendes et al., 2005). Mitochondrial Ca2+ overload 
provokes opening of the mitochondrial permeability transition pore (mPTP), a high 
conductance channel at the IMM formed by dimers of the c subunit of complex V 
(Giorgio et al., 2013). Opening of the mPTP increases the permeability of the IMM to 
ions and solutes. This results in the loss of membrane potential, osmotic swelling of 
mitochondria and the rupture of the OMM, leading to the release of pro-apoptotic 
factors into the cytosol and cell death (Rizzuto et al., 2009). The mechanism by which 
mitochondrial Ca2+ overload provokes opening of the mPTP remains unknown (La 
Rovere et al., 2016). Nevertheless, many observations support the role of ER-
mitochondrial Ca2+ flux in the regulation of apoptosis. The antiapoptotic proteins of 
Figure 1.9 A schematic of Ca2+ regulation of mitochondrial bioenergetics. 
Three TCA enzymes and complex V are stimulated by Ca2+ uptake to increase 
OXPHOS. Complexes III and IV and some of the mitochondrial carriers may 
also be regulated by mitochondrial matrix Ca2+ (Reproduced from Llorente-
Folch et al., 2015).   
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the Bcl-2 family are suggested to exert their effect in part by suppressing                              
ER-mitochondrial Ca2+ flux, either through depletion of the ER Ca2+ store or by 
inhibition of high-amplitude IP3R Ca
2+ transients (Distelhorst and Bootman, 2011). 
Moreover, factors that promote ER-mitochondrial Ca2+ transfer are known to correlate 
with an increased susceptibility of Ca2+-dependent mPTP activation, including the 
artificial tightening of the ER-mitochondrial interaction with a synthetic                                  
ER-mitochondrial linker or the induction of ER stress through treatment with cellular 
stressors (Csordas et al., 2006; Chami et al., 2008; Deniaud et al., 2008). 
1.8.6 ER stress and the MAM 
ER homeostasis is essential for cell function and conditions which compromise ER 
integrity such as genetic factors, elevated secretary protein synthesis or disturbed 
Ca2+ homeostasis result in ER stress and activation of an adaptive response known 
as the unfolded protein response (UPR) (Kaufman and Malhotra, 2014). The UPR 
comprises three overlapping pathways that are initiated by three ER transmembrane 
receptor proteins: activating transcription factor 6 (ATF6), protein kinase RNA (PKR) 
like kinase (PERK) and inositol requiring enzyme 1α (α1α). These pathways act in 
parallel to restore ER homeostasis by increasing ER chaperone synthesis, arresting 
mRNA translation and degrading accumulated proteins via ER associated protein 
degradation (ERAD) (Kaufman and Malhotra, 2014). However, if ER stress is 
prolonged, the UPR induces cell death via both mitochondrial dependent and 
independent pathways (Bravo-Sagua et al., 2013).   
Modulation of the MAM has been linked to the adaptive response to ER stress. 
At the onset of ER stress contact between the ER and mitochondria increases as a 
pro-survival response, this redistribution results in increased ER-mitochondrial Ca2+ 
flux and enhanced cellular bioenergetics (Bravo et al. 2011). In contrast, in the late 
stages of ER stress, prolonged ER-mitochondrial contact is associated with 
increased mitochondrial Ca2+ accumulation and apoptosis (Chami et al., 2008). 
1.8.7 The MAM and human disease 
The MAM is enriched in proteins associated with human disease and MAM 
dysfunction is currently associated with at least Alzheimer’s disease (AD), 
Parkinson’s disease (PD) and ALS (Area-Gomez et al., 2012; De Vos et al., 2012; 
Guardia-Laguarta et al., 2014).  
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Evidence suggests that presenilin 1 and presenilin 2 (both mutated in familial 
AD) and their activities are enriched at the MAM (Area-Gomez et al., 2009). Primary 
fibroblasts established from both familial and sporadic AD patients showed increased 
ER-mitochondrial apposition, which correlated with increased MAM function 
measured by upregulated cholesterol ester and phospholipid synthesis (Area-Gomez 
et al., 2012). These findings suggest that the altered Ca2+ homeostasis and disturbed 
mitochondrial function observed in previous models of AD are likely related to 
perturbed ER-mitochondria interactions at the MAM (Area-Gomez and Schon, 2016). 
Familial PD is caused by mutations in genes encoding the proteins α-
synuclein, Parkin, and protein deglycase DJ-1. Modifying the expression of these 
proteins has been shown to alter the apposition of the ER and mitochondria (Cali et 
al., 2013; Ottolini et al., 2013; Guardia-Laguarta et al., 2014). Moreover, ectopic 
expression of an α-synuclein mutant reduced the overall apposition between the ER 
and mitochondria, decreased MAM function and caused fragmentation of the 
mitochondrial network (Guardia-Laguarta et al., 2014). 
Numerous genes associated with familial ALS have been found to encode 
proteins which are enriched at the MAM. The Sigma1R is a chaperone protein 
localised at the MAM that regulates cellular Ca2+ signalling through the IP3R and has 
been implicated in a juvenile form of autosomal recessive ALS (Al-Saif et al., 2011). 
Sigma1R loss of function has been associated with altered ER structure, loss of ER-
mitochondrial contacts and disturbed Ca2+ homeostasis indicating that MAM 
dysfunction likely has a role in ALS pathogenesis (Hayashi and Su, 2007; Bernard-
Marissal et al., 2015). In addition, a dominant mutation in the gene encoding VAPB 
has been implicated in ALS; this mutation results in tightening of the VAPB-PTPIP51 
MAM protein tether and augmented Ca2+ transfer to mitochondria (De Vos et al., 
2012). Interestingly, overexpression of the ALS-associated mutant TDP43 has been 
shown to disrupt the VAPB-PTPIP51 MAM protein tether, thereby decreasing ER-
mitochondrial Ca2+ flux (Stoica et al., 2014).   
Together these findings implicate MAM dysfunction in human disease and 
emphasize the importance of MAM integrity for cellular function (Paillusson et al., 
2016).  
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1.9 Inherited optic neuropathies 
Retinal ganglion cells (RGCs) are specialised neurones located in the inner retina of 
the eye, whose long axons form the optic nerve and relay visual information gathered 
by the retina to the visual processing centres in the brain (Yu et al., 2013). Inherited 
optic neuropathies are a group of disorders characterised by the loss of RGCs, optic 
nerve atrophy and progressive visual impairment (Yu-Wai-Man et al., 2011a). These 
disorders collectively affect at least 1 in 10,000 of the population and patients can 
present with isolated optic atrophy or optic atrophy as part of a complex multi-
systemic disorder (Lopez Sanchez et al., 2016). 
The most common inherited optic neuropathies are Leber’s hereditary optic 
neuropathy (LHON) and DOA, which share overlapping clinical and pathological 
features, despite being caused by mutations in different genes. LHON is secondary 
to point mutations in the mtDNA, whereas, DOA is primarily caused by mutations in 
the OPA1 gene (Yu-Wai-Man et al., 2016). The characteristic pathological feature of 
these two disorders is the preferential loss of RGCs within the papillomacular bundle, 
a dense collection of small RGCs which subserve central vision, and this pattern of 
RGC loss results in a visual field defect that extends from the central vision known as 
a scotoma (Yu-Wai-Man et al., 2016). The loss of RGCs in both LHON and DOA is 
directly related to mitochondrial dysfunction. For unresolved reasons, RGCs appear 
to be particularly vulnerable to mitochondrial dysfunction and this disease mechanism 
underlies RGC loss throughout inherited optic neuropathies. With the exception of 
WFS1 and CISD2, all the genes associated with inherited optic neuropathies encode 
proteins that are directly related to mitochondrial function (Table 1.1) (Yu-Wai-Man et 
al., 2016).  
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Inheritance Locus Gene Phenotype 
Dominant 1p36.2 MFN2 Hereditary motor and sensory neuropathy type 6 
 3q28-q29 OPA1 Isolated optic atrophy and syndromic dominant optic atrophy 
 4p16.1 WFS1 Wolfram syndrome spectrum disorders 
 12p11.21 DRP1 Optic atrophy and abnormal brain development 
 19q13.2-q13.3 OPA3 Autosomal dominant optic atrophy and early-onset cataracts 
Recessive 3q26.33 DNAJC19 DMCA syndrome ± optic atrophy 
 4p16.1 WFS1 Wolfram syndrome 1 
 4q24 CISD2 Wolfram syndrome 2 
 5q22.1 SLC25A46 Optic atrophy ± peripheral neuropathy/cerebellar syndrome 
 6q21 RTN4IP1 Optic atrophy ± cerebella syndrome/mental retardation/epilepsy 
 9q13-q21.1 FXN Friedreich ataxia 
 11q14.1-q21 TMEM126A Optic atrophy ± auditory neuropathy 
 12q24.31 C12orf65 Optic atrophy ± spastic paraplegia/peripheral neuropathy 
 16q24.3 SPG7 Hereditary spastic paraplegia type 7 
 19q13.2-q13.3 OPA3 Type III 3-methylglutaconic aciduria 
 22q13.2 ACO2 Optic atrophy ± cerebellar syndrome/encephalopathy 
  Xq22.1 TIMM8A Mohr-Tranebjaerg syndrome ± optic atrophy 
Mitochondrial - - Leber’s hereditary optic neuropathy and overlapping phenotypes 
Table 1.1 Mitochondrial disorders associated with optic atrophy (Reproduced from Yu-Wai-Man et al., 2016).
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1.10 Disease mechanisms of inherited optic neuropathies 
A number of disease mechanisms have been proposed to explain RGC loss in 
inherited optic neuropathies including mitochondrial bioenergetic failure, oxidative 
stress, disturbed Ca2+ homeostasis and altered mitochondrial dynamics (Lopez 
Sanchez et al., 2016). The selective vulnerability of RGCs to mitochondrial 
dysfunction remains unresolved, although the unique structural properties of RGCs 
are thought to be relevant (Yu-Wai-Man et al., 2016). The final stage of the 
neurodegenerative process is suggested to be the inappropriate activation of 
apoptosis (Maresca et al., 2013). 
1.10.1 Anatomy of the optic nerve 
RGCs display the typical properties of central nervous system (CNS) neurones, and 
comprise dendritic and axonal compartments that are connected at the cell body or 
soma (Lopez Sanchez et al., 2016). The dendrites of RGCs receive visual input from 
photoreceptor cells (rods and cones) via two different neuronal cells: bipolar and 
amacrine cells (Yu et al., 2013). The RGC somata are located in the ganglion cell 
layer of the inner retina and have a non-linear distribution, being particularly 
concentrated in the central macular region (Carelli et al., 2004). The axons of RGCs 
are thin (0.5-1 µm) and long (~50 mm); they extend inwards and traverse across the 
retina towards the optic nerve head, turn, and exit the eye through pores in a 
collagen structure termed the lamina cribosa. The axons travel via the optic nerve, 
optic chiasm and optic tract to synapse with the main image forming nuclei including 
the lateral geniculate nucleus, superior colliculus and pretectal nuclei, which in turn 
relay information to the higher visual processing centers in the brain (Yu et al., 2013).  
1.10.2 Bioenergetic failure 
It is well established that RGCs have a high energy demand and rely on mitochondria 
for ATP production via OXPHOS (Yu et al., 2013). Inherited optic neuropathies are 
commonly associated with mitochondrial bioenergetic defects, primarily complex I 
dysfunction, indicating that bioenergetic failure likely contributes to RGC loss 
(Baracca et al., 2005; Chevrollier et al., 2008; Zanna et al., 2008). However, as other 
cell types such as photoreceptors or substantia nigra neurones have similar or higher 
energy demands than RGCs, bioenergetic failure alone cannot explain the 
vulnerability of RGCs to mitochondrial dysfunction (Yu-Wai-Man et al., 2011a).   
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1.10.3 Oxidative stress 
Another mechanism thought to contribute to RGC loss is oxidative stress, defined as 
an imbalance between ROS production and the antioxidant system (Hayashi and 
Cortopassi, 2015). OXPHOS dysfunction is associated with increased ROS 
production and elevated ROS levels have been described in cell culture, Drosophila 
and mouse models of LHON and DOA (Yarosh et al., 2008; Tang et al., 2009; Lin et 
al., 2012; Millet et al., 2016). However, the individual contribution of OXPHOS 
dysfunction or elevated ROS levels to RGC loss remains unclear (Yu-Wai-Man et al., 
2016). 
1.10.4 Disturbed Ca2+ homeostasis 
Emerging evidence implicates disturbed cellular Ca2+ homeostasis in the 
pathogenesis of inherited optic neuropathies. Basal mitochondrial Ca2+ content was 
increased in OPA1 knockdown RGCs, suggesting that mitochondria are dependent 
on OPA1 for the regulation of Ca2+ buffering (Dayanithi et al., 2010). In agreement, 
OPA1 knockdown HeLa cells and fibroblasts established from DOA patients 
harbouring OPA1 mutations showed enhanced ER-mitochondrial Ca2+ flux (Fulop et 
al., 2011; Fulop et al., 2015). Together these results indicate that OPA1 restrains 
mitochondrial Ca2+ uptake and suggest that OPA1 loss of function may be associated 
with mitochondrial Ca2+ overload and cell death. However, one study found that 
OPA1 knockdown in HeLa cells reduced ER-mitochondrial Ca2+ flux, and this was 
associated with decreased cytosolic Ca2+ buffering and an increased sensitivity to 
glutamate-mediated excitotoxicity in OPA1 knockdown RGCs (Kushnareva et al., 
2013). The relationship between LHON mutations and cellular Ca2+ homeostasis is 
unclear. No defect in agonist or perfusion induced mitochondrial Ca2+ uptake was 
found in an osteosarcoma-derived cybrid model harbouring all three common LHON 
mutations (Cruz-Bermudez et al., 2016). In contrast, mitochondrial Ca2+ buffering was 
disturbed in a teratoma-derived cybrid harbouring the m.11778G>A LHON mutation 
(Haroon et al., 2007). Despite differences, the overall picture suggests that 
dysregulation of cellular Ca2+ homeostasis contributes to RGC loss in optic 
neuropathies and further investigations are required to clarify the mechanisms. 
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1.10.5 Mitochondrial dynamics 
An important mechanism explaining RGC loss in inherited optic neuropathies is 
disturbed mitochondrial dynamics. The RGC soma is the biogenesis site of all the 
cells organelles, including mitochondria (Lopez Sanchez et al., 2016). Dynamic 
mitochondrial processes including fusion, fission and transport are therefore essential 
for the transport and maintenance of mitochondria throughout RGCs (Mishra and 
Chan, 2016). Alterations of mitochondrial network morphology have been reported in 
numerous models of DOA. Fibroblasts established from DOA patients showed 
normal or highly fragmented mitochondrial networks, dependent upon the OPA1 
mutation (Chevrollier et al., 2008; Zanna et al., 2008). Moreover, mitochondrial 
structural alterations have been observed in myotubes and skeletal muscle from DOA 
patients and in mouse models of DOA (Alavi et al., 2007; Davies et al., 2007; Amati-
Bonneau et al., 2008; Spinazzi et al., 2008). Importantly, it has been shown that 
alterations of mitochondrial network morphology induced by OPA1 deficiency in turn 
disturb mitochondrial transport in neuronal axons (Bertholet et al., 2013). 
The importance of mitochondrial dynamics in RGCs is related to their specific 
structural and functional properties (Lopez Sanchez et al., 2016). RGC axons only 
become myelinated beyond the lamina cribosa. The generation and propagation of 
action potentials in the prelaminar unmyelinated region of the RGC axon therefore 
requires a high energetic input (Carelli et al., 2004). Correspondingly, mitochondria 
show an uneven but specific distribution along the RGC axon and are concentrated 
in the prelaminar region in order to meet cellular energy demands (Figure 1.10) 
(Andrews et al., 1999a; Bristow et al., 2002). Consequently, the transport and 
distribution of mitochondria along RGC axons is critical for normal function (Yu et al., 
2013), and disturbance of this process due to disturbed ATP production, cellular Ca2+ 
homeostasis or mitochondrial morphology could explain the loss of RGCs in inherited 
optic neuropathies (Yu-Wai-Man et al., 2011a). 
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Figure 1.10 The distribution of mitochondria in the optic nerve. 
Mitochondria are concentrated in prelaminar unmyelinated region due to higher 
energy demands for signal conduction. The left panel shows a section of human 
optic nerve stained for COX/SDH; the darker COX staining in the prelaminar 
unmyelinated region is consistent with a higher density of mitochondria. The 
right panel is a schematic illustrating microtubule dependent mitochondrial 
transport and distribution (Reproduced from Yu-Wai-Man et al., 2011a). 
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1.11 Wolfram syndrome  
Wolfram syndrome is a multisystemic neurodegenerative disease characterised by 
the association of juvenile-onset diabetes mellitus and optic nerve atrophy, typically 
with a range of additional clinical features (Moosajee et al., 2016). The disorder was 
first reported in 1938 by Wolfram and Wagener, who described eight siblings, four of 
whom had juvenile-onset diabetes and optic atrophy (Wolfram and Wagener, 1938). 
Wolfram syndrome is considered a rare disease and has an estimated prevalence of 
1 in 770,000 in the UK, with a carrier prevalence of 1 in 354 (Barrett et al., 1995a). 
Other prevalence estimates include 1 in 100,000 in a North American population and 
1 in 710,000 in the Japanese population (Fraser and Gunn, 1977; Matsunaga et al., 
2014). The prognosis is poor and most patients die prematurely, usually due to 
respiratory failure and the median age of death is 27±11.4 years (de Heredia et al., 
2013). There are currently no treatments to halt or reverse the progression of 
Wolfram syndrome and care is purely supportive (Urano, 2016). Wolfram syndrome 
presents as two known clinical subtypes caused by mutations in two unrelated genes: 
Wolfram syndrome 1 (WFS1) and Wolfram syndrome 2 (WFS2) (Moosajee et al., 
2016). 
1.12 Wolfram syndrome 1  
WFS1 is characterised by diabetes insipidus, diabetes mellitus, optic atrophy and 
deafness (DIDMOAD). More than half of WFS1 patients will show the full ‘DIDMOAD’ 
phenotype and patients may also present with additional clinical features (Table 1.2) 
(de Heredia et al., 2013; Urano, 2016). WFS1 is primarily caused by recessive 
mutations in the WFS1 gene located on chromosome 4p16.1 (Inoue et al., 1998; 
Strom et al., 1998). Numerous mutations distributed throughout the entire WFS1 
gene have been reported including point mutations (missense, nonsense, splice site), 
deletions, insertions and duplications (de Heredia et al., 2013). Recessive WFS1 
mutations are predominantly deleterious for protein expression (Hofmann et al., 
2003; Hofmann and Bauer, 2006). In addition, dominant WFS1 mutations are 
increasingly being recognised and cause a Wolfram-like syndrome characterised by 
optic atrophy and sensorineural hearing loss (SNHL). The pathogenic mechanisms of 
dominant WFS1 mutations remain unknown, although a dominant negative effect has 
been proposed (Hogewind et al., 2010; Rendtorff et al., 2011). 
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Table 1.2 Common clinical manifestations of Wolfram syndrome (Reproduced 
from Urano, 2016). 
1.12.1 Functions of the Wolframin protein  
The WFS1 gene encodes an 890 amino acid transmembrane protein localised to the 
ER called Wolframin (Strom et al., 1998; Takeda et al., 2001). No significant 
homologies have been identified indicating that Wolframin is a member of a novel 
protein family (Takeda et al., 2001). The protein has nine predicted transmembrane 
domains and long hydrophilic stretches on the N- and the C-terminals, with the C-
terminal extending into the ER lumen and the N-terminal extending into the 
cytoplasm (Hofmann et al., 2003; Yamaguchi et al., 2004). Wolframin assembles into 
higher weight molecular complexes (~400 kDa) that are likely homo-oligomers of 
Wolframin monomers (100 kDa), although the contribution of other proteins to these 
complexes has not been excluded (Hofmann et al., 2003). The only post-translational 
modification of Wolframin appears to be asparagine (N)-linked glycosylation, which is 
essential for protein stability. The protein harbours 5 consensus sites for N 
glycosylation (NXS/T) at N28, N335, N500, N661 and N746, however only the N661 
Major symptoms Common symptoms 
Diabetes mellitus 
Optic nerve atrophy 
Diabetes insipidus 
Deafness 
Ataxia 
Urinary Tract Problems 
 Neurogenic bladder 
 Bladder Incontinence 
 Urinary tract infections 
 
General 
 Fatigue 
 Hypersomnolence 
Neurological  
 Apnea 
 Dysphagia 
 Headaches 
Psychiatric 
 Anxiety 
 Panic attacks 
 Depression 
 Mood swings 
Endocrine 
 Hypogonadism 
 Hyponatremia 
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and N746 sites are located within luminal domains (Hofmann et al., 2003). Wolframin 
is ubiquitously expressed in all tissue types though at different levels; it is highly 
expressed in the brain, pancreas, heart, muscle, lung and placenta (Inoue et al., 
1998; Hofmann et al., 2003). Wolframin is expressed in human RGCs and the protein 
is predominantly localised in the soma and the initial portion of the axon (Schmidt-
Kastner et al., 2009). The function of Wolframin is not fully characterised, studies 
have shown that the protein participates in the maintenance of ER homeostasis 
including a role in protein folding/maturation, in the response to ER stress termed the 
UPR and in the regulation of cellular Ca2+ homeostasis (Ishihara et al., 2004; 
Fonseca et al., 2005; Gharanei et al., 2013; Cagalinec et al., 2016).  
The loss of WFS1 function in pancreatic β-cells is associated with increased 
ER stress, activation of all three UPR pathways and an enhanced susceptibility to ER 
stress induced apoptosis, indicating that Wolframin is required for the maintenance of 
ER homeostasis in these cells (Ishihara et al., 2004; Fonseca et al., 2005; Yamada et 
al., 2006). ER stress has further been observed in WFS1 depleted human 
neuroblastoma SK-N-AS cells, Wfs1 deficient mouse retinas and WFS1 deficient 
neurones (Gharanei et al., 2013; Bonnet Wersinger et al., 2014; Cagalinec et al., 
2016). Wolframin is functionally linked to the ER stress response and increased 
expression of WFS1 mRNA and the Wolframin protein was found in response to the 
artificial induction of ER stress (Yamaguchi et al., 2004). Wolframin appears to be 
under the regulation of the IRE1α, PERK and ATF6β signalling pathways of the UPR 
(Fonseca et al., 2005; Odisho et al., 2015). A well conserved ER stress response 
element (ERSE)-like sequence in the WFS1 promoter region is suggested to be 
critical for X-box binding protein 1 (XBP1) dependent upregulation of the WFS1 gene. 
Notably, WFS1 was the most upregulated gene following transfection of a XBP1 
expressing vector in SH-SY5Y cells (Kakiuchi et al., 2006).  
Wolframin in turn is directly involved in the regulation of the UPR and 
negatively regulates the transcription factor ATF6α by promoting ubiquitination 
through the E3 ubiquitin protein ligase HRD1, which leads to proteasomal 
degradation. Under ER stress conditions, ATF6α is released from Wolframin 
regulation in order to activate its branch of the UPR. Loss of WFS1 function is linked 
with dysregulation of ATF6α turnover and hyperactivation of its downstream target 
genes (Fonseca et al., 2010). Two genes specifically induced by ATF6β are WFS1 
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and HRD1, suggesting that a Wolframin-dependent feedback mechanism exists to 
control ATF6α expression during prolonged ER stress (Odisho et al., 2015). 
However, it is likely that ER stress and activation of the UPR secondary to WFS1 loss 
of function are primarily due to the requirement of Wolframin for maintenance of ER 
homeostasis, upstream of the UPR signalling pathways, rather than dysregulation of 
any single UPR pathway (Fonseca et al., 2010). The exact requirement of Wolframin 
for ER homeostasis is unclear; Wolframin has been shown to interact with the sodium 
(Na+)-potassium (K+) ATPase β1 subunit supporting a role in protein maturation and 
several lines of evidence indicate Wolframin is essential for ER Ca2+ homeostasis 
(Osman et al., 2003; Zatyka et al., 2008).  
Reconstitution of Wolframin into lipid bilayers induced a cation-selective ion 
channel; however, it was not shown directly that Wolframin-dependent channels 
conducted Ca2+. Wolframin may therefore be a novel ER Ca2+ channel or function to 
regulate an existing ER channel involved in Ca2+ homeostasis (Osman et al., 2003). 
In agreement with a regulatory role, Wolframin has been shown to negatively 
regulate the expression of the SERCA, likely via proteasome-mediated degradation. 
SERCA is released from Wolframin regulation upon the onset of ER stress resulting 
in increased SERCA expression, a mechanism which is suggested to ensure ER 
Ca2+ homeostasis is maintained or restored (Zatyka et al., 2015). Wolframin has also 
been shown to interact with calmodulin (CaM), a protein which binds Ca2+ and 
coordinates a variety of downstream processes. CaM binds Wolframin at the 
cytoplasmic N-terminal domain in a Ca2+-dependent manner, indicating that CaM 
could regulate Wolframin function through a novel Ca2+ signalling pathway (Yurimoto 
et al., 2009). This pathway is likely important for regulating the role of Wolframin in 
ER Ca2+ homeostasis as Wolframin lacks Ca2+ or ATP binding domains (Osman et 
al., 2003; Yurimoto et al., 2009). At the ER, Wolframin appears to be involved in the 
positive regulation of the ER Ca2+ store; ER [Ca2+] was found to be decreased in 
WFS1 knockdown human embryonic kidney 293 (HEK293) cells compared to 
controls (Takei et al., 2006).  Knockdown of WFS1 in a pancreatic β-cell line and 
ectopic expression of a dominant Wolframin mutant in HEK293 cells have also been 
shown to cause depletion of ER Ca2+ levels (Hara et al., 2014). In contrast, no defect 
in ER Ca2+ homeostasis, including basal levels and maximal ER Ca2+ uptake 
capacity, was observed in WFS1 deficient neurones (Cagalinec et al., 2016). The link 
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between Wolframin and ER Ca2+ channels remains unresolved. The IP3R was shown 
to be dysfunctional in WFS1 deficient neurones, however, whether this was related to 
ER stress or through disturbed Wolframin-mediated IP3R regulation is unknown 
(Cagalinec et al., 2016).      
1.13 Wolfram syndrome 2 
WFS2 was first described in 3 consanguineous Jordanian families with 14 Wolfram 
syndrome patients. Affected individuals presented with diabetes mellitus, optic 
atrophy and high frequency SNHL, as well as features not previously described in 
WFS1 including peptic ulcer disease and bleeding tendencies secondary to defective 
platelet aggregation (El-Shanti et al., 2000). WFS2 is caused by autosomal recessive 
mutations in the CISD2 gene (CDGSH Iron Sulfur Domain 2, synonyms: MINER1, 
ZCD2, ERIS, NAF1) located on chromosome 4q24 (Amr et al., 2007). To date, five 
families have been described and reported mutations include a homozygous 
missense mutation (c.109 G>C, p. Glu37Gln) in Jordanian families, an intragenic 
exon 2 homozygous deletion in a European Caucasian female and a probable 
homozygous mutation (c.103+1 G>A) within a donor splice site in two sisters from an 
Italian family (Amr et al., 2007; Mozzillo et al., 2014; Rondinelli et al., 2015). The 
missense mutation, c.109 G>C, was found to disrupt mRNA splicing and eliminate 
the second exon, this results in a frameshift leading to a premature stop codon, which 
truncates 75% of the protein (Amr et al., 2007). The clinical features of the reported 
WFS2 patients are broadly similar and there is considerable overlap with the clinical 
features of WFS1 (Table 1.3); the presence of peptic ulcers and bleeding tendencies 
without diabetes insipidus can be considered diagnostic criteria for WFS2 (Mozzillo et 
al., 2014). 
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 WFS1 WFS2 
(El-Shanti et al., 2000) 
WFS2 
(Mozzilla et al., 2014) 
WFS2 
(Rondinelli et al., 2015)  
Diabetes mellitus Yes Yes Yes Yes 
Diabetes Insipidus Yes No No Suspected 
Optic Atrophy Yes Yes Yes Yes 
Hearing loss Yes Yes Yes Yes 
Peptic Ulcer No Yes Yes Yes 
Platelet aggregation 
defects 
No Yes Yes N/A 
Bladder dysfunction Yes Yes Yes Yes 
Psychiatric problems Yes Yes No Yes 
Table 1.3 Comparison of the phenotypes of WFS1 and WFS2  
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1.13.1 Function of the CISD2 protein 
The CISD2 gene implicated in WFS2 encodes a 135 amino acid protein called 
CDGSH iron-sulfur domain containing protein 2 (CISD2). CISD2 is a member of a 
small family of three proteins that are defined by a unique CDGSH domain with the 
consensus sequence C-X-C-X2-(S/T)-X2-P-X-C-D-G-(S/A/T)-H (Wiley et al., 2007a). 
The CDGSH domain binds a redox-active [2Fe-2S] cluster coordinated by a rare 
Cys3-His arrangement (Wiley et al., 2007b). CISD2 contains a single CDGSH 
domain, an N-terminal transmembrane domain and an atypical ER localisation 
sequence (Conlan et al., 2009). Numerous studies have confirmed that CISD2 
localises to the ER and that the protein is also enriched at the MAM (Amr et al., 2007; 
Wiley et al., 2007a; Wiley et al., 2013; Wang et al., 2014). One study in mouse has 
suggested that CISD2 is located at the OMM (Chen et al., 2009). Nevertheless, 
CISD2 is most likely an integral ER transmembrane protein and the CDGSH domain 
is oriented towards the cytosol (Wiley et al., 2013). Crystallographic studies of the 
soluble CISD2 form revealed that it exists as a homodimer, harbouring two labile and 
redox-active [2Fe-2S] clusters, one on each protomer (Conlan et al., 2009).  
One likely role for CISD2 is [2Fe-2S] cluster assembly and/or transfer. The 
rare Cys3-His [2Fe-2S] cluster coordination of the CDGSH domain has been found in 
other [Fe-S] cluster transfer proteins and it has been demonstrated that CISD2 can 
donate an [2Fe-2S] cluster to apo-ferredoxin, the standard protein used for Fe-S 
cluster transfer experiments (Qi and Cowan, 2011; Zuris et al., 2011). The 
significance of CISD2 [2Fe-2S] cluster transfer in vivo is not entirely clear and the 
physical recipients of [2Fe-2S] clusters are not well characterised. CISD2 could 
participate in both Fe/S cluster protein repair and in the biogenesis of cytosolic and 
nuclear Fe/S cluster proteins (Tamir et al., 2013; Lipper et al., 2015). It is possible 
that CISD2 acts as [2Fe-2S] cluster reservoir, providing [2Fe-2S] clusters when in an 
oxidised state, for example when the cell is stressed (Tamir et al., 2013). CISD2 may 
also be involved in the biogenesis of cytosolic and nuclear Fe/S proteins and link the 
mitochondrial iron-sulfur cluster (ISC) assembly machinery with the cytosolic Fe/S 
protein assembly (CIA) apparatus (Lipper et al., 2015).  
In addition to its function as a Fe/S cluster protein, CISD2 is also implicated in 
the regulation of macroautophagy (hereafter referred to as ‘autophagy’), and cellular 
Ca2+ homeostasis via protein-protein interactions with Bcl-2 and the IP3R (Chang et 
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al., 2010). Autophagy is an essential cellular process responsible for the turnover of 
cellular macromolecules and dysfunctional organelles. Basal levels of autophagy 
maintain cellular homeostasis, whereas, upregulated autophagy in response to 
various physiological stresses serves as a cell survival mechanism (Decuypere et al., 
2012). CISD2 was shown to be required for the negative regulation of autophagy by 
Bcl-2 in response to nutrient depletion in H1299 epithelial cells by contributing to the 
interaction of Bcl-2 with Beclin 1, a key member of an autophagy initiating complex 
(Chang et al., 2010).  
The generation and characterisation of two Cisd2 deficient mouse models 
(hereafter referred to as ‘ageing Cisd2-/- mice’ and ‘skeletal Cisd2-/- mice’) also 
support a role for Cisd2 in autophagy regulation (Chen et al., 2009; Chang et al., 
2012). Ageing Cisd2-/- mice are characterised by a premature ageing phenotype, 
with neuronal and muscle degeneration and clinical manifestations of WFS2 including 
optic nerve degeneration and impaired glucose tolerance. This phenotype was 
associated with mitochondrial abnormalities and increased autophagy was detected 
in cardiac and skeletal muscle (Chen et al., 2009). Skeletal Cisd2 -/- mice are 
characterised by the early degeneration of skeletal muscle. Autophagy markers were 
increased in skeletal, diaphragm and tibialis anterior muscle of skeletal Cisd2 -/- 
mice. Moreover, increased autophagic flux was found in primary myoblasts isolated 
from the diaphragm of the skeletal Cisd -/- mice. In contrast to the ageing Cisd2 -/- 
mouse model there was no evidence of mitochondrial dysfunction, rather 
mitochondria appeared enlarged and elongated with dense cristae in the skeletal 
Cisd -/- mice, which is likely an adaptive response to stress (Chang et al., 2012). 
Despite differences in phenotype both Cisd-/- mouse models suggest that Cisd2 has 
a role in autophagy regulation. Interestingly, there was no evidence of apoptosis in 
either mouse model suggesting that neuronal and muscle degeneration secondary to 
Cisd2 loss of function could be linked to autophagic cell death (Chen et al., 2009; 
Chang et al., 2012).  
Finally, CISD2 has been shown to interact with the IP3R, suggesting that 
CISD2 is involved in the regulation of Ca2+ homeostasis. The function of this 
interaction is thought to be coupled to Bcl-2 and CISD2 was shown to be required for 
Bcl-2 mediated depression of ER Ca2+ stores upon overexpression of ER targeted 
Bcl-2 (Chang et al., 2010). However, the regulation of ER Ca2+ homeostasis by Bcl-2 
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is complex and conflicting evidence exists. It is suggested that ER localised Bcl-2 
acts to decrease ER [Ca2+]. Although, other studies have suggested that Bcl-2 does 
not decrease ER Ca2+ levels, instead it is proposed that Bcl-2 regulates IP3R mediate 
Ca2+ flux by inhibiting high amplitude Ca2+ transients that lead to cell death and 
stimulating low amplitude Ca2+ transients that promote cell survival (Distelhorst and 
Bootman, 2011). The role of CISD2 in cellular Ca2+ homeostasis remains unclear; it 
is uncertain if CISD2 modulates IP3R activity and/or ER [Ca
2+] under basal 
conditions, whether CISD2 has functions relating to Ca2+ homeostasis that are 
independent of Bcl-2 and there are differing reports on how CISD2 deficiency 
disturbs ER Ca2+ homeostasis (Chang et al., 2010; Chang et al., 2012; Wiley et al., 
2013; Wang et al., 2014). Direct measurement of ER [Ca2+] levels with ER targeted 
aequorin (ER-Aeq) in two different CISD2-deficient cell lines (H1299 epithelial cells 
and MEFS) suggests that ER [Ca2+] is not disturbed under basal conditions (Chang et 
al., 2012; Wang et al., 2014). However, analysis of cytosolic Ca2+ following 
modulation of ER Ca2+ stores with thapsigargin in a lymphoblastoid cell line 
established from a WFS2 patient, with the homozygous missense mutation c.109 
G>C, suggested ER [Ca2+] was increased secondary to CISD2 mutations (Amr et al., 
2007). 
1.14 Mitochondrial dysfunction and the pathophysiology of Wolfram syndrome 
Wolfram syndrome was initially suspected to be a mitochondrial disease 
because the multisystemic clinical features were similar to the phenotypes associated 
with classical mitochondrial disease and the organs affected had a high metabolic 
demand (Bu and Rotter, 1993). However, this hypothesis was challenged by the 
identification of the WFS1 and CISD2 genes and the subsequent localisation of the 
respective proteins to the ER (Inoue et al., 1998; Strom et al., 1998; Amr et al., 2007; 
Wiley et al., 2013). Furthermore, no evidence for marked respiratory chain 
dysfunction was found in Wolfram syndrome patient muscle biopsies and numerous 
studies have demonstrated that WFS1 or CIDS2 deficiency perturbs ER 
homeostasis, indicating that Wolfram syndrome is an ER-related disease (Jackson et 
al., 1994; Barrett et al., 1995b; Barrett et al., 2000; Fonseca et al., 2005; Wiley et al., 
2013; Bonnet Wersinger et al., 2014). ER dysfunction is a distinct disease 
mechanism underlying RGC loss, which is otherwise predominantly associated with 
mitochondrial dysfunction (Maresca et al., 2013). However, recent studies have 
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provided evidence that mitochondrial dysfunction likely participates in the 
pathophysiology of Wolfram syndrome, raising the possibility that Wolfram syndrome 
is a disease caused by primary ER dysfunction and secondary mitochondrial 
impairment ( Ross-Cisneros et al., 2013; Cagalinec et al., 2016).   
The phenotype caused by dominant WFS1 mutations is intriguingly similar to 
the phenotype described in patients with specific pathogenic OPA1 mutations who 
presented with optic atrophy and deafness (Amati-Bonneau et al., 2005; Hogewind et 
al., 2010). These OPA1 mutations were associated with mitochondrial network 
fragmentation, loss of mitochondrial membrane potential and impaired ATP synthesis 
in patient derived fibroblasts (Amati-Bonneau et al., 2005). The association of optic 
atrophy and deafness without other clinical features is rare and appears to only be 
attributable to mutations in the OPA1 and WFS1 genes (Amati-Bonneau et al., 2005; 
Rendtorff et al., 2011). In addition, the pattern of optic nerve degeneration observed 
in WFS1 primarily involving the papillomacular bundle, is similar to the pattern of 
RGC loss in LHON and other mitochondrial optic neuropathies (Ross-Cisneros et al., 
2013). Furthermore, the localisation of Wolframin in RGCs, with high expression in 
the prelaminar region of the optic nerve corresponds with the distribution of 
mitochondria in RGCs (Schmidt-Kastner et al., 2009; Ross-Cisneros et al., 2013). 
Together, these observations suggest that mitochondrial dysfunction, which is a 
common theme underlying RGC loss in inherited optic neuropathies, extends to 
Wolfram syndrome. 
Mitochondrial dysfunction has been found in models of WFS1 and CISD2 
deficiency. A recent study has demonstrated that dynamic mitochondrial processes 
including fusion, fission, transport and turnover were disturbedl in WFS1 deficient 
neurones (Cagalinec et al., 2016). In these neurones there was a decreased rate of 
the fusion and fission, which was associated with decreased average mitochondrial 
length indicative of mitochondrial network fragmentation. Further observations 
included decreased mitochondrial axonal and decreased mitochondrial density in the 
axons of the WFS1 deficient neurones. These mitochondrial dynamic defects were 
accompanied by decreased mitochondrial membrane potential and reduced ATP 
levels. Importantly, the mitochondrial dysfunction in WFS1 deficient neurones was 
shown to be secondary to disturbed ER homeostasis, IP3R dysregulation and 
increased cytosolic [Ca2+] (Cagalinec et al., 2016). In ageing Cisd2-/- mice, 
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mitochondrial degeneration, characterised by breakdown of the OMM and 
disturbance of the cristae, was observed by TEM in numerous tissues. Furthermore, 
mitochondria isolated from skeletal muscle of the ageing Cisd2-/- mice, displayed 
decreased oxygen consumption (substrates: glutamate, malate and ADP) and 
decreased electron transport activity between complexes (Chen et al., 2009).  
Overall, these observations indicate that WFS1 or CISD2 deficiency can 
disturb mitochondrial function and support the view that mitochondrial dysfunction is 
involved in the pathophysiology of Wolfram syndrome. 
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Chapter 2. Aims 
 
This project was undertaken to further explore the genetic and molecular basis of 
inherited optic neuropathies, in particular the disease mechanisms associated with 
Wolfram syndrome. The specific aims were: 
1. To screen a well-characterised cohort of patients with suspected inherited optic 
atrophy, who do not harbour pathogenic mutations in the OPA1 or OPA3 genes, 
for possible pathogenic mutations in the WFS1, RTN4IP1 and C12orf65 genes. 
2. To study and compare the pathological consequences of dominant and recessive 
WFS1 mutations in patient-derived mutant primary fibroblast cell lines. 
3. To investigate the disease mechanisms associated with a novel homozygous 
CISD2 mutation in a patient with Wolfram syndrome 2. 
4. To optimise an in vivo technique for visualising and quantifying mitochondrial 
axonal transport in a zebrafish model.      
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Chapter 3. Materials and Methods 
3.1 Polymerase chain reaction 
Polymerase chain reactions (PCRs) were carried out on a 96 well Veriti Thermal 
Cycler (ThermoFisher, Loughborough, UK). DNA samples were amplified in a 25 µl 
reaction mix: 2.5 µl ImmoBuffer (10x; Bioline, London, UK), 2.5 µl dNTP mix (2 mM 
each dNTP) (Bioline), 0.2 µl Immolase DNA polymerase (Bioline), 0.63 µl forward 
primer (10 µM), 0.63 µl reverse primer (10 µM), 2 µl MgCl2 (50 mM; Bioline), 15.54 µl 
dH2O and 1 µl sample DNA. The reaction conditions were: initial activation at 95 °C 
for 7 minutes, followed by 30 cycles of denaturation at 95 °C for 1 minute, annealing 
at 65 °C and extension at 72 °C for 1 minutes, then a final extension step at 72 °C for 
10 minutes. Six annealing temperatures ranging from 55 °C to 65 °C at 2 °C intervals 
were tested for each primer set to determine the optimal conditions. Betaine (Sigma-
Aldrich, Dorset, UK) was used to enhance PCR for primer sets that had poor 
specificity or yield under standard conditions.   
3.2 Agarose gel electrophoresis 
Agarose (1 g) was dissolved in TAE buffer (100 ml; TAE, Tris-acetate-EDTA) by 
heating in a microwave for two minutes. After cooling, 40 µl ethidium bromide (1 
mg/ml; Sigma-Aldrich) was added and the solution was poured into a casting tray, a 
gel comb was inserted and the gel was allowed to set. Gel electrophoresis was 
carried out in a horizontal gel unit (Scie-Plas, Cambridge, UK) in TAE buffer and run 
at 65 V for 45 minutes. Gels were imaged using a GelDoc-It imaging system (UVP, 
California, USA). For PCR analysis by agarose gel electrophoresis, 6 µl of PCR 
product was mixed with 6 µl of Orange G loading buffer (0.1% w/v Orange G powder; 
Sigma-Aldrich) and 10 µl was loaded onto the gel. 5 µl of Hyperladder IV (100bp to 
1013bp, Bioline) was used as a molecular weight marker. 
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3.3 Sequencing 
3.3.1 Exo I/Fast AP DNA purification  
Prior to sequencing, PCR products were purified with an Exo I/FastAP mixture 
(ThermoFisher) consisting of 0.5 µl Exo I and 1 µl FastAP added to 3 to 5 µl of PCR 
product on ice. The mixture was incubated for 15 minutes at 37 °C followed by 15 
minutes at 85 °C in a Veriti Thermal Cycler. 
3.3.2 BigDye terminator cycle sequencing 
Following Exo I/FastAP purification, terminator cycle sequencing was performed 
using the BigDye Terminator v3.1 Cycle Sequencing Kit (ThermoFisher). The 
reaction mix consists of 1 µl Big Dye, 2 µl BigDye Terminator Sequencing Buffer, 1 µl 
forward or reverse primer (10 µM) and 11 µl dH2O. The reaction mix was added to 3-
5 µl purified PCR product. The sequencing reaction conditions were: initial 
denaturation at 96 °C for 1 minute, followed by 25 cycles of 96 °C for 10 seconds,             
50 °C for 5 seconds and 60 °C for 4 minutes.   
3.3.3 Ethanol Precipitation 
The terminator cycle sequencing product was purified by ethanol precipitation to 
remove excess salt and unincorporated dye terminators. 2 µl sodium acetate (3 M, 
Sigma-Aldrich), 2 µl EDTA (125 nM; Sigma-Aldrich) and 70 µl 100 % ethanol was 
added to product. The solution was mixed, incubated at room temperature for 15 
minutes and then centrifuged at 2000 x g for 30 minutes. Following centrifugation the 
supernatant was removed, 70 µl of 70 % ethanol was added and the sample was 
centrifuged at 1650 x g for a further 12 minutes. The supernatant was removed and 
the precipitated product was allowed to air dry in the dark. 
3.3.4 Sequencing 
The precipitated product was resuspended in 10 µl Hi-Dye (ThermoFisher) and 
denatured at 95 °C for 2 minutes. Sequencing was performed by capillary 
electrophoresis on a 3130 Genetic Analyser (ThermoFisher). Gene sequences were 
analysed using SeqScape Software V2.6 (ThermoFisher) by alignment with the 
corresponding GenBank gene reference sequence. 
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3.4 Fibroblast Cell Culture 
3.4.1 Fibroblast cell maintenance 
Human skin fibroblasts were cultured in low glucose minimum essential media (MEM; 
ThermoFisher) supplement with fetal bovine serum (FBS, 10 % v/v; Sigma-Aldrich), 
50 units/ml penicillin (ThermoFisher), 50 µg/ml streptomycin (ThermoFisher), MEM 
vitamin solution (1 % v/v; ThermoFisher), non-essential amino acids (1 % v/v; 
ThermoFisher), sodium pyruvate (1 mM; ThermoFisher) and L-glutamine (2 mM; 
ThermoFisher). Fibroblasts were grown in standard cell culture flasks (VWR, 
Lutterworth, UK) at 37 °C in a humidified cell culture incubator (Heracell 150i, 
ThermoFisher) containing 5 % CO2. Fibroblasts were monitored with an inverted 
microscope. Media was changed as required, ~3-4 days. 
3.4.2 Subculture of fibroblasts 
Once fibroblasts reached 90% confluency, they were passaged. To subculture 
fibroblasts, the media was aspirated and the cells were washed once with phosphate 
buffered saline (PBS; ThermoFisher) and treated with Trypsin-EDTA (ThermoFisher) 
for 5 minutes at 37 °C in a humidified cell culture incubator to detach the cells from 
the flask. Fresh media was added and the cells were pelleted at 1300 x g for 5 
minutes in a bench centrifuge (Heraeus Megafuge 16; ThermoFisher). Following 
centrifugation, the supernatant was aspirated and the cell pellet was resuspended in 
fresh media. The cell suspension was split 1 in 3 into fresh cell culture flasks. All 
experiments were performed on fibroblasts with similar passage numbers, ranging 
from 4 to 12. 
3.4.3 Cell counting and seeding 
Cell counting was performed using a haemocytometer (AC1000 Improved Neubauer; 
Hawksley, Lancing, UK). Cells were harvested as described in Section 3.4.2. 
Following cell resuspension, 10 µl of the cell suspension was mixed with 10 µl of 
Trypan blue (Sigma-Aldrich), a vital stain used to assess cell viability. Then 10 µl of 
the stained cell suspension was applied to the haemocytometer chamber and 
covered with a glass coverslip. Using an inverted microscope, the viable cells 
(unstained) in the four large corner squares of the haemocytometer chamber were 
counted. The average cell count from the four squares was multiplied by two to 
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correct for the Trypan blue dilution, and then multiplied by 104 to obtain the number of 
cells per ml. 
3.4.4 Cryopreservation 
For long-term storage, cells were frozen and stored in liquid nitrogen. Cells were 
harvested as described in Section 3.4.2. The pelleted cells were resuspended in 
freezing medium: FBS and 5% (v/v) dimethyl sulfoxide (DMSO; Sigma-Aldrich), 
filtered sterilized through a 0.22 µm PES filter (PALL, Portsmouth, UK). The cell 
suspension was transferred to a cryovial. The cryovial was placed in a Mr Frosty 
(Nalgene, Matlock, UK) filled with isopropanol (Sigma-Aldrich), which ensures a 
gradual freezing process, and the Mr Frosty was placed at -80 °C. After 24 hours, the 
cryovial was removed and transferred to liquid nitrogen.   
To recover cells from liquid nitrogen, cells were rapidly thawed and transferred to a 
15 ml conical centrifuge tube containing 5 ml media. The cells were pelleted at 1300 
x g for 5 minutes in a bench centrifuge. The supernatant was aspirated and the cell 
pellet was resuspended in fresh media. The cell suspension was transferred to a 
standard cell culture flask and maintained as described in Section 3.4.1.  
3.5 Protein extraction from fibroblasts 
Cells were harvested as described in Section 3.4.2. On ice, the cell pellet was 
washed twice with PBS and resuspended in 50 µl lysis buffer (50 mM Tris-HCl pH 
7.5, 130 mM NaCl, 2 mM MgCl2, 0.1% Triton X and a protease inhibitor cocktail tablet 
EDTA-free (Roche, West Sussex, UK)). The cell suspension was vortexed for 30 
seconds every 5 minutes for 15 minutes. Following lysis, the cell suspension was 
centrifuged at 2600 x g for 2 minutes at 4 °C. The supernatant was collected and the 
cell debris was discarded.     
3.6 Bradford assay 
The Bradford assay was used to determine the total protein concentration of cell 
lysates (Bradford, 1976). Bovine serum album (BSA; Sigma-Aldrich) was used to 
create a standard curve of known protein concentrations: 0, 0.05, 0.1, 0.2, 0.3, 0.4 
and 0.5 mg/ml. On a 96 well microplate (ThermoFisher), 10 µl of each standard and 
each sample was measured in triplicate; 190 µl of diluted Bradford reagent (Bio-Rad 
Laboratories, Hertfordshire, UK) was added to each well and absorbance was 
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measured at 595 nm on a Multiskan ascent (ThermoFisher). Sample protein 
concentrations were calculated based on the standard curve.   
3.7 Western blotting 
3.7.1 Lithium dodecyl sulfate-polyacrylamide gel electrophoresis (LDS-PAGE) 
Cell lysates containing 40 µg of protein (prepared in NuPage LDS Sample Buffer and 
NuPage Sample Reducing Agent (ThermoFisher)) were loaded onto pre-cast 
NuPAGE 4-12% Bis-Tris gels (ThermoFisher) in an XCell SureLock electrophoresis 
system (ThermoFisher). Electrophoresis was carried out in NuPage MES running 
buffer (ThermoFisher) with 435 µl NuPage Antioxidant added to the upper buffer 
chamber (ThermoFisher) at 200 V for ~40 minutes. Two molecular markers were run 
in parallel to visualise protein molecular weight: SeeBluePlus2 (ThermoFisher) and a 
biotinylated protein ladder (Cell Signalling, Boston, USA). For high molecular weight 
(HMW) proteins a Precision Plus Protein Dual Color Standards (Bio-Rad) molecular 
marker was used and electrophoresis duration was extended as required.   
3.7.2 Protein transfer to PVDF membrane and antibody incubation 
Following LDS-PAGE, proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane using iBlot 2 Transfer Stacks (ThermoFisher) and an iBlot 2 Dry Blotting 
System (ThermoFisher). The iBlot transfer stack was assembled according to the 
manufacturer’s instructions: bottom stack-membrane-gel-top stack. The assembled 
stack was placed into the iBlot system and a pre-programmed method was used for 
the transfer of proteins: 20 V for 1 minute, 23 V for 4 minutes and 25 V for 2 minutes. 
For HMW proteins a custom method was used: 25 V for 10 minutes. Following 
transfer, the membrane was removed from the stack and blocked in 5 % (w/v) milk in 
Tris buffer saline (Santa Cruz, Dallas, USA) with 1 % (v/v) Tween 20 (TBST; Sigma-
Aldrich) for 1 hour at room temperature. After blocking, the membrane was incubated 
in the primary antibody (Table 3.1) overnight at 4 °C. The membrane was washed 3 
times for ten minutes with TBST and incubated in the appropriate secondary antibody 
(Table 3.1) and an anti-biotin antibody (Table 3.1) (Cell signalling) for 1 hour at room 
temperature. The membrane was washed 4 times for 5 minutes with TBST prior to 
being developed.  
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Antibody Manufacturer  Dilutions 
anti-Wolframin  Proteintech, Manchester, UK (1158-1-AP)   1:500 
anti-GRP94  Cell Signaling (#2104)  1:4000 
anti-Bip Abnova, Cambridge, UK (PAB2462) 1:1000 
anti-IP3R Santa Cruz (SC-377518) 1:100 
anti-SERCA Santa Cruz (SC-376235) 1:500 
anti-VDAC Abcam, Cambridge (ab14734) 1:500 
anti-MCU Sigma-Aldrich (HP016480) 1:500 
anti-pPDH Abcam (ab168379) 1:2000 
anti-total-PDH Abcam (ab177461) 1:500 
anti-Caspase 3 Cell Signaling (#9662)  1:1000 
anti-PARP Cell Signaling (#9542) 1:1000 
anti-Tubulin Abcam (ab59680) 1:2000 
Rabbit anti-mouse Dako, Cambridge, UK (P0260) 1:1000 
Swine anti-rabbit Dako (P0399) 1:1000 
anti-Biotin Cell Signaling (#7727)  1:2000 
Table 3.1 Antibodies 
3.7.3 Chemiluminescent Detection and Densitometry 
Signals were visualised using Clarity Western ECL substrate (Bio-Rad) and imaged 
with an Amersham Imager 600 (GE Healthcare, Amersham, London, UK. 
Densitometry was performed using ImageQuant TL 8.1 software (GE Healthcare). 
Tubulin was used for signal normalisation.  
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3.8 Cloning 
3.8.1 Plasmids 
The following plasmids were used: pcDNA-D1ER (Addgene #36325, a gift from Amy 
Palmer and Roger Tsien), pAC-GFPC1-Sec61beta (Addgene #15108, a gift from 
Tom Rapoport), neuroD:GFP (a gift from Tamily A. Weismann) and neuroD:mito-RFP 
(a gift from Tamily A. Weismann). 
3.8.2 Transformation  
Transformations were performed using JM109 high efficiency competent cells 
(Promega, Southampton, UK). 2X Yeast Tryptone (2YT) broth and 2YT agar plates 
were used as growth medium. 2YT broth and 2YT agar were autoclaved and allowed 
to cool before the addition of the appropriate antibiotics. Agar plates were prepared 
under aseptic conditions, allowed to solidify at room temperature, dried at 37 °C and 
stored at 4 °C for up to one month. On ice, plasmid DNA was added to pre-aliquoted 
competent cells (25 µl), gently mixed and incubated for 20 minutes. The cells were 
heat-shocked for 45 seconds at 42 °C, and returned to ice for 2 minutes. Then 475 µl 
of 2YT broth was added and the mixture was incubated at 37 °C for 1 hour with 
shaking. Under ascetic conditions, 100 µl of each transformation culture was spread 
onto an agar plate. Plates were inverted and incubated overnight at 37 °C.   
3.8.3 Plasmid purification 
Growth medium was inoculated with a single colony carrying the plasmid and 
incubated overnight at 37 °C with shaking. On the following day, the cell suspension 
was centrifuged at 6000 x g for 15 minutes at 4 °C. Plasmid purification was 
performed using a Qiagen Plasmid Kit (Qiagen, Manchester, UK); a Mini or Maxi prep 
was performed as appropriate according to the manufacturer’s instructions. Plasmid 
DNA was resuspended in 500 µl dH20. Plasmids were analyzed by agarose gel 
electrophoresis by comparison to a molecular weight marker as described in Section 
3.2. The concentration of DNA was determined using a NanoDrop 2000 UV-Vis 
spectrophotometer (ThermoFisher). 
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3.9 Live Cell Confocal Microscopy 
3.9.1 ER Ca2+ measurement 
The ER targeted fluorescence resonance energy transfer (FRET) based probe D1ER 
was used to measure ER Ca2+ levels. D1ER consists of a Ca2+ binding calmodulin 
domain between two fluorescent proteins: enhanced cyan fluorescent protein (CFP) 
and citrine fluorescent protein (YFP). A calreticulin targeting sequence and a KDEL 
ER retention sequence ensure D1ER is localised to the ER. When calmodulin binds 
Ca2+ an intramolecular rearrangement occurs bringing the CFP and YFP into close 
proximity, which leads to FRET from the CFP to YFP. The FRET signal enables the 
ratiometric assessment of free ER Ca2+ using the FRET to CFP ratio (Figure 3.1).  
 
 
 
 
 
 
 
Fibroblast cell lines were seeded at 100,000 cells/dish on glass bottom dishes 
(Willco, Amsterdam, Netherlands) 3 days before the experiment. Cells were 
transiently transfected with D1ER 2 days before imaging in opti-MEM (ThermoFisher) 
with GeneJuice Transfection Reagent (Merck Millipore, Watford, UK) and 2 µg of 
plasmid DNA. Cells were washed twice with PBS and imaged in Hank’s balanced salt 
solution (HBSS) without phenol red or Ca2+ (ThermoFisher) and supplemented with   
5 mM glucose (Sigma-Aldrich) and 25 mM HEPES (Sigma-Aldrich) at pH 7.4. Live 
cell imaging was performed at room temperature with a Nikon A1R inverted confocal 
microscope equipped with a x60, 1.40 NA oil objective (Nikon, Surrey, UK). The 
filters used were a 457 nm excitation filter and two emission filters: 482 nm for CFP 
Figure 3.1 Schematic of the D1ER probe. Showing the CFP, calmodulin 
domain and YFP under low and high Ca2+ conditions, when the calmodulin 
domain binds Ca2+ the CFP and YFP are brought into close proximity resulting 
in increased FRET signal. 
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and 540 nm for YFP. The FRET to CFP ratio was calculated by ratioing the emission 
at 540 nm and 482 nm. To calibrate the D1ER probe, cells were permeabilized with 
600 nM digitonin and ER Ca2+ was depleted with 9 mM EGTA or ER Ca2+ was 
increased with 30 mM CaCl2 (Sigma-Aldrich), 3 mM ATP (Sigma-Aldrich) and 3 mM 
MgCl2 (Sigma-Aldrich).      
3.9.2 ER Ca2+ flux analysis 
Fibroblast cell lines were seeded at 100,000 cells/dish on glass bottom dishes and 
allowed to adhere overnight. Fluo-4-am (ThermoFisher) and Rhod-2-am 
(ThermoFisher) were used to evaluate cytosolic and mitochondrial Ca2+, respectively. 
Fluo-4 (4 µM) was loaded at 37 °C for 15 minutes or Rhod-2 (8 µM) was loaded at 
room temperature for 30 minutes. Cells were washed twice with PBS and incubated 
in tyrodes solution (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.2 mM Na2HPO4, 12 
mM NaHCO3, 2 mM CaCl2, 10 mM Glucose, pH 7 (All Sigma-Aldrich)) for 15 minutes.  
Dynamic measurements of cytosolic and mitochondrial Ca2+ were performed at room 
temperature with a Nikon A1R inverted confocal microscope equipped with a x60, 
1.40 NA oil objective in resonant scanning mode at 3.7fps for 5 minutes. After one 
minute (providing basal fluorescence) histamine (100 µM; Sigma-Aldrich) was added 
to evoke IP3R dependent ER Ca
2+ release and the Ca2+ transient was monitored. 
Image analysis was performed in Fiji, the background was subtracted and Ca2+ levels 
were calculated as (F-Fo)/Fo where F indicates fluorescence and Fo indicates basal 
fluorescence. 
3.9.3 Mitochondrial-ER colocalisation and morphology analysis 
Fibroblast cell lines were seeded at 100,000 cells/dish on glass bottom dishes three 
days before the experiment. GFP-Sec61β was transiently transfected to detect the 
ER. Cells were transfected ~48 hours before imaging in opti-MEM with GeneJuice 
Transfection Reagent and 1 µg of plasmid DNA. Mitotracker red (75 nM, 
ThermoFisher) was loaded at 37°C for 30 minutes to detect mitochondria 
immediately before imaging. Cells were washed twice with PBS and imaged in MEM 
without phenol red (ThermoFisher) supplemented with 25 mM HEPES. Live cells 
were imaged at room temperature with a Nikon A1R inverted confocal microscope 
equipped with a x60, 1.40 NA oil objective. Sixty nine Z-stacks were acquired across 
the cell at 0.11 µm increments using a high speed piezo Z stage. All image analysis 
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was performed in Huygens Essential Software (SVI, Hilversum, Netherlands). Images 
were deconvolved and 3D-reconstructed. Colocalisation of the ER and mitochondria 
signals was quantified using the Manders’ coefficient. M1 indicates the fraction of ER 
that colocalises with mitochondria and M2 indicates the fraction of mitochondria that 
colocalises with ER. 
Analysis of the mitochondrial network and ER volume was performed individually 
using Huygens Essentials software. The Huygens Object Analyser was used to 
calculate the length and volume of each mitochondrial fragment or the total volume of 
the ER in a 3D-reconstructed image. The following parameters were analyzed for 
mitochondria in each cell line: (i) the average length of mitochondrial fragments, (ii) 
the average volume of mitochondrial fragments, (iii) the total length of the 
mitochondrial network, (iv) the total volume of the mitochondrial network and (v) the 
total number of mitochondrial fragments. The distribution of the length and volume of 
mitochondrial fragments within the mitochondrial network was calculated. Individual 
mitochondrial fragments were sorted into bins based on their length and volume. For 
length, the mitochondrial fragments were sorted into bins of: <2 µm, 2 to 5 µm, 5 to 
10 µm and >10 µm. For volume, the mitochondrial fragments were sorted into bins of: 
<0.5 µm3, 0.5 to 1 µm3, 1 to 5 µm3, 5 to 10 µm3 and 10 µm3.  
3.9.4 Analysis of mitochondrial membrane potential  
Fibroblast cell lines were seeded at 100,000 cells/dish on glass bottom dishes and 
allowed to adhere overnight. Mitochondrial membrane potential was assessed with 
tetramethylrhodamine, methyl ester (TMRM; ThermoFisher) a cell-permeant, cationic 
fluorescent dye that is sequestered by active mitochondria. TMRM (10 nM) was 
loaded at 37 °C for 40 minutes. Cells were washed twice with PBS and incubated in 
tyrodes solution. Imaging was performed at room temperature with a Nikon A1R 
inverted confocal microscope equipped with a x60, 1.40 NA oil objective. After one 
minute, carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 10 µM; Sigma-
Aldrich) was added to dissipate the membrane potential. Image analysis was 
performed in Fiji. Basal TMRM signal was normalised to the remaining signal 
following FCCP application and presented as (F/Fo) where F is basal fluorescence 
and Fo is fluorescence after FCCP application.   
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3.10 Cytosolic Ca2+ measurement 
Cytosolic [Ca2+] was determined using the ratiometric Ca2+ sensitive fluorescent dye 
Fura-2-am at basal levels and after thapsigargin induced ER Ca2+ depletion. Fura-2-
AM shows dual excitation; Ca2+-bound Fura-2-am has a peak excitation wavelength 
of 340 nm and Ca2+-free Fura-2-AM has a peak excitation wavelength of 380 nm. 
Free cytosolic [Ca2+] is therefore proportional to the ratio of 340/380 emission 
intensities detected at 510 nm. Fibroblast cell lines were seeded at 40,000 cells/well 
on black 96 well optical bottom microplates (ThermoFisher) the day before the 
experiment. Cells were loaded with 5µM Fura-2 (ThermoFisher) at 37°C for 1 hour 30 
minutes, then washed twice with PBS and incubated for a further 30 minutes. 
Fluorescence was monitored on a VarioskanTM LUX multimode microplate reader 
(ThermoFisher) at emission wavelength 510 nm following alternate excitations at 340 
nm and 380 nm. ER Ca2+ depletion was triggered by addition of 1 µM thapsigargin. 
To calibrate the Fura-2 probe, Rmin was determined by addition of 2 µM ionomycin 
(ThermoFisher) and 3 mM EGTA (Sigma), and Rmax was determined by addition of 2 
µM ionomycin (ThermoFisher) and 10 mM CaCl2 (Sigma). The standard equation 
was used to calculate cytosolic [Ca2+]: [Ca2+] = Kd x Q x [(R-Rmin)/Rmax-R], where R is 
the 340/380 ratio, Rmin is the 340/380 ratio under Ca
2+ free conditions, Rmax is the 
340/380 ratio under Ca2+ saturating conditions, Q is the ratio of emission intensity at 
380 nm for Ca2+ free and Ca2+ saturated Fura-2 and Kd was assumed to be 225 nM.  
3.11 Mitochondrial OXPHOS analysis 
3.11.1 Seahorse XFe Extracellular Flux Analyzer  
The Seahorse XFe Extracellular Flux Analyzer (Agilent Technologies, California, 
USA) was used to measure oxygen consumption rate (OCR) as a measure of 
mitochondrial respiratory function in whole cells. Fibroblast cell lines were seeded at 
40,000 cells/well on XF96 cell culture microplates (Agilent Technologies) and allowed 
to adhere overnight. Prior to analysis the medium was exchanged to unbuffered 
DMEM supplemented with 5 mM glucose (Sigma-Aldrich), 1 mM sodium pyruvate 
(Sigma-Aldrich) and 2 mM L-glutamine (ThermoFisher) and cells were incubated at 
37 °C in a non-CO2 incubator for 1 hour. OCR was measured on a Seahorse XF
e 
Extracellular Flux Analyzer under basal conditions and following the sequential 
addition of oligomycin (1µM; Sigma-Aldrich) to inhibit complex V, the uncoupled 
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FCCP (0.5 µM) to measure maximal uncoupler stimulated OCR and rotenone (1µM; 
Sigma-Aldrich) together with antimycin A (1µM; Sigma-Aldrich) to inhibit complexes I 
and III and measure non-mitochondrial OCR. OCR was normalized to mg of protein 
using the Bradford assay. Four parameters of mitochondrial respiratory function were 
calculated: (i) basal respiration, (ii) ATP-linked respiration, (iii) proton leak and (iv) 
maximal respiration. Basal respiration was determined as the difference between 
OCR under basal conditions and non-mitochondrial OCR. ATP-linked respiration was 
determined as the difference between OCR under basal conditions and OCR 
following oligomycin treatment. Proton leak was determined as the difference 
between OCR following oligomycin injection and non-mitochondrial OCR. Maximal 
respiration was determined as the difference between OCR following FCCP 
stimulation and non-mitochondrial respiration.  
3.11.2 Oxygraph respirometer  
Respiration was measured in permeabilized fibroblasts at 37 °C in a high-resolution 
Oxygraph-2K respirometer (Oroboros, Innsbruck, Austria) in 2 ml glass chambers. 
Stirrer speed was set to 750 rpm and data was recorded in DatLab software 
(Oroboros, Innsbruck, Austria) at 2 second intervals. Fibroblasts were grown to ~70-
80% confluency, harvested as described in Section 3.4.2 and resuspended in 
respiratory buffer (0.5 mM EGTA, 3 mM MgCl2.6H2O, 60 mM Lactobionate, 20 mM 
Taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM sucrose and 1mg/ml BSA at 
pH7.1(All Sigma-Aldrich)). The fibroblasts were transferred to the Oxygraph chamber 
and digitonin (4 µg/million cells; Sigma-Aldrich) was added to selectively 
permeabilize the plasma membrane whilst leaving intracellular organelle membranes 
and the ER-mitochondria interaction intact. Following the loss of plasma membrane 
integrity the cytosol and all solutes leak from the cell and the composition of the 
intracellular space completely equilibrates with the incubation medium. Accordingly, 
the stepwise addition of substrates or inhibitors facilitates the site-specific analysis of 
mitochondrial respiratory chain function in a mostly intact cellular environment. 
Respiration was started with complex I-dependent substrates by addition of pyruvate 
(5 mM; Sigma-Aldrich) and malate (5 mM; Sigma-Aldrich). Complex I-coupled 
respiration was determined by addition of NAD+ (0.5 mM; Sigma-Aldrich) and ADP 
(1.5 mM; Merck Millipore). Succinate (10 mM; Sigma-Aldrich) was added to reach 
maximal coupled respiration, and then rotenone (1µM) was added to determine 
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complex II-dependent respiration. Antimycin A (2.5 µM) was added to determine non-
mitochondrial respiration. The results were expressed as flux control ratios; complex I 
(CI)-dependent respiration and complex II (CII)-dependent respiration were both 
normalised to the maximal respiratory rate by complexes I and II (CI+CII), determined 
as indicated in figure 6.3A.    
3.11.3 CellTiter-Glo ATP Assay 
ATP levels were measured using the CellTiter-Glo Luminescent Assay (Promega, 
Southampton, UK) according to the manufacturer’s instructions. Fibroblast cell lines 
were seeded at 40,000 cells/well on 96 well white microplates (ThermoFisher) and 
allowed to adhere overnight. The cells were incubated for 1 hour 30 minutes at 37 °C 
in either (i) glucose (5 mM)  to measure ATP under basal conditions; (ii) 2-deoxy-D-
glucose (2-DG; 5 mM, Sigma-Aldrich), which inhibits glycolysis and activates 
mitochondrial OXPHOS, to measure ATP due to OXPHOS; (iii) oligomycin (2.5 
µg/ml), a complex V inhibitor, to measure ATP due to glycolysis and (iv) 2-DG (5 mM) 
and oligomycin (2.5 µg/ml) as a positive control. Following incubation, 90 µl of buffer 
was removed and 100 µl of CellTiter-glo reagent was added to each well. Following 
25 minutes incubation in the dark with 10 minutes shaking, luminescence was 
measured on a Luminoskan Ascent (ThermoFisher) with a 1000 ms integration time.  
Luminescence signal was normalized to mg of protein using the Bradford assay. 
3.12 Measurement of ROS 
The fluorescent probe 2', 7'-dichlorodihydrofluorescein diacetate (H2DCFDA; 
ThermoFisher) was used to measure ROS levels. Fibroblast cell lines were seeded at 
a 25,000 cells/well on black 96 well optical bottom microplates and allowed to adhere 
overnight. Cells were washed with PBS and incubated with H2DCFDA (20 µM) in 100 
µl PBS or H2DCFDA (20 µM) and hydrogen peroxide (H202) (80 µM; Sigma-Aldrich) in 
100 µl PBS for 30 minutes at 37°C. Following incubation, cells were washed twice 
with PBS and fluorescence was measured on a Fluoroskan Ascent (ThermoFisher) at 
emission wavelength 535 nm following excitation at 485 nm. Fluorescence signal was 
normalized to mg of protein using the Bradford assay.  
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3.13 Real-time quantitative PCR  
3.13.1 DNA extraction from fibroblasts 
Total DNA was extracted from cell pellets using a DNeasy Blood and Tissue Kit 
(Qiagen) according to the manufacturer’s instructions; all buffers were provided by 
the kit and the centrifuge steps were performed at room temperature. The 
concentration of eluted DNA was determined using a NanoDrop 2000 UV-Vis 
spectrophotometer. 
3.13.2 mtDNA Copy Number 
Real-time quantitative PCR (RT-qPCR) is a reliable method to measure the quantity 
of DNA product being amplified in ‘real-time’ during the PCR reaction. The 
quantification of the relative mtDNA copy number was performed using a duplex 
qPCR assay with primers specific to the mitochondrial-encoded MTND1 gene and 
the nuclear-encoded B2M gene. Target specific probes were designed within the 
target specific primers, which are covalently attached to a fluorescent reporter dye on 
the 5’ end and a non-fluorescent quencher dye on the 3’ end. During the PCR 
reaction when the amplicon extends, the fluorescent reporter dye is cleaved from the 
probe by Taq polymerase endonuclease activity and the emission spectra of the 
reporter can be measured. Primer and probe details are given in Table 3.2. 
Reactions were performed using the iQ5 thermocycler (Bio-Rad) in 96 well plates in 
25 µl reactions containing: 0.75 µl of each primer, 0.5 µl of each probe, 12.5 µl iTaq 
SuperMix (Bio-Rad), 7.5 µl dH2O and 1 µl sample DNA. The reaction conditions 
were: initial denaturation at 95 °C for 3 minutes, followed by 40 cycles of denaturation 
at 95 °C for 10 seconds, and annealing/extension at 62.5 °C for 1 minute. 
Fluorescent levels were measured during each annealing and extension phase and 
mtDNA copy number was calculated with the comparative threshold method. 
For each target, a standard curve was used to assess amplification efficiency. 
Templates for each gene were amplified using standard PCR (Section 3.1), and 
separated by agarose gel electrophoresis (Section 3.2). The fragments were 
extracted and purified from the agarose gel using a QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s instructions. Templates were serially diluted 
with dH2O to generate a standard curve ranging from 10
9 to 102 copies and included 
on each reaction plate.    
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Target Forward Primer Reverse primer Dye Probe 
B2M CACTGAAAAAGATGAGTATGCC AACATTCCCTGACAATCCC FAM CCGTGTGAACCATGTGACTTTGTC 
MTND1 ACGCCATAAAACTCTTCACCAAAG GGGTTCATAGTAGAAGAGCGATGG HEX ACCCGCCACATCTACCATCACCCTC 
Table 3.2 RT-qPCR probes and primers for quantification of mtDNA copy number 
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3.14 Cell viability Analysis  
3.14.1 Drugs 
The following cellular stressors were used to assess fibroblast sensitivity to stress: 
staurosporine (STS; Merck Millipore), tert-Butyl hydroperoxide solution (t-BH; Sigma-
Aldrich), thapsigargin (Sigma-Aldrich).  
3.14.2 MTT assay 
Fibroblast cell lines were seeded at 40,000 cells/well on 96 well microplates and 
allowed to adhere overnight. Cell viability was determined after exposure to STS (1 
µM), t-BH (200 µM) or thapsigargin (4 µM) at 0, 2, 5 and 8 hours with the MTT assay 
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT); Sigma-Aldrich). 
At the selected time point, MTT (0.5 mg/ml final concentration) was added to each 
well and plates were incubated at 37 °C for 1 hour. Following incubation, the media 
was carefully removed from each well, 100 µl DMSO (Sigma-Aldrich) was added to 
solubilise the formazan crystals and absorbance was measured at 570 nm on a 
Multiskan ascent. MTT absorbance at 0 hours was considered 100 % cell viability 
and signals at 2, 5 and 8 hours were presented as percentage of the signal at 0 
hours. 
3.14.3 Caspase 3 activity assay     
Fibroblast cell lines were seeded at 40,000 cells/well on black 96 well optical bottom 
microplates and allowed to adhere overnight. Caspase 3 activity was assessed 
following treatment with cellular stressors with the fluorescent substrate, N-Acetyl-
Asp-Glu-Val-Asp-7-amido-4-Trifluoromethylcoumarin (AC-DEVD-AFC; Cayman 
Chemical, Michigan, USA). Caspase 3 selectivity cleaves the DEVD sequence 
releasing the fluoregenic AFC and caspase activity is expressed as ΔF/min/mg of 
protein. Cells were incubated with STS (1 µM), t-BH (200 µM) or thapsigargin (4 µM) 
for 5 hours. Following treatment, the media was removed, the cells were washed with 
PBS and 20 µl of lysis buffer (50 mM HEPES, 0.1% CHAPS pH 7.4) was added, the 
cells were lysed by shaking at 1000 rpm for 30 minutes at 4°C. Once the cells were 
lysed, an equal volume of assay buffer (40 mM HEPES, 0.2% CHAPS, 4 mM EDTA 
pH 7.4) with 200 µM Ac-DECD-AFC was added. Following 30 minutes incubation at 
37°C, fluorescence was monitored at emission wavelength 505 nm following 
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excitation at 400 nm on Tecan Infinite 200 microplate reader (Tecan, Männedorf, 
Switzerland). 
3.15  Statistical Analysis  
Statistical analysis was performed in GraphPad Prism 5 (GraphPad Software, La 
Jolla, USA) using a two-tailed unpaired t test. Comparisons were considered non-
significant (NS) if the P value was greater than 0.05 and significant if the P value was 
less than 0.05. 
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Chapter 4. Optic Neuropathy Gene Screening 
4.1 Introduction 
Inherited optic neuropathies are a genetically heterogeneous group of disorders 
characterised by irreversible RGC loss, optic atrophy and progressive visual 
impairment. Mutations in a number of genes have been identified (Table 1.1), some 
of which are relatively rare, and the mode of inheritance is traditionally classified as 
maternal (mitochondrial), autosomal dominant, autosomal recessive or X-linked (Yu-
Wai-Man et al., 2011a). 
The referral of patients with unexplained visual failure or suspected inherited 
optic neuropathies to the neuro-ophthalmology and neurogenetics services in 
Newcastle upon Tyne has led to the establishment of a comprehensively phenotyped 
cohort of patients with a likely genetic basis for their optic atrophy. LHON and DOA 
are the two most common inherited optic neuropathies seen in clinical practice, and 
with current genetic testing protocols a confirmed molecular diagnosis can be 
achieved in ~50% of patients (Ferre et al., 2009; Yu-Wai-Man et al., 2011b; Chen et 
al., 2014). Optic atrophy is also common in hereditary neurodegenerative disorders 
as part of a complex spectrum of clinical features caused by underlying mitochondrial 
dysfunction (Yu-Wai-Man et al., 2011a). Novel genes associated with optic atrophy 
continue to be identified and the phenotypic spectrum and mode of inheritance of 
known optic atrophy genes, such as OPA1 and WFS1, are being revised as more 
patients are identified and genetic testing becomes more widely available (Angebault 
et al., 2015; Charif et al., 2015; Grenier et al., 2016; Spiegel et al., 2016). Reaching a 
confirmed molecular diagnosis can be challenging and the genetic defect responsible 
for the development of optic atrophy and visual failure remains unresolved in a 
significant proportion of patients.   
Genetic testing has important benefits for patients and their families by 
enabling informed genetic counselling and assessment of the likely disease 
progression and severity (Yu-Wai-Man et al., 2011a). Patients can be advised on the 
avoidance of risk factors associated with increased risk of visual failure, such as 
smoking and alcohol for LHON carriers (Kirkman et al., 2009). Importantly, prenatal 
testing can be offered to women of childbearing age and individuals who are eligible 
for recruitment into clinical trials can be identified (Yu-Wai-Man et al., 2011a).     
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4.1.1 WFS1 
The WFS1 gene (4p16.1) consists of 8 exons, 7 of which encode Wolframin, a 
transmembrane protein that localizes to the ER (Inoue et al., 1998; Strom et al., 
1998). Mutations in the WFS1 gene are associated with WFS1 and related disorders, 
in which optic atrophy is a constant and central feature (Moosajee et al., 2016).  
4.1.2 RTN4IP1 
The RTN4IP1 gene (6q21) encodes for a mitochondrial protein that was identified in 
a yeast two-hybrid screen using reticulon 4 (RTN4) as bait. The RTN4IP1 gene 
comprises of 9 protein-coding exons and the resulting protein has a putative N-
terminal mitochondrial targeting sequence. The function of RTN4IP1 remains 
unknown, although it has been confirmed to localise to mitochondria (Hu et al., 2002). 
Mutations in RTN4IP1 have recently been associated with inherited optic neuropathy. 
A homozygous mutation, c.308G>A (p.Arg103His), was identified as the cause of   
early-onset recessive optic neuropathy in two siblings from a consanguineous 
Moroccan family. This variant modifies an evolutionary conserved amino acid, which 
was predicted to be pathogenic by in silico analysis, and the variant segregated with 
the disease in the family. Four additional subjects harbouring RTN4IP1 mutations 
were identified by Sanger sequencing in 240 European inherited optic neuropathy 
probands with no previous genetic diagnosis, implying that this gene is likely to be a 
rare recessive cause of inherited optic neuropathy. Two subjects were homozygous 
for the same c.308G>A mutation and two subjects harboured compound 
heterozygous mutations, including the c.308G>A mutation and a nonsense mutation 
c.601A>T, (p.Lys201*) (Angebault et al., 2015). 
4.1.3 C12orf65 
The C12orf65 gene (12q24.31) encodes for a mitochondrial matrix protein that is part 
of the mitochondrial translation system. C12orf65 belongs to a family of mitochondrial 
class 1 peptide release factors characterized by a peptidyl-hydrolase domain 
containing a conserved glycine-glycine-glutamine (GGQ) motif. Peptide release 
factors recognize when a stop codon on translated mRNA enters the mitoribosome 
and terminate translation through hydrolysis of the ester bond connecting the nascent 
polypeptide to the peptidyl-tRNA, thus releasing the newly synthesized protein 
(Antonicka et al., 2010; Duarte et al., 2012). The C12orf65 protein contains a release 
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factor-1 (RF-1) domain (amino acids 53-146) containing the GGQ motif (amino acids 
71-73), but its precise function remains unclear (Antonicka et al., 2010). C12orf65 
does not exhibit peptidyl-tRNA hydrolase activity or coprecipitate with the 
mitoribosome and it is instead hypothesized to participate in the recycling of abortive 
peptidyl-tRNAs released from the ribosome (Antonicka et al., 2010; Duarte et al., 
2012).  
The C12orf65 gene consists of three exons and 501bp from exons two and 
three comprise its protein-coding region. Mutations in C12orf65 were first described 
in three patients from two unrelated families presenting with optic atrophy, 
opthalmoplegia and progressive encephalomyopathy (Antonicka et al., 2010). 
Subsequently, at least nine recessive C12orf65 mutations have been reported 
associated with a range of clinical features including optic atrophy, peripheral 
neuropathy and spastic paraplegia (Antonicka et al., 2010; Shimazaki et al., 2012; 
Buchert et al., 2013; Heidary et al., 2014; Pyle et al., 2014; Spiegel et al., 2014; Tucci 
et al., 2014; Imagawa et al., 2016). All reported C12orf65 mutations led to truncation 
of the C12orf65 protein and a genotype-phenotype relationship has been established 
where N-terminal mutations that disrupt the RF-1 domain are associated with a 
severe phenotype and C-terminal mutations that do not affect the RF-1 domain are 
associated with a milder phenotype (Figure 4.1) (Spiegel et al., 2014; Imagawa et al., 
2016). 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Schematic of C12orf65 structure. The protein structure and 
previously reported C12orf65 mutations, arrows indicate the resulting 
protein truncation.   
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Due to the previous association of the WFS1, RTN4IP1 and C12orf65 genes with 
inherited optic atrophy phenotypes (Inoue et al., 1998; Strom et al., 1998; Antonicka 
et al., 2010; Angebault et al., 2015), the purpose of this study was to screen these 
genes for potential pathogenic mutations in a selected group of patients from the 
Newcastle optic atrophy cohort.  
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4.2 Materials and Methods 
4.2.1 Patient Cohort 
The Newcastle optic atrophy cohort consisted of 30 patients who had previously been 
diagnosed with likely inherited optic atrophy, but who do not harbour pathogenic 
mutations in the OPA1 or OPA3 gene (Table 4.1). Genomic DNA was available for 
each patient. 
Patient Clinical features 
1 Optic atrophy, diabetes, ataxia and stoke-like episodes 
2 Optic atrophy and deafness 
3 Optic atrophy plus 
4 Optic atrophy plus, ataxia and peripheral neuropathy 
5 Optic atrophy 
6 Optic atrophy, CPEO and peripheral neuropathy 
7 CAPOS 
8 CAPOS 
9 CAPOS 
10 Optic atrophy and diabetes mellitus 
11 Optic atrophy plus, ataxia and peripheral neuropathy 
12 Optic atrophy plus, CPEO, spastic paraplegia and ataxia 
13 Optic atrophy plus 
14 Optic atrophy plus 
15 Optic atrophy and peripheral neuropathy 
16 Optic atrophy plus, CPEO and proximal myopathy 
17 Optic atrophy 
18 Optic atrophy plus, CPEO and ataxia 
19 Optic atrophy and deafness 
20 Optic atrophy and deafness 
21 Optic atrophy and ataxia 
22 Optic atrophy 
23 Optic atrophy 
24 Optic atrophy 
25 Optic atrophy 
26 Optic atrophy 
27 Optic atrophy and nystagmus 
28 Optic atrophy 
29 Optic atrophy and deafness 
30 Optic atrophy and raised 3-methylglutaconic acid 
Table 4.1 The Newcastle optic atrophy cohort. The clinical features of each 
patient. CAPOS, cerebellar ataxia, areflexia, pes cavus, optic atrophy and 
sensorineural hearing loss; CPEO, chronic progressive external ophthalmoplegia.  
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4.2.2 Sequencing 
Primer sets for WFS1 (Table 4.2), RTN4IP1 (Table 4.3) and C12orf65 (Table 4.4) 
were designed with Primer3 and primer specificity was confirmed using Primer-Blast 
(Untergasser et al., 2012; Ye et al., 2012). The entire coding regions and exon-intron 
boundaries of the WFS1, RTN4IP1 C12orf65 genes were amplified by PCR and PCR 
products were Sanger sequenced as described in Sections 3.1-3.3.  
4.2.3 Sequencing Analysis 
Sequencing results were analyzed as described in Section 3.3.4. The following 
GenBank reference sequences were used: WFS1 (NG_011700.1), RTN4IP1 
(NG_047205.1) and C12orf65 (NG_027517.1). Identified variants were described 
according to the Human Genome Variation Society nomenclature (den Dunnen et al., 
2016). All variants were checked against the literature, mutation databases where 
appropriate (https://lovd.euro-wabb.org, accessed on 9 October 2016) and the 
National Centre for Biotechnology Information (NCBI) Single Nucleotide 
Polymorphism Database (dbSNP) (Sherry et al., 2001). As required, the likelihood of 
a non-synonymous variant being pathogenic was determined with PolyPhen2. This 
tool predicts the impact of an amino acid substitution and scores a variant from 0.0 
(tolerated) to 1.0 (deleterious) (http://genetics.bwh.harvard.edu/pph2/, accessed on 9 
October).  
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Exon Amplicon 
size (bp) 
Forward primer Reverse primer 
1 366 CGGAGATGTGGAGTGATTGG 
 
ACAGTGCCTCAGGGCTCTT 
2 491 TCAGCGAGATCCTGTATGGA 
 
AGCTGCACAATGCTGAACTG 
3 499 TTCCCTGTCTGTGTCTGTGTCT 
 
GAGGTGATGCCCAAGATGAG 
4 926 AAGCCCTTTTATGGGCTCTC 
 
AATTTCCCAACAGCATCACC 
5 495 CCCTGGTAACCAAGTCCTGA 
 
GCACGGTCTCTACAGGAAGG 
6 395 ATGATCCCCAGAACGTAGGA 
 
ACCGCCTGAGATCCTAGCAG 
7 684 GTCACCCGTGCTGTGAGAA 
 
GGCACGGCTGTAAGACACTC 
8a 497 GTCAGAGGGAGGCGTGAGAT 
 
GGGATGCAGTCCTTGCTG 
8b 540 CAACCTGGATGTGGAGCAG 
 
TCCATCGGCTACTTCCTCTT 
8c 482 TTTCAAGGGCACCTACTGCT 
 
CCATGTTGGTCTCCTTCCAG 
8d 384 GGTCAAGCTCATCCTGGTGT 
 
CTCTGTCGCCTTAAGCTGCT 
8e 599 ACATGCTCCCGTTCTTCATC 
 
CACTGGTGCATGCCTGTC 
Table 4.2 WFS1 primer sets 
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Exon Amplicon 
size (bp) 
Forward primer Reverse primer 
1a 567 GCGCAGCCATCTTTAATTGT 
 
TGAACTGCGTGCTCAAATTC 
1 649 GCGAAGAGCGGAATAACAGT 
 
AGAAGGATTCCCTGGCCATT 
2 465 CCATGTCTTTGCTGTTGTGAA 
 
CAGATTCAGGGAGCAGAAGC 
3 475 GGATATGCTGGCATCTGCTT 
 
GCAGGCAGTGTTACTGAATGG 
4 495 GGTTTTGCTGGTCTCAGAGG 
 
CTGAGAATCCACAGAATGAAGC 
5 336 CTGCAGTTTCTTGGTGAACCT 
 
CCAGACCTACCTTTCTCTCAGC 
6 455 TCTCTGACAGATGGCTTCCT 
 
GCCAACCTAAGTAACTTCTAGT 
GACA 
7 486 CCTTCCATCTCCATCAAAGC 
 
GTGACTGCAGAGTCCATGCT 
8 366 AGTCATTGTGCCAAGGTGCT 
 
AAGGTCAGGTGAGCAGGCTA 
9 397 ACCTGGGTCCACTGGAGAG 
 
ACTGGCCAAAATGGTGTGTT 
 
Table 4.3 RTN4IP1 primer sets 
Exon Amplicon 
size (bp) 
Forward primer Reverse primer 
2 486 TACCCTGCACTGCTTTCCTT  
 
CAGGACTGTTTTCACCATTGTAG 
3 397 GCAACCAACAAAACCAGCAA  
 
CAGGACTGTTTTCACCATTGTAG 
Table 4.4 C12orf65 primer sets 
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4.3 Results 
4.3.1 WFS1 genetic screen 
The WSF1 gene was sequenced in 14 patients. In total, 13 exonic WFS1 variants 
were identified, including three non-synonymous variants (Table 4.5). All 13 WFS1 
variants have previously been reported in healthy controls on dbSNP.  
Location DNA Protein dbSNP Heterozygous Homozygous 
Exon 5 c.612C>T p.(Val204=) Yes 1 0 
Exon 6 c.684C>G p.(Arg228=) Yes 6 6 
Exon 8 c.997G>A p.(Ile333Val) Yes 5 4 
Exon 8 c.1023C>T p.(Phe341=) Yes 2 0 
Exon 8 c.1185C>T p.(Val395=) Yes 9 4 
Exon 8 c.1367G>A p.(Arg456His) Yes 2 0 
Exon 8 c.1500C>T p.(Asn500=) Yes 8 4 
Exon 8 c.1725C>T p.(Ala575=) Yes 2 0 
Exon 8 c.1832G>A p.(Arg611His) Yes 9 3 
Exon 8 c.2322G>A p.(Lys774=) Yes 9 4 
Exon 8 c.2424C>T p.(Ser808=) Yes 1 0 
Exon 8 c.2433G>A p.(Lys811=) Yes 9 4 
Exon 8 c.2565 A>G p.(Ser855=) Yes 7 6 
Table 4.5 WFS1 variants identified 
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4.3.2 RTN4IP1 genetic screen  
The RTN4IP1 gene was sequenced in 11 patients. Overall, three synonymous 
variants were identified, all of which have previously been reported in healthy controls 
on dbSNP (Table 4.6). 
Location DNA Protein dbSNP Heterozygous Homozygous 
Exon 1b c.114 T>A p.(Pro38=) Yes 5 0 
Exon 2 c.201 C>T p.(IleI67=) Yes 1 0 
Exon 9 c.1182 C>T p.(Asn394=) Yes 1 0 
Table 4.6 RTN4IP1 variants identified 
4.3.3 C12orf65 genetic screen 
The C12orf65 gene was sequenced in 29 patients and two variants were identified. 
One variant was synonymous and one was non-synonymous; both have previously 
been reported in healthy controls on dbSNP (Table 4.7). In addition, the non-
synonymous variant scored 0.179 on PolyPhen2, indicating the variant is likely 
benign (http://genetics.bwh.harvard.edu/pph2/, accessed on 9 October).   
Location DNA Protein dbSNP Heterozygous Homozygous 
Exon 2 c.44G>A p.(Arg15Gly) Yes 2 0 
Exon 2 c.273C>T p.(Ile91=) Yes 1 0 
Table 4.7 C12orf65 variants identified 
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4.4 Discussion 
Inherited optic neuropathies are genetically heterogeneous and the underlying 
genetically defect remains unknown in ~40-60 % of patients referred to tertiary 
centres for further investigation (Ferre et al., 2009; Yu-Wai-Man et al., 2011b). In this 
study, a well-characterised cohort of patients with likely inherited optic atrophy, but no 
molecular diagnosis, was screened for possible pathogenic mutations in the WFS1, 
RTN4IP1 and C12orf65 genes (Inoue et al., 1998; Strom et al., 1998; Antonicka et 
al., 2010; Angebault et al., 2015).  
The WFS1 gene was sequenced in 14 patients and 13 exonic variants were 
identified, including three non-synonymous variants. All variants had previously been 
reported on dbSNP and are likely non-pathogenic. Wolfram syndrome has an 
estimated prevalence of 1 in 770,000 in the UK (Barrett et al., 1995a), and at least 
281 unique WFS1 mutations have been reported to date (https://lovd.euro-wabb.org, 
accessed on 9 October 2016). It is not entirely unexpected that no WFS1 mutations 
were identified in the patient cohort. Most patients did not fit the minimal diagnostic 
criteria for Wolfram syndrome, which is the co-occurrence of diabetes mellitus and 
optic atrophy typically with juvenile onset and approximately 85 % of patients will 
have both clinical features by the second decade (Rigoli et al., 2011; de Heredia et 
al., 2013). Nevertheless, dominant mutations in the WFS1 gene are associated with 
optic atrophy and SNHL, also referred to as Wolfram-like syndrome (Hogewind et al., 
2010; Rendtorff et al., 2011), and recently, recessive WFS1 mutations have been 
reported in the context of isolated optic atrophy (Chaussenot et al., 2015; Grenier et 
al., 2016). Therefore, although no pathogenic mutations were identified, the 
systematic analysis of the WFS1 gene is warranted in patients with suspected 
inherited optic neuropathy.  
The RTN4IP1 gene was sequenced in 11 patients and three synonymous 
variants were identified. All variants have previously been reported and are likely 
non-pathogenic. To date, RTN4IP1 mutations have been identified in six subjects 
from four families associated with both isolated and syndromic optic neuropathy 
(Angebault et al., 2015). The fact that no pathogenic RTN4IP1 mutations were 
identified in the Newcastle optic atrophy cohort further suggests that mutations in the 
RTN4IP1 gene are likely a rare cause of inherited optic atrophy.  
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The C12orf65 gene was sequenced in 29 patients and two variants were 
identified. One variant was synonymous and has previously been reported on 
dbSNP. A non-synonymous variant (c.273C>T, p.Arg15Gly) was also identified. The 
variant is likely non-pathogenic as it has previously been reported on dbSNP, 
although the submission has not been validated, and it was predicted to be benign by 
in silico analysis on PolyPhen-2. Furthermore, the variant is a missense mutation in a 
heterozygous state, which does not affect the RF-1 domain, whereas previous 
C12orf65 mutations have primarily been nonsense truncating mutations with a 
recessive mode of inheritance (Imagawa et al., 2016).  
One limitation of this study is that deep intronic mutations or large-scale 
deletions/duplications cannot be excluded. However, the relevance of these 
mutational subtypes in the context of RTN4IP1 and C12orf65 remains unclear. In rare 
cases, large deletions of the WFS1 gene have been described in Wolfram syndrome 
(Chaussenot et al., 2015).  
In summary, no pathogenic mutations in the WFS1, RTN4IP1 or C12orf65 
genes have been identified in a well-characterised cohort of 30 patients with 
suspected inherited optic neuropathy. Further investigations are underway to 
ascertain the cause of optic atrophy in these patients with next-generation whole 
exome and genome sequencing. 
 
 
 
 
. 
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Chapter 5. Ca2+ Homeostasis at the Mitochondria Associated      
Membrane in Wolfram Syndrome 1 
5.1 Introduction 
Wolfram syndrome is a multisystemic neurodegenerative disease characterised by 
diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) 
(Wolfram and Wagener, 1938). This disorder is primarily caused by recessive 
mutations in the WFS1 gene (4p16.1), although dominant mutations associated with 
Wolfram-like syndrome are increasingly being reported (Inoue et al., 1998; Strom et 
al., 1998; Hogewind et al., 2010; Rendtorff et al., 2011). The WFS1 gene encodes a 
transmembrane ER protein termed Wolframin, which is involved in ER maintenance 
and the regulation of cellular Ca2+ homeostasis (Takeda et al., 2001; Takei et al., 
2006; Hara et al., 2014). Numerous studies have reported that WFS1 deficiency 
induces ER stress and disturbs cellular Ca2+ homeostasis (Hara et al., 2014; Lu et 
al., 2014; Cagalinec et al., 2016).  
Historically, Wolfram syndrome was initially suspected to be a mitochondrial 
disease because the multisystemic clinical manifestations were reminiscent of the 
complex phenotypes observed in classical mitochondrial disease and the organ 
systems affected had a high metabolic demand (Bu and Rotter, 1993). However, the 
identification of the WFS1 gene and the observation that Wolframin deficiency led to 
ER dysfunction put this hypothesis into question and suggested that Wolfram 
syndrome was instead an ER-related disease (Fonseca et al., 2005; Yamada et al., 
2006). Nevertheless, the disease mechanisms underlying Wolfram syndrome have 
not been fully resolved and there is mounting evidence that WFS1 mutations cause 
mitochondrial dysfunction (Ross-Cisneros et al., 2013; Cagalinec et al., 2016). The 
histopathological investigation of optic nerve degeneration in post-mortem retinal 
tissue from a WFS1 patient revealed a pattern of RGC loss that is characteristic of 
mitochondrial optic neuropathies (Ross-Cisneros et al., 2013). Furthermore, a recent 
investigation of mitochondrial function in WFS1 deficient neurones revealed 
mitochondrial defects including disturbed mitochondrial dynamics and impaired 
OXPHOS function. Notably, mitochondrial dysfunction was shown to be secondary to 
ER stress and perturbed cytosolic Ca2+ homeostasis (Cagalinec et al., 2016).   
It is possible that primary ER dysfunction in Wolfram syndrome may cause 
mitochondrial impairment through disturbed ER-mitochondria interactions. The ER 
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and mitochondria interact physically and functionally at interfaces termed MAMs, and 
it is now becoming apparent that dysfunction in either organelle can have a negative 
impact on the other (Paillusson et al., 2016). The MAM is enriched in proteins 
associated with cellular Ca2+ signalling and a key function is the efficient transfer of 
Ca2+ from the ER to mitochondria, which serves to regulate cellular Ca2+ 
homeostasis, mitochondrial bioenergetics and apoptosis (van Vliet et al., 2014). 
Compelling evidence exists for a link between MAM dysfunction, disturbed Ca2+ 
homeostasis and neurodegenerative diseases such as AD, PD and ALS (Paillusson 
et al., 2016). Perhaps the strongest evidence for MAM dysfunction in disease exists 
for ALS and several proteins enriched at the MAM have been implicated in familial 
ALS, including VAPB and Sigma1R (Al-Saif et al., 2011; De Vos et al., 2012). 
Established concepts include tightening of the VAPB-PTP5IP1 MAM protein tether 
and enhanced ER-mitochondrial Ca2+ flux secondary to mutations in the gene 
encoding VAPB (De Vos et al., 2012), and altered ER ultrastructure, loss of ER-
mitochondrial contact and disturbed cellular Ca2+ homeostasis as a consequence of 
Sigma1R deficiency (Hayashi and Su, 2007; Al-Saif et al., 2011). Interestingly, 
Wolframin was identified in three different proteomic studies of the MAM. This 
indicates that Wolframin is enriched at the MAM and likely has functions within this 
domain, possibility related to regulation of Ca2+ homeostasis. Importantly, these 
observations suggest that WFS1 mutations could disturb the function of the MAM 
(Zhang et al., 2011; Poston et al., 2013; Horner et al., 2015)  
To further clarify the deleterious consequences of WFS1 mutations, the 
present study used a cell culture model consisting of fibroblasts derived from 
Wolfram syndrome patients harbouring recessive or dominant WFS1 mutations to 
explore cellular Ca2+ homeostasis and the ER-mitochondrial axis. 
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5.2 Methods 
5.2.1 Patient Cohort 
Primary fibroblast cell lines were established from five probands (W1-W5) with a 
clinical diagnosis of Wolfram syndrome or Wolfram-like syndrome and with confirmed 
pathogenic WFS1 mutations (Table 5.1; hereafter referred to as WFS1 fibroblasts). 
All five patients have optic atrophy associated with marked thinning of the RGC layer 
on optical coherence tomography (OCT) imaging. The mode of inheritance was 
autosomal recessive for three patients (W1-W3) and autosomal dominant for two 
patients (W4-W5). Three control fibroblast cell lines (C1-C3) were included for 
comparison (Table 5.2). 
The project underwent appropriate ethical review before commencement. 
Ethical approval was obtained from the National Research Ethics Service; now part 
of the Health Research Authority. The project was then reviewed, ethically assessed, 
and approved by Newcastle University.  
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Proband Age Sex OA onset Clinical features Visual acuity Nucleotide change Protein change 
 (years)  (years) RE LE 
W1 33 Female 4 Optic atrophy, deafness and 
progressive ataxia 
CF CF c.409_424dup16 
c.2262_2263del2 
p.V142GfsX110 
p.C755SfsX3 
W2 26 Male 12 DIDMOAD 6/60 6/60 c.1433G>A 
c.2648_2651del4 
p.W478X 
p.F883SfsX68 
W3 49 Male 24 Optic atrophy, deafness and 
diabetes mellitus 
CF CF c.1558C>T 
c.1372G>A 
p.Q520X 
p.A458T 
W4 49 Female 6 Optic atrophy and deafness CF CF c.2161A>T p.N721Y 
W5 65 Male 52 Optic atrophy and deafness 6/36 6/36 c.2051 C>T p.A684V 
 
 
 
Table 5.1 Clinical features and WFS1 mutations of the Wolfram syndrome patient cohort. OA, optic atrophy; CF, counting 
fingers; RE, right eye; LE, left eye.  
 73 
Control Age (years) Sex 
C1 45 Female 
C2 51 Male 
C3 - - 
Table 5.2 Details of the control fibroblast cell lines.  
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5.3 Results 
5.3.1 Wolframin protein expression in WFS1 fibroblasts 
Wolframin protein expression was assessed in WFS1 and control fibroblasts by 
western blot analysis. Recessive WFS1 mutations (W1-W3) caused complete loss of 
Wolframin signal (Figure 5.1). In contrast, the steady-state levels of Wolframin, when 
normalized to tubulin, did not appear to be affected in fibroblasts with dominant 
WFS1 mutations (Figure 5.1). As recessive WFS1 mutations caused complete loss 
of the Wolframin protein, fibroblasts carrying recessive WFS1 mutations were 
merged into one group termed WFS1 rec for further analysis.  
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Figure 5.1 Western blot analysis of Wolframin in WFS1 fibroblasts.                     
(A) Representative western blot of Wolframin in WFS1 (W1-W5) and control 
(C1-C3) fibroblasts. (B) Densitometric analysis of Wolframin levels normalized 
against tubulin. Data are mean ± SEM. n = 3. No results were significantly 
different when compared to controls, two-tailed unpaired t test. 
 75 
5.3.2 Expression of ER stress markers in WFS1 fibroblasts 
To evaluate ER homeostasis in WFS1 fibroblasts the protein levels of two ER 
chaperones, glucose regulated protein 94 (GRP94) and binding immunoglobulin 
protein (Bip), were assessed by western blot analysis. There was no significant 
difference observed in GRP94 or Bip levels in WFS1 fibroblasts when compared with 
controls (Figure 5.2). 
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Figure 5.2 Western blot analyses of ER stress markers in WFS1 
fibroblasts. (A) Representative western blots of GRP94 and Bip in WFS1 and 
control fibroblasts. (B, C) Densitometric analysis of (B) GRP94 and (C) Bip 
levels normalized against tubulin. Data are mean ± SEM. n = ≥ 3. No results 
were significantly different when compared to controls, two-tailed unpaired t 
test. 
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5.3.3 Analysis of ER Ca2+ levels with the D1ER probe in WFS1 fibroblasts 
The ER-targeted cameleon D1ER was used to assess ER Ca2+ levels in WFS1 and 
control fibroblasts. To confirm the D1ER probe was functioning correctly it was 
expressed in control cells (Figure 5.3). FRET/CFP ratios were then assessed in 
digitonin permeabilized cells following treatment with either the Ca2+ chelator EGTA 
to decrease ER [Ca2+] or with a combination of Ca2+, MgCl2 and ATP to increase ER 
[Ca2+]. As expected treatment with EGTA decreased the FRET/CFP ratio and 
treatment with Ca2+, MgCl2 and ATP increased the FRET/CFP ratio (Figure 5.4). 
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Figure 5.3 Imaging of the D1ER probe. (A, B) Representative confocal 
images of control fibroblasts expressing D1ER: (A) the CFP signal and (B) the 
YFP signal. The reticular pattern is indicative of ER localisation. Regions of 
interest were analysed using Fiji. 
Figure 5.4 Optimization of the D1ER probe. (A, B) Control cells were 
permeabilized with digitonin and treated with (A) EGTA to deplete ER Ca2+ or 
(B) Ca2+, MgCl2 and ATP to increase ER Ca
2+ and monitored for 15 minutes. 
FRET/CFP ratios were calculated using Fiji. 
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Once validated the D1ER probe was used to assess ER Ca2+ levels in WFS1 and 
control fibroblasts. No significant difference was observed in the average FRET/CFP 
ratios of WFS1 fibroblasts in comparison with controls, indicating that ER Ca2+ levels 
are not disturbed in WFS1 fibroblasts (Figure 5.5). 
.    
   
 
 
 
 
 
5.3.4 Cytosolic Ca2+ levels are not disturbed in WFS1 fibroblasts 
The ratiometric Ca2+ sensitive fluorescent dye Fura-2-am was used to measure 
cytosolic [Ca2+] at basal levels and following thapsigargin induced ER Ca2+ depletion 
in WFS1 and control fibroblasts.  
Two thapsigargin concentrations (1 µM and 10 µM) were tested on a                     
Fura-2-AM loaded control cell line to determine the optimal thapsigargin 
concentration to inhibit SERCA and induce ER Ca2+ depletion in fibroblasts. Both       
1 µM and 10 µM thapsigargin significantly increased cytosolic [Ca2+] in comparison to 
basal cytosolic [Ca2+]. There was no significant difference in peak cytosolic [Ca2+] 
levels induced by 1 µM and 10 µM thapsigargin, therefore 1 µM thapsigargin was 
chosen for the ER Ca2+ depletion experiments (Figure 5.6).   
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Figure 5.5 Analysis of ER Ca2+ levels in WFS1 fibroblasts. The average 
FRET/CFP ratios of WFS1 and control fibroblasts. Data are mean ± SEM.                    
n = ≥ 15. No results were significantly different when compared to controls, two-
tailed unpaired t test. 
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The optimized Fura-2-AM assay was used to assess cytosolic Ca2+ homeostasis in 
WFS1 fibroblasts. There was no significant difference observed in basal cytosolic 
[Ca2+] in WFS1 fibroblasts when compared to controls (Figure 5.7). Likewise, both 
peak cytosolic [Ca2+] measured following thapsigargin treatment and thapsigargin 
sensitive Ca2+ stores, defined as the difference between peak cytosolic [Ca2+] and 
basal cytosolic [Ca2+], were similar between WFS1 and control fibroblasts (Figure 
5.8) 
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Figure 5.6 Optimization of thapsigargin induced ER Ca2+ depletion in 
fibroblasts.  Comparison of cytosolic [Ca2+] in control fibroblasts at basal and 
following treatment with two thapsigargin (Tg) concentrations: 1 µM and 10 µM. 
Data are mean ± SEM. n = 3 (triplicate of a single experiment). ** p = ≤ 0.01, 
when compared to basal, two-tailed unpaired t test. NS - when 1 µM Tg and 10 
µM Tg were compared, two-tailed unpaired t test.       
Figure 5.7 Analysis of basal cytosolic [Ca2+] in WFS1 fibroblasts. Data are 
mean ± SEM. n = 3. No results were significantly different when compared to 
controls, two-tailed unpaired t test. 
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Figure 5.8 Analysis of thapsigargin induced ER Ca2+ depletion in WFS1 
fibroblasts. (A, B) Analysis of (A) peak cytosolic [Ca2+] following thapsigargin 
treatment and (B) thapsigargin (Tg) sensitive Ca2+ stores in WFS1 and control 
fibroblasts. Data are mean ± SEM. n = 3. No results were significantly different 
when compared to controls, two-tailed unpaired t test. 
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5.3.5 ER to mitochondrial Ca2+ flux is decreased in WFS1 fibroblasts 
To assess ER-mitochondrial Ca2+ flux in WFS1 and control fibroblasts, histamine   
(100 µM) was used to induce IP3R dependent ER Ca
2+ release and the following 
Ca2+ transient was monitored by high speed confocal microscopy in the mitochondria 
and cytosol with the Ca2+ sensitive fluorescent dyes Rhod-2-AM and Fluo-4-AM, 
respectively (Figure 5.9). Representative traces of mitochondrial and cytosolic Ca2+ 
transients are shown in figure 5.10 B, D. 
Histamine stimulated peak mitochondrial Ca2+ levels were significantly reduced in 
WFS1 rec and W4 fibroblasts when compared to controls. No significant difference 
was observed in peak cytosolic Ca2+ levels in these cell lines in comparison to 
controls (Figure 5.10 A, C). Conversely, in W5 fibroblasts peak mitochondrial Ca2+ 
levels were normal and peak cytosolic Ca2+ levels were significantly reduced in 
comparison to controls (Figure 5.10 A, C). 
 
 
 
 
 
 
 
 
Basal Histamine (100 µM) 
A B 
C D 
Figure 5.9 Imaging of cellular Ca2+ transients with Ca2+ sensitive 
fluorescent dyes. (A-D) Representative images demonstrating analysis of (A, 
B) mitochondrial Ca2+ with Rhod-2-AM (red) and (C, D) cytosolic Ca2+ with Fluo-
4-AM (green) before and after histamine application. Regions of interest were 
analysed using Fiji.    
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Figure 5.10 Disturbed Ca2+ flux in WFS1 fibroblasts. (A, C) Analysis of average peak (A) mitochondrial 
and (C) cytosolic Ca2+ levels following histamine induced ER Ca2+ release in WFS1 and control fibroblasts. 
Data are mean ± SEM. n = ≥ 8. *** p = ≤ 0.001, * p = ≤ 0.05, two-tailed unpaired t test. (B, D) 
Representative traces of (B) mitochondrial and (D) cytosolic Ca2+ transients in WFS1 and control 
fibroblasts. Where indicated the cells were stimulated with histamine.   
 82 
5.3.6 ER-mitochondrial contact is not disturbed in WFS1 fibroblasts with 
reduced mitochondrial Ca2+ uptake  
The interaction between the ER and mitochondria was assessed in WFS1 and 
control fibroblasts. Fibroblasts were transfected with GFP Sec61β to detect ER and 
loaded with MitoTracker Red to stain mitochondria (Figure 5.11A). Sixty nine Z-
stacks were acquired across the cell at 0.11 µm increments with live cell confocal 
microscopy. After image deconvolution and 3D reconstruction of Z-axis stacks, 
colocalization of the two signals was quantified using the Manders’ coefficient, M1 
and M2, in Huygens Object Analyser (Figure 5.11B). M1 indicates the fraction of ER 
that colocalises with mitochondria and M2 indicates the fraction of mitochondria that 
colocalises with ER. 
 
 
 
 
 
 
 
  
 
 
 
There was no significant difference observed in the Manders’ coefficient M1 or M2 in 
WFS1 rec and W4 fibroblasts when compared to the corresponding Manders’ 
coefficient in controls. In contrast, in W5 fibroblasts Manders’ coefficient M2 was 
significantly increased in comparison to controls and Manders’ coefficient M1 was 
normal; indicating that mitochondria are more closely associated with the ER in this 
cell line (Figure 5.12). 
 
B A 
Figure 5.11 Representative images demonstrating analysis of ER-mitochondrial 
contact. (A) GFP Sec61β labelled ER (green) and MitoTracker Red labelled 
mitochondria (red) in a control cell line (B) Zoomed 3D-reconstruction of the ER 
(green) and mitochondrial network (red) in a control cell line created in Huygens 
Object Analyzer. 
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5.3.7 Analysis of mitochondrial membrane potential in WFS1 fibroblasts 
Mitochondrial membrane potential was assessed in WFS1 and control fibroblasts 
using confocal microscopy and the cell permeant dye TMRM which accumulates 
within mitochondria as a function of membrane potential (Figure 5.13A). TMRM 
signal was normalised to the remaining TMRM signal following dissipation of the 
membrane potential with FCCP (10 µM). There was no significant difference in 
TMRM intensity in WFS1 fibroblasts compared to controls suggesting that 
mitochondrial membrane potential is normal in WFS1 fibroblasts (Figure 5.13B).    
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Figure 5.12 Analysis of ER-mitochondrial contact in WFS1 fibroblasts.             
(A-B) Analysis of (A) Manders’ coefficient M1 ER/Mitochondrial (Mito) 
colocalisation and (B) Manders’ coefficient M2 Mito/ER colocalisation in WFS1 
and control fibroblasts. Data are mean ± SEM. n = ≥ 16. ** p = ≤ 0.01, two-tailed 
unpaired t test. 
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5.3.8 Expression of key Ca2+ channels and pumps in WFS1 fibroblasts 
Expression of the IP3R, SERCA, VDAC and MCU were assessed by western blot 
analysis in WFS1 and control fibroblasts. There was no significant difference 
observed in IP3R levels between WFS1 and control fibroblasts (Figure 5.14A, B). 
SERCA levels were significantly increased in WFS1 rec and W4 fibroblasts when 
compared to controls. SERCA levels were increased in W5 fibroblasts in comparison 
to controls, although the increase was not statistically significant (Figure 5.14A, C). 
VDAC levels were not significantly different between WFS1 fibroblasts and controls 
(Figure 5.14A, D). No significant difference was observed in MCU levels in WFS1 
rec and W4 fibroblasts compared to controls, whereas, expression of the MCU was 
significantly increased in W5 fibroblasts compared with controls (Figure 5.14A, E).  
Figure 5.13 Mitochondrial membrane potential assessed by TMRM in 
WFS1 fibroblasts. (A) Representative image of a TMRM loaded control 
fibroblast. Regions of interest were analyzed using Fiji. (B) Analysis of the 
average TMRM intensity of WFS1 and control fibroblasts. Data are mean ± 
SEM. n = ≥ 5. No results were significantly different when compared to controls, 
two-tailed unpaired t test. 
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Figure 5.14 Western blot analyses of key Ca2+ channels and pumps in 
WFS1 fibroblasts. (A) Representative western blots of the IP3R, SERCA, 
VDAC and MCU in WFS1 and control fibroblasts. (B-E) Densitometric analysis 
of the (B) IP3R, (C) SERCA, (D) VDAC and (E) MCU levels normalized against 
tubulin. Data are mean ± SEM. n = ≥ 2. * p = ≤ 0.05, ** p = ≤ 0.01, two-tailed 
unpaired t test. 
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5.4 Discussion  
This study demonstrates that WFS1 mutations impair ER-mitochondrial Ca2+ flux at 
the MAM. A number of potential mechanisms underlying reduced Ca2+ flux were 
explored, but the exact nature of reduced mitochondrial Ca2+ uptake needs to be 
further clarified. Interestingly, one cell line carrying a dominant WFS1 mutation (W5) 
showed normal ER-mitochondrial Ca2+ flux and this was associated with increased 
mitochondrial-ER contact and upregulation of MCU expression. Although speculative, 
the latter could represent a secondary compensatory mechanism that partially 
alleviates the deleterious impact of this specific WFS1 mutation. 
Five primary fibroblast cell lines established from Wolfram syndrome patients 
were included in this study (Table 5.1). In agreement with previous studies, recessive 
WFS1 mutations caused complete loss of the Wolframin protein. Nonsense and 
frameshift mutations in the WFS1 gene have been shown to cause protein loss due 
to unstable WFS1 mRNA and subsequent nonsense mediated mRNA decay 
(Hofmann et al., 2003). Missense mutations in the WFS1 gene are suggested to 
cause Wolframin loss due to protein instability and rapid proteasomal degradation 
(Hofmann and Bauer, 2006). These mechanisms likely contribute to Wolframin loss in 
the fibroblasts harbouring recessive WFS1 mutations. In contrast, dominant 
missense mutations in WFS1 did not appear to affect the steady-state levels of 
Wolframin. However, there was variability in Wolframin expression across the control 
cell lines, including one control cell line showing notably increased Wolframin levels 
in comparison with the two other control cell lines. The pathogenic mechanisms of 
dominant WFS1 mutations still remain to be defined, although a dominant negative 
effect has been proposed (Hogewind et al., 2010; Rendtorff et al., 2011). 
No evidence of ER stress was observed in WFS1 fibroblasts by western blot 
analysis of the ER chaperones GRP94 or Bip suggesting that WFS1 mutations do not 
induce ER stress in primary fibroblast cell lines. Consistent with this observation, it 
has previously been demonstrated that Wolfram syndrome patient and control 
fibroblasts were not sensitive to treatment with a range of ER stress inducers 
including brefeldin A, thapsigargin, ionophore 2957, bradykinin and lactocysteine 
(Philbrook et al., 2005). ER stress induction in Wfs1 deficient mice was also found 
specifically in pancreatic β-cells and not in heart, skeletal muscle or brown adipose 
tissue (Yamada et al., 2006). Together, these results suggest that ER stress 
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induction due to WFS1 mutations is likely to be cell type specific. The induction of ER 
stress by WFS1 deficiency in pancreatic β-cells has been explained by the heavy 
demands placed on the ER in β-cells during insulin biosynthesis, which sensitizes β-
cells to disturbances in ER homeostasis (Fonseca et al., 2010). ER stress has also 
been described in WFS1 deficient neurones and in the retina of Wfs1 deficient mice 
(Gharanei et al., 2013; Bonnet Wersinger et al., 2014; Cagalinec et al., 2016). In 
order to conclusively confirm the absence of ER stress in WFS1 fibroblasts more 
sensitive methods such as qRT-PCR analysis of the UPR signalling pathways or 
luciferase based promoter assays that reflect UPR activation should be considered  
in addition to western blot analysis (Oslowski and Urano, 2011). 
Disturbed cellular Ca2+ homeostasis is emerging as a key pathogenic 
mechanism in Wolfram syndrome. Previous studies have primarily focused on the 
impact of WFS1 deficiency on Ca2+ homeostasis in the ER and cytosolic 
compartments. The transfer of Ca2+ from the ER to mitochondria is an important 
mechanism by which the ER and mitochondria communicate to maintain cellular 
homeostasis and was therefore assessed in WFS1 fibroblasts. Importantly, following 
IP3R dependent ER Ca
2+ release, significantly reduced peak mitochondrial Ca2+ 
levels were observed in WFS1 rec and W4 fibroblasts, demonstrating that WFS1 
mutations had a deleterious impact on Ca2+ flux between the ER and mitochondria. 
Interestingly, normal ER-mitochondrial Ca2+ flux was found in W5 fibroblasts. Only 
one study has previously assessed mitochondrial Ca2+ homeostasis secondary to 
WFS1 deficiency using WFS1 knockdown HEK293 cells (Takei et al., 2006). In this 
particular experimental model, peak mitochondrial [Ca2+] was significantly reduced 
upon Ca2+ readdition following ER Ca2+ depletion induced by cyclopiazonic acid 
(CPA; SERCA inhibitor) (Takei et al., 2006). This previous study is not entirely 
comparable with the present analysis of ER-mitochondrial Ca2+ flux in WFS1 
fibroblasts as two different methods of ER Ca2+ modulation were used. Nevertheless, 
both studies suggest that mitochondrial Ca2+ uptake is disturbed by WFS1 deficiency. 
MAM dysfunction is increasingly being implicated in other neurodegenerative 
disorders, establishing disturbed ER-mitochondria interactions as an important 
disease mechanism (Area-Gomez et al., 2012; Guardia-Laguarta et al., 2014). The 
reduced ER-mitochondrial Ca2+ flux found in WFS1 fibroblasts provides a potential 
mechanism by which WFS1 mutations could impact mitochondrial function.   
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No disturbance was observed in ER or cytosolic Ca2+ homeostasis in WFS1 
fibroblasts, which is in contrast with previous studies showing disturbed ER and 
cytosolic Ca2+ homeostasis in WFS1 deficient cells (Takei et al., 2006; Hara et al., 
2014; Lu et al., 2014; Cagalinec et al., 2016). Although, the results of this study are 
consistent with the normal ER Ca2+ homeostasis reported in WFS1 deficient 
neurones and the normal basal cytosolic [Ca2+] observed in a WFS1 depleted MIN6 
insulinoma cell line (Zatyka et al., 2015; Cagalinec et al., 2016). Contrasting results 
have been reported in the different WFS1 deficient models that have been 
characterised, including pancreatic β-cell lines, neuronal cell lines, HEK293 cells, and 
the Wolfram syndrome fibroblasts used in this study. The effect of WFS1 deficiency 
on cellular Ca2+ homeostasis therefore appears to be cell type dependent. One 
limitation of this study is that fibroblasts may not be fully representative of the 
neuropathology of Wolfram syndrome and it would preferable to study the neuronal 
populations that are affected in this disorder, including RGCs. Fibroblasts have been 
shown to be resistant against most stressors and it is likely that fibroblasts are less 
susceptible to WFS1 deficiency than pancreatic β or neuronal cell lines, which are 
anatomically and functionally more complex cell types (Philbrook et al., 2005; 
Auburger et al., 2012).  
A number of potential molecular mechanisms underlying reduced                           
ER-mitochondrial Ca2+ flux in WFS1 fibroblasts were investigated including                     
ER-mitochondrial interactions, mitochondrial membrane potential and protein 
expression of Ca2+ channels. However, WFS1 fibroblasts that previously showed 
reduced ER-mitochondrial Ca2+ flux showed no significant disturbance in any of these 
parameters. Additionally, measurement of ER Ca2+ demonstrated that reduced                 
ER-mitochondrial Ca2+ flux was not due to depletion of the ER Ca2+ store. In contrast, 
W5 fibroblasts, showed significantly increased mitochondrial-ER association and 
upregulation of MCU expression. Increased ER-mitochondrial areas of contact are 
known to correlate with increased mitochondria Ca2+ uptake following ER Ca2+ 
release (Csordas et al., 2006). Moreover, MCU overexpression has been shown to 
increase mitochondrial Ca2+ buffering following agonist-induced IP3R-dependent ER 
Ca2+ release, which in turn decreased cytosolic Ca2+ transients (De Stefani et al., 
2011). The increased ER-mitochondrial apposition and the greater MCU expression 
in W5 fibroblasts could therefore represent a compensatory mechanism to maintain 
 89 
mitochondrial Ca2+ uptake. These observations can explain the normal mitochondrial 
transients and significantly reduced peak of cytosolic Ca2+ transients observed in W5 
fibroblasts. It is unclear why W5 fibroblasts have a different cellular phenotype to the 
WFS1 rec and W4 fibroblasts. The p.A684V mutation in W5 fibroblasts has 
previously been reported in six families with Wolfram syndrome so there can be no 
doubt about its pathogenicity (Rendtorff et al., 2011). Further studies are required to 
investigate the apparent compensatory mechanisms that are active in W5 fibroblasts 
as these could help inform possible therapeutic strategies.  
The observations in W5 fibroblasts confirm that the assays used to measure 
ER-mitochondrial apposition and Ca2+ channel expression are sensitive enough to 
identify any disturbance in the WFS1 fibroblasts with reduced ER-mitochondria Ca2+ 
flux. Nevertheless, there are limitations to the ER-mitochondria imaging analysis 
used for this study on WFS1 fibroblasts, including the spatial resolution limits of 
confocal microscopy. Furthermore, western blot analysis does not exclude a 
functional defect in the Ca2+ signalling apparatus at the MAM. A recent study has 
demonstrated that IP3R mediated Ca
2+ release is reduced in WFS1 deficient 
neurones (Cagalinec et al., 2016). It is possible that a similar mechanism is active in 
WFS1 fibroblasts and is responsible for the reduced mitochondrial Ca2+ uptake 
following IP3R-dependent ER Ca
2+ release. Future investigations should determine 
whether Wolframin directly interacts with and regulates the IP3R. Moreover, 
investigation of the MAM domain with higher resolution imaging modalities such as 
electron microscopy and quantification of the IP3R and VDAC interaction would 
further clarify the nature of mitochondrial Ca2+ defect in WFS1 fibroblasts (Tubbs et 
al., 2014). These investigations may also further elucidate the molecular mechanism 
underlying the compensatory response in W5 fibroblasts.  
Finally, SERCA expression was assessed in WFS1 fibroblasts. It has 
previously been demonstrated that Wolframin is involved in the regulation of SERCA 
and that SERCA levels are increased in WFS1 depleted cells (Zatyka et al., 2015). In 
agreement with this previous study, SERCA levels were significantly increased in all 
the WFS1 fibroblasts, except for W5 fibroblasts. Increased SERCA expression did 
not correlate with any disturbance in basal ER Ca2+ levels or peak cytosolic [Ca2+] 
following SERCA inhibition in WFS1 fibroblasts. Further investigations are required to 
determine the impact of increased SERCA expression in WFS1 fibroblasts.    
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In summary, this study demonstrates a functional defect in the                               
ER-mitochondrial interaction in fibroblasts harbouring recessive or dominant WFS1 
mutations, thus, providing a powerful mechanism by which WFS1 mutations can 
disturb mitochondrial function (Figure 5.15). The reduced ER-mitochondrial Ca2+ flux 
could impact on a host of mitochondrial functions regulated by Ca2+ uptake such as 
OXPHOS and mitochondrial-mediated apoptosis. These pathological mechanisms 
are likely to be relevant to the underlying neuropathology of Wolfram syndrome, and 
these results support mitochondrial dysfunction as a key player that could potentially 
be modulated to slow or halt disease progression for patients with progressive and 
disabling visual loss and neurological deficits. 
 
WFS1 fibroblasts 
Figure 5.15 Schematic model highlighting the proposed dysfunction in 
WFS1 fibroblasts. WFS1 mutations had a deleterious impact on                             
ER-mitochondrial Ca2+ flux. No difference was found in ER Ca2+ levels,                      
ER-mitochondrial apposition or expression level of key Ca2+ channels, although, 
SERCA levels were increased. 
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Chapter 6. Mitochondrial Function in Wolfram Syndrome 1 
6.1 Introduction 
The functional interaction between the ER and mitochondria at the MAM is critical for 
cellular homeostasis and MAM dysfunction is increasingly being recognised as an 
important contributor to both monogenic and complex neurodegenerative diseases 
(Paillusson et al., 2016). As described in Chapter 5, fibroblasts established from 
patients with Wolfram syndrome harbouring dominant or recessive WFS1 mutations 
showed evidence of disturbed ER-mitochondrial interactions. An important 
observation was that WFS1 mutations had a deleterious impact on ER-mitochondrial 
Ca2+ transfer. 
The transfer of Ca2+ from the ER to the mitochondria is an essential function of 
the MAM and regulates cellular Ca2+ homeostasis, mitochondrial bioenergetics and 
mitochondrial-mediated apoptosis (van Vliet et al., 2014). Under basal conditions, 
ER-mitochondrial Ca2+ transfer is necessary to stimulate OXPHOS and maintain ATP 
synthesis (Cardenas et al., 2010). A rise in mitochondrial matrix Ca2+ promotes 
respiration and ATP production by stimulating the Ca2+-dependent dehydrogenases 
of the TCA cycle, increasing the production of reducing equivalents which drive the 
respiratory chain, and by activating complex V (Glancy and Balaban, 2012). 
Conversely, excessive mitochondrial Ca2+ uptake is associated with the induction of 
cell death and factors that decrease or increase ER-mitochondrial Ca2+ flux have 
been shown to reduce or enhance the susceptibility of cells to apoptosis induction, 
respectively (Bononi et al., 2013).  
To determine the consequences of disturbed ER-mitochondrial interactions on 
mitochondrial function in Wolfram syndrome, mitochondrial bioenergetics and cell 
viability were characterised in WFS1 fibroblasts (Table 5.1). OXPHOS function was 
determined by measuring mitochondrial respiration, cellular ATP content and ROS 
levels. Cell viability was assessed under basal conditions and following the treatment 
with selected cellular stressors including STS, a non-specific kinase inhibitor that 
induces apoptosis; t-BH, an oxidative stressor that has also been suggested to 
mobilise Ca2+ from the ER to the mitochondria (Bononi et al., 2013); and 
thapsigargin, an inhibitor of the SERCA that induces ER stress through ER Ca2  
depletion (Zatyka et al., 2015).  
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6.2 Results 
6.2.1 Analysis of mitochondrial respiration in WFS1 fibroblasts  
To investigate mitochondrial respiratory function, OCR was measured in intact WFS1 
and control fibroblasts using the Seahorse XFe Extracellular Flux Analyzer. OCR was 
measured at basal and following the sequential addition of: (i) oligomycin to inhibit 
complex V, (ii) FCCP to measure maximal uncoupler stimulated OCR and (iii) 
rotenone together with antimycin A to inhibit mitochondrial respiration and measure 
non-mitochondrial OCR (Figure 6.1).  
 
 
 
 
 
 
 
 
Four parameters of mitochondrial respiratory function were calculated as described in 
Section 3.11.1: (i) basal respiration, (ii) ATP-linked respiration, (iii) proton leak and 
(iv) maximal respiration. A disturbance in one or more of these parameters would be 
indicative of disturbed respiratory function. However, no significant difference was 
observed in all four parameters in WFS1 rec and W4 fibroblasts compared to controls 
(Figure 6.2). Surprisingly, W5 fibroblasts showed significantly increased OCR in all 
four parameters when compared to controls (Figure 6.2).  
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Figure 6.1 Representative Seahorse measurement of OCR in WFS1 
fibroblasts. Example OCR traces for WFS1 rec (dark blue), W4 (blue), W5 
(light blue) and control (black) fibroblasts. Oligomycin (Oligo), FCCP and 
rotenone/antimycin A (Rot/AA) were added where indicated. 
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Figure 6.2 Parameters of mitochondrial respiratory function in WFS1 fibroblasts determined by 
Seahorse analysis. (A) Basal respiration. (B) ATP-linked respiration. (C) Proton Leak. (D) Maximal 
Respiration. Data are mean ± SEM. n = 3. * p = ≤ 0.05, ** p = ≤ 0.01, two-tailed unpaired t test. 
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6.2.2 Complex I-dependent respiration is reduced in WFS1 fibroblasts  
To assess the absence of a respiratory defect in WFS1 fibroblasts with reduced 
mitochondrial Ca2+ uptake, complex I-dependent respiration and complex II-
dependent respiration were assessed in permeabilized WFS1 and control fibroblasts 
with the Oxygraph respirometer (Figure 6.3A). The results were expressed as flux 
control ratios.  
The CI/(CI+CII) ratio which indicates complex I-dependent respiration was 
significantly reduced compared to controls in WFS1 rec and W4 fibroblasts. In 
contrast, the CI/(CI+CII) ratio was not significantly different between controls and W5 
fibroblasts (Figure 6.3B). No significant difference was observed in the CII/(CI+CII) 
ratios between WFS1 and control fibroblasts (Figure 6.3C), indicating complex II-
dependent respiration is normal in WFS1 fibroblasts.   
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Figure 6.3 Complex I-dependent respiration is reduced in WFS1 fibroblasts. (A) Example Oxygraph traces of 
permeabilized WFS1 (blue) and control (red) fibroblasts. Substrates and inhibitors were added where indicated. CI, CII 
and CI+CII respiration were determined as shown. (B, C) Analysis of (B) CI/(CI+CII) and (C) CII/(CI+CII) ratios in 
permeabilized WFS1 and control fibroblasts. Data are mean ± SEM. n = ≥ 3. * p = ≤ 0.05, two-tailed unpaired t test. 
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6.2.3 Pyruvate dehydrogenase regulation in WFS1 fibroblast 
To further investigate the reduced complex I-dependent respiration observed in 
WFS1 fibroblasts the phosphorylation status of the PDH (pPDH) at serine 293 was 
assessed by western blot analysis. However, no significant difference was observed 
in PDH phosphorylation between WFS1 and control fibroblasts (Figure 6.4). 
Suggesting that substrate flux through the PDH is not disturbed in WFS1 fibroblasts 
under basal conditions. 
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Figure 6.4 PDH regulation in WFS1 fibroblast. (A) Representative western 
blots of pPDH and total PDH in WFS1 and control fibroblasts. (B) Densitometric 
analysis of pPDH levels normalized against total PDH. Data are mean ± SEM.    
n = 3. No results were significantly different when compared to controls,                   
two-tailed unpaired t test. 
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6.2.4 Analysis of ATP content in WFS1 fibroblasts 
To conclude the OXPHOS analysis, ATP content was determined in WFS1 and 
control fibroblasts with the CellTiter-Glo ATP assay, in which luminescence signal is 
proportional to ATP content. For a thorough analysis, ATP content was determined 
under four conditions: (i) glucose, (ii) 2-DG, (iii) oligomycin and (iv) 2-DG and 
oligomycin, as described in Section 3.11.3. ATP content was depleted under 2-DG 
and oligomycin in all cell lines, confirming the assay functioned as expected (Figure 
6.5).  
ATP content was normal in WFS1 rec and W4 fibroblasts under all four assay 
conditions, confirming the lack of a severe OXPHOS defect in these fibroblasts 
(Figure 6.5). In contrast, ATP content was increased under glucose and significantly 
increased under 2-DG conditions in W5 fibroblasts compared to controls (Figure 
6.5). Notably, 2-DG treatment resulted in decreased ATP content in comparison to 
glucose in all cell lines except W5 fibroblasts where ATP content was mostly 
maintained. Moreover, no significant difference was observed between W5 
fibroblasts and controls under oligomycin conditions, where fibroblasts are reliant on 
glycolysis for ATP, further suggesting that the increased ATP content in W5 
fibroblasts is directly related to OXPHOS function (Figure 6.5).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 ATP content in WFS1 fibroblasts. ATP content was assessed in 
WFS1 and control fibroblasts under four conditions: glucose, 2-DG, oligomycin 
(oligo) and 2-DG+oligo. Data are mean ± SEM. n = 4. * p = ≤ 0.05, two-tailed 
unpaired t test   
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6.2.5 Determination of ROS levels in WFS1 fibroblasts  
ROS levels were assessed in WFS1 and control fibroblasts using H2DCFDA, an 
indicator of generalised oxidative stress that fluoresces upon oxidation. ROS levels 
were determined under basal conditions and following H202 treatment as a positive 
control. As expected, H202 treatment increased ROS levels compared to basal 
conditions. No significant difference was observed in ROS levels between WFS1 and 
control fibroblasts under either condition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Assessment of ROS levels in WFS1 fibroblasts using H2DCFDA. 
ROS levels at basal and following H202 treatment. Data are mean ± SEM. n = 3. 
No results were significantly different when compared to controls, two-tailed 
unpaired t test. 
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6.2.6 mtDNA Copy Number Analysis in WFS1 fibroblasts 
The copy number of mtDNA was measured via RT-qPCR in WFS1 and control 
fibroblasts. Amplification of the mtDNA gene ND1 was compared to the                        
nuclear-encoded gene B2M. No significant difference was observed in mtDNA copy 
number between WFS1 and control fibroblasts (Figure 6.7).     
 
 
 
 
 
6.2.7 Sensitivity of WFS1 fibroblasts to cell stressors 
Cell viability was determined in WFS1 and control fibroblasts following treatment with 
STS (1 µM), t-BH (200 µM) or thapsigargin (4 µM) at 2, 5 and 8 hours with the MTT 
assay.  No significant difference was observed in cell viability between WFS1 and 
control fibroblasts following treatment with STS or t-BH at all-time points (Figure 6.8 
A, B). Unexpectedly, following treatment with thapsigargin, cell viability was 
significantly increased in WFS1 rec and W4 fibroblasts compared with controls. In 
contrast, thapsigargin treatment seemed to reduce cell viability in W5 fibroblasts 
compared with controls, although this decrease was not statistically significant at any 
time point (Figure 6.8C).  
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Figure 6.7 mtDNA Copy Number in WFS1 fibroblasts. Data are mean ± 
SEM. n = 3. No results were significantly different when compared to controls, 
two-tailed unpaired t test. 
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Figure 6.8 Viability of WFS1 following treatment with cell stressors.                 
(A-C) Cell viability was determined in WFS1 and control fibroblasts following 
treatment with (A) STS (B) t-BH or (C) thapsigargin (Tg) at 2, 5 and 8 hours with 
the MTT assay. Data are mean ± SEM. n = ≥ 3. * p = ≤ 0.05, ** p = ≤ 0.01,                  
two-tailed unpaired t test.   
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6.2.8 Caspase 3 Activity 
Apoptosis induction is usually associated with caspase activation; therefore, 
measurement of caspase 3 activity determines whether cells are committed to 
irreversible apoptosis. Caspase 3 activity was assessed in WFS1 and control 
fibroblasts at basal condition and following treatment with STS (1 µM), t-BH (200 µM) 
or thapsigargin (4 µM) for 5 hours by measurement of Ac-DEVD-AFC substrate 
processing. Caspase 3 activity was not significantly different between WFS1 and 
control fibroblasts for all conditions (Figure 6.9). STS treatment induced increased 
levels of caspase 3 activity in all cell lines compared to basal conditions, suggesting 
the assay functioned as expected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 Caspase 3 activities in WFS1 fibroblasts following treatment 
with cell stressors. Caspase 3 activity was determined in WFS1 and control 
fibroblasts using Ac-DEVD-AFC substrate processing under basal conditions 
and following treatment with STS, t-BH or thapsigargin for 5 hours. Data are 
mean ± SEM. n = 3. No results were significantly different when compared to 
controls, two-tailed unpaired t test.   
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6.3 Discussion 
This study investigated the downstream consequences of disturbed ER-mitochondrial 
interactions in fibroblasts established from Wolfram syndrome patients with WFS1 
mutations by characterising mitochondrial bioenergetics and cell viability. No severe 
OXPHOS defect was observed in WFS1 rec or W4 fibroblasts, which previously 
showed reduced ER-mitochondrial Ca2+ flux. However, these fibroblasts did have a 
selective decrease in complex I-dependent respiration, which has previously been 
reported in cell lines harbouring pathogenic OPA1 mutations or the primary LHON 
mtDNA mutations (Baracca et al., 2005; Chevrollier et al., 2008; Zanna et al., 2008). 
In contrast, OXPHOS was significantly enhanced in W5 fibroblasts, which had normal 
mitochondrial Ca2+ uptake. Interestingly, WFS1 rec and W4 fibroblasts were less 
sensitive to treatment with the ER stressor thapsigargin. This observation contrasts 
with the enhanced susceptibility to ER stress induced cell death found in WFS1 
deficient β-cells (Ishihara et al., 2004; Fonseca et al., 2005; Yamada et al., 2006). 
Despite the reduced ER-mitochondrial Ca2+ transfer, no severe OXPHOS 
defect was found in intact WFS1 rec or W4 fibroblasts. In particular, basal respiration, 
FCCP stimulated maximal respiration and ATP content under ‘forced OXPHOS’ (2-
DG) conditions were comparable to controls. These results are consistent with 
previous investigations of muscle biopsies from patients with Wolfram syndrome that 
did not reveal any evidence of marked respiratory chain dysfunction (Jackson et al., 
1994; Barrett et al., 1995b). In contrast, WFS1 deficient neurones showed decreased 
mitochondrial membrane potential together with lower cytosolic ATP levels and a 
WFS1 depleted MIN6 insulinoma cell line presented with decreased total ATP 
content and an impaired ATP rise in response to high glucose (Zatyka et al., 2015; 
Cagalinec et al., 2016). Only low level Ca2+ transfer was found necessary to maintain 
OXPHOS in lymphocyte cells and it is possible that the observed decrease in 
mitochondrial Ca2+ uptake is not sufficient to adversely affect mitochondrial 
bioenergetics in WFS1 fibroblasts (Cardenas et al., 2010). Furthermore, WFS1 
mutations in fibroblasts, unlike the situation in neuronal population including RGCs, 
may not stress mitochondria to the point where relevant disease-associated changes 
are evident. It is likely that WFS1 deficient neuronal or pancreatic β cells are less 
tolerant of disturbed Ca2+ homeostasis and are more likely to show mitochondrial 
dysfunction (Wiley et al., 2013).  
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Interestingly, W5 fibroblasts showed significantly enhanced OXPHOS activity, 
highlighted by increased ATP-linked respiration and increased ATP content under 
‘forced OXPHOS’ conditions. Increased OXPHOS has previously been described in 
lymphoblastoid cell lines established from OPA1-linked DOA patients that maintained 
visual function, indicating that increased OXPHOS is likely a compensatory response 
to pathogenic mutations (Van Bergen et al., 2011). The enhanced OXPHOS 
observed in W5 fibroblasts is therefore likely part of the compensatory response to 
WFS1 mutation that appears to be active in this cell line. It remains to be determined 
how enhanced OXPHOS is related to the remodelling of the ER-mitochondrial axis 
observed in W5 fibroblasts. No difference was observed in mitochondrial mass or 
mtDNA copy number in W5 fibroblasts suggesting that increased mitochondrial 
biogenesis does not underlie the compensatory mechanism in W5 fibroblasts. Further 
investigations are required to determine the molecular mechanisms underlying this 
compensatory response.   
Although no severe OXPHOS defect was found in intact WFS1 fibroblasts, 
reduced complex I-dependent respiration was observed in WFS1 rec and W4 
fibroblasts upon site-specific analysis of the mitochondrial respiratory chain. This 
defect was not found in W5 fibroblasts suggesting that it is specifically related to 
disturbed ER-mitochondrial Ca2+ flux. Isolated complex I-deficiency is the most 
frequently observed defect of mitochondrial bioenergetics (Distelmaier et al., 2009). 
Importantly, complex I-deficiency is a common feature of mitochondrial optic 
neuropathies and has been previously described in studies of LHON and DOA 
(Baracca et al., 2005; Chevrollier et al., 2008; Zanna et al., 2008). This suggests that 
a common biochemical is shared by Wolfram syndrome, LHON and DOA. Similar to 
fibroblasts established from LHON or DOA patients, WFS1 fibroblasts appear to 
compensate for the reduced complex I-dependent respiration as no difference was 
observed in respiratory capacity or ATP content in intact WFS1 fibroblasts (Baracca 
et al., 2005; Zanna et al., 2008). It is possible that the complex I-deficiency is only 
apparent when the substrates available for respiration are controlled, in this case 
pyruvate and malate, and the defect might not be due to primary respiratory chain 
dysfunction, but rather decreased PDH activity, which is activated by a                             
Ca2+-dependent pyruvate dehydrogenase phosphatase (Denton, 2009). PDH activity 
could therefore be perturbed secondary to the reduced mitochondrial Ca2+ uptake in 
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WFS1 fibroblasts. However, no difference was observed in the phosphorylation 
status of the PDH at serine 293 suggesting that PDH regulation, at least in the basal 
state, is not disturbed in WFS1 fibroblasts. Further investigations are required to 
determine the nature of the complex I defect in WFS1 fibroblasts. Analysis of 
complex I-dependent respiration with different substrates, such as glutamate and 
malate, and blue native electrophoresis followed by in-gel catalytic activity assays 
would clarify how the OXPHOS system is perturbed in WFS1 fibroblasts (Wittig et al., 
2007). Further investigation of the PDH in WFS1 fibroblasts should include analysis 
of the three PDH phosphorylation sites, PDH enzyme activity and the cellular 
NAD/NADH ratio at basal and under galactose conditions (to shift ATP production to 
OXPHOS) (Rardin et al., 2009; Wiley et al., 2013).  
ROS homeostasis is critical for cellular function and excessive ROS levels 
have been reported in many neurodegenerative diseases, including LHON and DOA 
(Yarosh et al., 2008; Tang et al., 2009; Lin et al., 2012). ROS levels, assessed by 
H2DCFDA, were normal in WFS1 fibroblasts. However, H2DCFDA has various 
limitations and reacts with a broad range of cellular ROS (Kalyanaraman et al., 
2012). Further investigations are required to confirm the absence of oxidative stress 
in WFS1 fibroblasts.  
No difference was observed in cell viability between WFS1 and control 
fibroblasts following treatment with STS or t-BH. This suggests that decreased Ca2+ 
flux does not affect Ca2+ mediated cell death in WFS1 fibroblasts. Surprisingly, WFS1 
rec and W4 fibroblasts were less susceptible to thapsigargin treatment than controls, 
demonstrated by increased viability of these fibroblasts at all time points on the MTT 
assay. This observation compares with previous investigations of Wolfram syndrome 
patient fibroblasts, where cell death was not detected following treatment with a 
range of ER stressors including thapsigargin (Philbrook et al., 2005). In contrast, 
WFS1 deficient pancreatic β-cells showed increased susceptibility to ER stress 
induced apoptosis (Yamada et al., 2006). Overall, these findings imply that increased 
susceptibility to ER stress-induced cell death is not present in a primary fibroblast 
model of Wolfram syndrome. Although ER stress sensitivity has been excluded, the 
reasons why WFS1 rec and W4 fibroblasts are less susceptible to thapsigargin 
treatment remain unknown. Increased SERCA expression has previously been 
described in thapsigargin resistant hamster smooth muscle cells (Rishi et al., 1998). 
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It is possible that a similar mechanism is active in the WFS1 fibroblasts as SERCA 
expression was found to be significantly increased in WFS1 rec and W4 fibroblasts 
compared to controls. 
One limitation of these conclusions is that measurement of cell viability via the 
MTT assay indicates metabolic activity rather than cell death. Caspase 3 activity was 
assessed in WFS1 fibroblasts following treatment with cellular stressors; however, 
the assay had limitations including large variation between assay replicates. 
Following treatment with t-BH or thapsigargin, caspase 3 activity was similar to basal 
conditions in all cell lines, indicating that caspase 3-dependent apoptosis was not 
measured under these conditions.  Caspase 3 has previously been shown to be 
involved in t-BH and thapsigargin induced cell death, suggesting that cell death 
following treatment is unlikely to be caspase 3 independent (Dahmer, 2005; Bononi 
et al., 2013).  It is possible that caspase 3 activity was not increased at the time point 
measured in the present assay. Further work is required to conclusively confirm the 
absence of a defect in Ca2+-mediated apoptosis or lack of ER stressor sensitivity in 
WFS1 fibroblasts. 
In summary, this study has shown that disturbed ER-mitochondrial interactions 
in WFS1 fibroblasts results in impairment of complex I-dependent respiration. WFS1 
fibroblasts are able to compensate and maintain OXPHOS function in intact cells. 
The present data provides clues to the disease mechanisms of Wolfram syndrome 
and these results further support the hypothesis that mitochondrial dysfunction plays 
an important role in Wolfram syndrome, providing an attractive target for therapeutic 
modulation. 
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Figure 6.10 Schematic highlighting the mitochondrial parameters 
investigated in WFS1 fibroblasts. OXPHOS function, ROS levels and mtDNA 
copy number was assessed in WFS1 fibroblasts. No gross OXPHOS defect 
was found in WFS1 fibroblasts with reduced Ca2+ uptake, however, these cells 
did show a selective decrease in complex I-dependent respiration. There was 
no disturbance found in ROS levels or mtDNA copy number. 
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Chapter 7. Investigation of Disease Mechanisms in Wolfram        
Syndrome 2 
7.1 Introduction 
WFS2 is a rare disorder caused by recessive mutations in the CISD2 gene (Amr et 
al., 2007). Patients with WFS2 manifest the main clinical features of Wolfram 
syndrome, namely optic atrophy and diabetes, but in addition, they have distinct 
phenotypic features that include peptic ulcers, bleeding tendencies secondary to 
defective platelet aggregation and the absence of diabetes insipidus (El-Shanti et al., 
2000). To date, WFS2 has been described in 13 patients across six families (Amr et 
al., 2007; Mozzillo et al., 2014; Rondinelli et al., 2015). 
Interestingly, both WFS1 and CISD2 encode transmembrane proteins 
localised to the ER that appear to regulate cellular Ca2+ homeostasis. Moreover, 
deficiencies in both genes are associated with mitochondrial abnormalities that are 
potentially secondary to disrupted cytosolic Ca2+ signalling and/or disturbed                        
ER-mitochondrial interactions at the MAM (Amr et al., 2007; Wiley et al., 2013; Lu et 
al., 2014; Cagalinec et al., 2016). Wolframin and CISD2 have both been localised to 
the MAM suggesting they have roles within this domain, a key function of which is the 
transfer of Ca2+ from the ER to mitochondria, which in turn regulates cellular Ca2+ 
signalling, mitochondrial bioenergetics and apoptosis (Wiley et al., 2013; Horner et 
al., 2015).  
However, it is unclear how CISD2 regulates Ca2+ homeostasis and there is no 
consensus on how CISD2 loss of function disrupts Ca2+ homeostasis in the three 
main cellular Ca2+ compartments: the ER, the cytosol and mitochondria (Amr et al., 
2007; Chang et al., 2012; Wiley et al., 2013; Wang et al., 2014). In addition, only one 
study has assessed cellular Ca2+ homeostasis secondary to pathogenic CISD2 
mutations and the analysis was restricted to the cytosol (Amr et al., 2007). Further 
studies are required to understand the disease mechanisms of WFS2, specifically 
how pathogenic CISD2 mutations affect cellular Ca2+ homeostasis and the MAM 
domain, and whether WFS1 and WFS2 share overlapping pathological pathways. 
The present study used a fibroblast cell line established from a patient harbouring a 
novel homozygous CISD2 mutation to investigate how cellular Ca2+ homeostasis, the 
mitochondria-ER axis and mitochondrial function are affected in this disorder.  
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7.2 Methods 
7.2.1 Patient Cohort 
The patient is a Moroccan male born from consanguineous parents. He developed 
diabetes mellitus at age 8 and progressive visual impairment first attributed to 
diabetic retinopathy. At age 45, neurological examination showed cerebellar ataxia, 
myoclonic tremor, dysarthria, dysexecutive syndrome and pseudobulbar affect. Brain 
MRI showed supra- and infratentorial brain atrophy. Ophthalmological examination 
with fundoscopy and OCT revealed bilateral optic atrophy without evidence of 
diabetic retinopathy. Visual acuity without correction was 1/20 (right eye) and 1/10 
(left eye). The patient had a normal audiogram and there was no evidence of 
diabetes insipidus, haematologic abnormalities, peptic ulcers or urinary tract 
abnormalities. 
Screening of the WFS1 and CISD2 genes revealed a novel homozygous CISD2 
mutation (c.215 A>G, p.Asn72Ser). In support of pathogenicity, the mutation 
segregated with the disease in the family, modified a highly conserved amino acid, 
was absent from control databases and was predicted to be pathogenic by in silico 
analysis and 3D structural analysis.  
Fibroblasts (referred to as CISD2 fibroblasts) were established from the patient. 
Western blot analysis revealed no significant difference in the expression level of the 
CISD2 protein between CISD2 and control fibroblasts. The patient information, 
CISD2 western blot analysis and CISD2 fibroblasts were provided by Dr Cécile 
Rouzier and Professor Véronique Paquis-Flucklinger (Nice Sophia-Antipolis 
University) as part of an ongoing collaboration with Dr Patrick Yu-Wai-Man. Three 
control fibroblast cell lines were included for comparison (Table 5.2). 
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Figure 7.1 Imaging the D1ER probe. (A.B) Representative confocal images of 
CISD2 fibroblasts expressing D1ER: (A) the CFP signal and (B) the YFP signal. 
The reticular pattern is indicative of ER localisation. Regions of interest were 
analysed using Fiji. 
7.3 Results 
7.3.1 ER Ca2+ levels are not disturbed in CISD2 fibroblasts  
FRET experiments using the ER-targeted cameleon probe, D1ER, were performed to 
assess ER Ca2+ levels in CISD2 fibroblasts. Briefly, the FRET signal produced from 
CFP to the YFP upon D1ER binding of Ca2+ enabled the ratiometric assessment of 
free ER Ca2+ using the FRET to CFP ratio (Figure 7.1).  
 
  
 
 
 
 
 
 
 
 
 
There was a trend for slightly increased FRET/CFP ratios in the CISD2 
fibroblasts (Figure 7.2), although there was no statistical significant difference when 
compared with controls. This suggests that there is no gross variation in basal ER 
Ca2+ levels between CISD2 and control fibroblasts. 
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7.3.2 CISD2 fibroblasts show increased cytosolic [Ca2+]  
The ratiometric Ca2+ sensitive fluorescent dye Fura-2-am was used to measure 
cytosolic [Ca2+] in CISD2 and control fibroblasts at basal and following thapsigargin 
induced ER Ca2+ depletion. Basal cytosolic [Ca2+] was significantly increased in 
CISD2 fibroblasts when compared with controls (Figure 7.3).  
 
 
 
 
 
 
 
 
 
Figure 7.2 Evaluation of ER Ca2+ levels with the D1ER probe. Comparison 
of the average FRET/CFP ratios of CISD2 and control fibroblasts. Data are 
mean ± SEM. n = ≥ 16. No significant difference when compared to controls, 
two-tailed unpaired t test. 
Figure 7.3 Increased cytosolic [Ca2+] in CISD2 fibroblasts. Comparison of 
cytosolic [Ca2+] in CISD2 and control fibroblast. Data are mean ± SEM. n = 3.          
** p = ≤0.01, two-tailed unpaired t test. 
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Peak cytosolic [Ca2+] following thapsigargin treatment was similar between 
CISD2 and control fibroblasts (Figure 7.4A), whereas, thapsigargin sensitive Ca2+ 
stores, defined as the difference between peak cytosolic [Ca2+] and basal cytosolic 
[Ca2+], were decreased in CISD2 fibroblasts in comparison to controls, although this 
decrease did not quite reach statistical significance (Figure 7.4B). 
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Figure 7.4 Analysis of thapsigargin induced ER Ca2+ depletion in CISD2 
fibroblasts. Comparison of (A) peak cytosolic [Ca2+] levels after thapsigargin 
treatment and (B) thapsigargin (Tg)-sensitive Ca2+ stores in CISD2 and control 
fibroblasts. Data are mean ± SEM. n = 3. No results were significantly different 
when compared to controls, two-tailed unpaired t test. 
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7.3.3 ER to Mitochondrial Ca2+ flux is increased in CISD2 fibroblasts 
To evaluate Ca2+ flux between the ER and mitochondria in CISD2 fibroblasts, 
histamine stimulated IP3R-dependent ER Ca
2+ transients were monitored in the 
mitochondria and cytosol with the Ca2+ sensitive fluorescent dyes Rhod-2-AM and 
Fluo-4-AM, respectively (Figure 7.5). Peak mitochondrial Ca2+ levels following 
histamine stimulation were significantly increased in CISD2 fibroblasts compared to 
controls (Figure 7.6A). In contrast, peak cytosolic Ca2+ levels were significantly 
decreased in CISD2 fibroblasts in comparison to controls (Figure 7.6C). 
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Figure 7.5 Imaging of cellular Ca2+ flux with Ca2+ sensitive fluorescent 
dyes. (A-D) Representative images demonstrating analysis of (A, B) 
mitochondrial Ca2+ with Rhod-2-AM (red) and (C, D) cytosolic Ca2+ with Fluo-4-
AM (green) before and after histamine stimulation. Regions of interest were 
analysed using Fiji.  
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Figure 7.6 Disturbed Ca2+ flux in CISD2 fibroblasts. (A, C) Analysis of average peak (A) mitochondrial 
and (C) cytosolic Ca2+ levels following histamine induced ER Ca2+ release in CISD2 and control 
fibroblasts. Data are mean ± SEM. n = ≥ 14. * p = ≤ 0.05, two-tailed unpaired t test. (B, D) Representative 
traces of (B) mitochondrial and (D) cytosolic Ca2+ transients in CISD2 and control fibroblasts. Where 
indicated the cells were stimulated with histamine.   
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7.3.4 ER-mitochondrial contact is increased in CISD2 fibroblasts 
ER-mitochondrial contact is critical for mitochondrial Ca2+ uptake following ER Ca2+ 
release and was therefore assessed in CISD2 fibroblasts. Briefly, GFP Sec61β was 
transfected to visualize the ER and MitoTracker Red was loaded to label the 
mitochondrial network. Z-axis stacks were acquired by confocal microscopy for 3D-
reconstruction and colocalisation analysis was performed using the Manders’ 
Coefficient: M1 and M2 in Huygens Object Analyser (Figure 7.8). M1 indicates the 
fraction of ER that colocalises with mitochondria and M2 indicates the fraction of 
mitochondria that colocalises with ER. Both Manders’ coefficient M1 and M2 were 
significantly increased in CISD2 fibroblasts compared to controls (Figure 7.7).    
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Figure 7.7 Increased ER-mitochondrial contacts in CISD2 fibroblasts.     
(A-B) Analysis of (A) Manders’ coefficient M1 ER/Mitochondrial (Mito) 
colocalisation and (B) Manders’ coefficient M2 Mito/ER colocalisation in CISD2 
and control fibroblasts. Data are mean ± SEM. n = ≥ 26. *** p ≤0.0001, * p = 
≤0.05, two-tailed unpaired t test. 
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Figure 7.8 Representative images of the ER and mitochondrial network in control and CISD2 fibroblasts.                      
(A, D) Fibroblasts were transfected with GFP Sec61β to label ER and (B, E) loaded with MitoTracker Red to label mitochondria, 
signal acquisition was performed simultaneously. Cell lines are indicated. (C, F) Analysis was performed on merged images.        
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7.3.5 CISD2 fibroblasts show an elongated mitochondrial network 
In parallel with the analysis of ER-mitochondria contacts, mitochondrial network 
morphology and ER volume were investigated in CISD2 and control fibroblasts. The 
mitochondrial network appeared more fused and elongated in CISD2 fibroblasts in 
comparison with controls (Figure 7.8 B, E). To obtain a robust analysis of the 
mitochondrial network morphology Huygens Essentials Software was used to 
measure the length and volume of each mitochondrial fragment within the 
mitochondrial network in 3D-reconstructions of CISD2 and control fibroblasts (Figure 
7.9).  
 
 
 
 
 
 
 
 
 
 
 
 
As expected from the gross morphological analysis the average length of 
mitochondrial fragments was significantly increased in CISD2 fibroblasts compared 
with controls (Figure 7.10A). Likewise, the average volume of mitochondrial 
fragments was significantly increased in CISD2 fibroblasts compared with controls 
(Figure 7.10B). Furthermore, the total number of mitochondrial fragments was 
significantly decreased in CISD2 fibroblasts in comparison with controls (Figure 
7.10C). Taken together, these results suggest that the mitochondrial network is more 
fused and elongated in CISD2 fibroblasts than in controls. 
 
Control CISD2 
Figure 7.9 Example 3D-reconstructed mitochondrial networks in control 
and CISD2 fibroblasts. Huygens Object Analyzer was used to determine the 
length and volume of each mitochondrial fragment. Cell lines are indicated. 
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Figure 7.10 Altered mitochondrial fragment morphology in CISD2 
fibroblasts. Analysis of average (A) mitochondrial fragment length, (B) 
mitochondrial fragment volume and (C) number of mitochondrial fragments in 
CISD2 and control fibroblasts. Data are mean ± SEM. n = ≥ 25. *** p = ≤0.0001,                            
** p = ≤0.01, two-tailed unpaired t test. 
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The distribution of the length and volume of mitochondrial fragments in CISD2 
fibroblasts and controls were also evaluated, with individual mitochondrial fragments 
being sorted into bins based on their length and volume. There was a shift in 
mitochondrial fragment morphology in CISD2 fibroblasts, with significantly more 
‘larger fragments’ and significantly less ‘smaller fragments’ for both length and 
volume in CISD2 fibroblasts compared to controls (Figure 7.11).    
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Figure 7.11 Distribution of the length and volume of mitochondrial 
fragments in CISD2 fibroblasts. Data are mean ± SEM. n = ≥ 25.  *** p = ≤ 
0.001, * p = ≤ 0.05, two-tailed unpaired t test. 
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To conclude the analysis of the mitochondrial network in CISD2 fibroblasts the 
total length and volume of the mitochondrial network was compared between CISD2 
and control fibroblasts. Despite an increased average fragment length, the total 
length of the mitochondrial network was significantly decreased in CISD2 fibroblasts 
compared to controls (Figure 7.12A). In contrast, the total volume of the 
mitochondrial network was significantly increased in CISD2 fibroblasts in comparison 
to controls (Figure 7.12B). 
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Figure 7.12 Altered mitochondrial network morphology in CISD2 
fibroblasts. Analysis of average (A) total mitochondrial network length and (B) 
total mitochondrial network volume in CISD2 and control fibroblasts. Data are 
mean ± SEM. n = ≥ 25. ** p = ≤0.01, * p = ≤ 0.05, two-tailed unpaired t test. 
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The ER morphology was compared between CISD2 and control fibroblasts. Analysis 
was restricted to total ER volume because the ER was represented by one large 
continuous compartment. There was no significant difference observed in total ER 
volume between the CISD2 and control fibroblasts (Figure 7.13). 
    
 
  
 
  
 
 
7.3.6 ATP content and cell viability of CISD2 fibroblasts 
The transfer of Ca2+ from the ER to the mitochondria regulates mitochondrial 
bioenergetics and apoptosis. To investigate OXPHOS function in CISD2 fibroblasts 
ATP levels were determined with the CellTiter-Glo ATP assay under four conditions: 
(i) glucose, (ii) 2-DG, (iii) oligomycin and (iv) 2-DG and oligomycin. There was a trend 
for decreased ATP levels under all four assay conditions in the CISD2 fibroblasts 
compared to controls, however no significant difference was observed under any 
condition between the two groups (Figure 7.14). Apoptosis was assessed in 
untreated CISD2 and control fibroblasts by western blot analysis of the apoptosis 
markers caspase 3 and poly (ADP-ribose) polymerase (PARP); they both undergo 
proteolytic processing during apoptosis which is detected using western blot as 
cleaved-caspase 3 (19, 17 kDa) and cleaved-PARP (89 kDa). There was no 
evidence of proteolytic processing of either marker in CISD2 or control fibroblasts 
(Figure 7.15).  
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Figure 7.13 The average total ER volume in CISD2 fibroblasts. Data are 
mean ± SEM. n = ≥ 25. No significant difference when compared to controls, 
two-tailed unpaired t test. 
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Figure 7.14 ATP content in CISD2 fibroblasts. ATP content was assessed 
under four conditions: glucose, 2-DG, oligomycin (oligo) and 2-DG+oligo. Data 
are mean ± SEM. n = 3. No results were significantly different when compared 
to controls, two-tailed unpaired t test. 
Figure 7.15 Western blot analysis of apoptosis in CISD2 fibroblasts.                   
(A) Representative western blots of caspase 3 and PARP in untreated CISD2 
and control fibroblasts. (B) Caspase 3 and PARP antibodies had previously 
been validated on a STS treated controls. 
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7.4 Discussion 
Wolfram syndrome is genetically heterogeneous with the majority of patients 
harbouring WFS1 mutations, but in rare cases, CISD2 mutations have been reported 
(Inoue et al., 1998; Strom et al., 1998; Amr et al., 2007). Using a fibroblast cell line 
established from a patient harbouring a novel homozygous CISD2 mutation 
(c.215A>G; p.Asn72Ser), the present study demonstrates that CISD2 mutation 
disturbs cellular Ca2+ homeostasis comprising enhanced Ca2+ flux from the ER to 
mitochondria and cytosolic Ca2+ abnormalities. This Ca2+ dysregulation was 
associated with increased ER-mitochondrial contact and a ‘hyperfused’ mitochondrial 
network. There were no obvious downstream effects of disturbed Ca2+ homeostasis 
on cellular bioenergetics and apoptosis. These results provide important insight into 
the potential disease mechanisms underlying CISD2 mutations and WFS2. 
CISD2 deficiency has previously been shown to disturb basal cytosolic and 
mitochondrial Ca2+ levels, although conflicting results have been reported (Wiley et 
al., 2013; Wang et al., 2014). No studies have assessed the impact of CISD2 
mutations on IP3R dependent ER-mitochondria Ca
2+ flux, which is an important 
potential mechanism linking ER dysfunction with mitochondrial impairment in 
Wolfram syndrome. In CISD2 fibroblasts, Ca2+ flux from the ER to mitochondria was 
enhanced as demonstrated by significantly increased peak mitochondrial Ca2+ levels 
following IP3R dependent ER Ca
2+ release. In addition, CISD2 fibroblasts showed 
significantly increased basal cytosolic [Ca2+], which was coupled with a significant 
decrease in the amplitude of cytosolic Ca2+ transients following IP3R dependent ER 
Ca2+ release. In agreement with previous studies, no difference was observed in ER 
Ca2+ levels by direct assessment with the D1ER probe in CISD2 fibroblasts (Chang 
et al., 2012; Wang et al., 2014). This suggests that the disturbed Ca2+ homeostasis in 
CISD2 fibroblasts is not due to alterations in ER Ca2+ levels.  
The increased ER-mitochondrial Ca2+ flux observed in CISD2 fibroblasts has 
potential consequences for a number of mitochondrial functions including 
mitochondrial bioenergetics and mitochondrial-mediated apoptosis (van Vliet et al., 
2014). However, under ‘forced OXPHOS’ conditions with 2-DG supplementation, 
ATP levels were not significantly different between CISD2 and control fibroblasts 
suggesting that OXPHOS function is not adversely affected by the homozygous 
CISD2 mutation. In contrast, immortalized Cisd2-/- MEFs were found to have 
 123 
increased mitochondrial Ca2+ loading under basal conditions, which was associated 
with increased mitochondrial respiration and enhanced cellular ATP utilization (Wiley 
et al., 2013). Given that ER-mitochondrial Ca2+ flux was increased, it is expected that 
the CISD2 fibroblasts would show increased sensitivity to Ca2+ mediated apoptosis 
induction. Excessive mitochondrial Ca2+ accumulation can cause cell death via 
opening of the mPTP, loss of mitochondrial integrity and release of pro-apoptotic 
factors (La Rovere et al., 2016). No evidence of apoptosis was found by western blot 
analysis of caspase 3 and PARP under basal conditions in CISD2 fibroblasts. 
However, this represents a restricted analysis to a single cell death pathway under 
basal conditions. Future investigations to determine the sensitivity of CISD2 
fibroblasts to stressors that mobilise Ca2+ from the ER to mitochondria (e.g. t-BH or 
ceramide) are needed to clarify this potential pathogenic mechanism (Bononi et al., 
2013).  
There are also potential pathological consequences of the disturbed cytosolic 
Ca2+ homeostasis observed in CISD2 fibroblasts. To regulate diverse processes, 
cytosolic Ca2+ signals have unique spatiotemporal signatures (Smedler and Uhlen, 
2014). Thus, the decreased amplitude of cytosolic Ca2+ transients following ER Ca2+ 
release and consistently elevated basal cytosolic [Ca2+] in CISD2 fibroblasts 
suggests that CISD2 mutations disrupts cellular Ca2+ signalling. These results agree 
with two previous studies which have shown increased cytosolic [Ca2+] secondary to 
CISD2 deficiency (Chang et al., 2012; Wang et al., 2014), but contrast with previous 
studies which have shown normal or decreased basal cytosolic [Ca2+] and increased 
IP3R dependent cytosolic Ca
2+ transients (Amr et al., 2007; Wiley et al., 2013). These 
differences are likely due to factors such as the unique properties of the different cell 
lines used including primary and immortalised cell lines, the difference between 
CISD2 knockout and pathogenic CISD2 mutations, and the different experimental 
conditions.  
Despite the differences reported in the literature, the overall picture indicates 
that CISD2 deficiency disturbs cytosolic Ca2+ homeostasis and further studies are 
required to determine the exact downstream consequences. Consistently elevated 
basal cytosolic [Ca2+] has been shown to lead to the pathological activation of Ca2+ 
dependent enzymes in other neurodegenerative diseases, for example calpain and 
calcineurin, which induce apoptosis through various pathways (Vosler et al., 2008; 
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Mukherjee and Soto, 2011). Increased cytosolic [Ca2+] secondary to WFS1 deficiency 
has been shown to cause calpain activation in a neuronal progenitor cells derived 
from Wolfram syndrome induced pluripotent stem cells (iPSCs) (Lu et al., 2014). 
Moreover, CISD2 has been shown to negatively regulate calpain-2 by direct protein-
protein interactions and CISD2 deficiency resulted in calpain activation in a neuronal 
cell line (Lu et al., 2014). It is unclear whether calpains are activated in CISD2 
fibroblasts and these Ca2+ signalling pathways deserve further investigation.  
Analysis of ER-mitochondrial signal colocalisation in the CISD2 fibroblasts 
suggested an increased degree of ER-mitochondria contact, possibly at the MAM.  A 
greater area of physical contact between the ER and mitochondrial compartments 
has been shown to correlate with increased ER-mitochondria Ca2+ flux (Csordas et 
al., 2006). The increased ER-mitochondria contact observed in CISD2 fibroblasts 
could therefore explain the increased Ca2+ flux between these two organelles. 
However, this hypothesis needs to be substantiated by further investigations of the 
ER-mitochondria interaction through biomaging methods with a significantly higher 
spatial resolution than is possible with confocal microscopy. Moreover, increased ER-
mitochondria signal colocalisation, whilst an important observation, does not 
necessarily indicate greater functional interactions. For example, it is possible that 
the increased mitochondrial-ER signal colocalisation is an artefact secondary to the 
significantly increased total volume of the mitochondrial network observed in CISD2 
fibroblasts and does not represent an increased functional interaction between the 
two organelles. Further investigation of the MAM domain including electron 
microscopy analysis, quantification of the IP3R and VDAC interaction and direct 
measurement of Ca2+ hotspots on the OMM in CISD2 fibroblasts would clarify the 
impact of CISD2 mutations on the MAM domain (Giacomello et al., 2010; Tubbs et 
al., 2014). 
It is intriguing why ER-mitochondrial contacts are increased in CISD2 
fibroblasts. One explanation is that increased ER-mitochondrial contact is due to ER 
stress, which has been shown to lead to increased MAM apposition, either as an 
adaptive response or due to apoptosis induction (Chami et al., 2008; Bravo et al., 
2011). Both WFS1 and CISD2 deficiency have previously been shown to disturb ER 
homeostasis leading to ER stress and activation of the UPR (Fonseca et al., 2010; 
Wiley et al., 2013). Whether these cellular mechanisms are relevant to CISD2 
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fibroblasts is unclear and further investigation of the three main UPR signalling 
pathways and ER chaperone levels is needed to clarify whether CISD2 fibroblasts 
are under ER stress. 
Alternatively, disturbed Ca2+ homeostasis and increased ER-mitochondria 
interactions in CISD2 fibroblasts could be caused by dysregulation of the IP3R. 
CISD2 has previously been shown to interact with the IP3R, and evidence suggests 
that CISD2 is required for Bcl-2 mediated regulation of cellular Ca2+ homeostasis 
(Chang et al., 2010). Bcl-2 is proposed to functionally interact with the IP3R and 
inhibit high amplitude Ca2+ transients and promote low amplitude Ca2+ transients 
(Chen et al., 2004). The Bcl-2-IP3R interaction also negatively regulates IP3R 
dependent Ca2+ transfer to mitochondria (Hanson et al., 2008). CISD2 may therefore 
have a role in the negative regulation of IP3R dependent Ca
2+ release. Loss of this 
function in CISD2 fibroblasts could account for the observed increased cytosolic 
[Ca2+] and ER-mitochondrial Ca2+ flux. IP3R dependent ER Ca
2+ release has also 
been shown to decrease mitochondrial movement which is suggested to facilitate the 
formation of stable ER-mitochondrial interactions (Wang et al., 2000; Yi et al., 2004). 
Therefore, dysregulation of the IP3R secondary to CISD2 mutations may also 
promote undesirable ER-mitochondria interactions. Further investigations are 
required to clarify IP3R function secondary to CISD2 deficiency and address these 
potential pathogenic mechanisms.  
Interestingly, one mitochondrial abnormality observed in CISD2 fibroblasts 
was an elongated mitochondrial network, demonstrated by significantly increased 
average length and volume of mitochondrial fragments in the CISD2 fibroblast 
compared with controls. This conclusion was further supported by a detailed analysis 
of the distribution of the length and volume of mitochondrial fragments in CISD2 and 
control fibroblasts. CISD2 fibroblasts contained significantly more ‘larger’ 
mitochondrial fragments and less ‘smaller’ mitochondrial fragments than controls. In 
agreement with these observations, it has previously been reported that mitochondria 
are significantly enlarged and elongated in diaphragm muscle and myoblasts from 
skeletal Cisd2-/- mice (Chang et al., 2012). On the other hand, transient CISD2 
knockdown (<4 hours) in H1299 epithelial cells had no effect on mitochondrial 
morphology (Chang et al., 2010). These results suggest that CISD2 is not directly 
involved in mitochondrial network dynamics, unlike direct mediators such as MFN2 
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and OPA1, and that the elongated mitochondrial network in CISD2 fibroblasts is likely 
a compensatory response to adverse cellular conditions caused by the CISD2 
mutation identified in the patient. Consistent with this concept, mitochondria have 
been shown to undergo hyperfusion termed ‘stress-induced mitochondrial 
hyperfusion’ in response to various cellular stressors (Tondera et al., 2009). Similarly, 
mitochondria have been shown to fuse and elongate during starvation induced 
autophagy to protect mitochondria from degradation and maintain ATP production 
(Gomes et al., 2011; Rambold et al., 2011). Increased autophagy has been observed 
in two Cisd2 deficient mouse models and there was no evidence of increased 
mitophagy (Chen et al., 2009; Chang et al., 2012), this suggests that mitochondrial 
elongation in CISD2 fibroblasts could be a compensatory response to cellular stress, 
possibly dysregulated autophagy. Interestingly, patient cell lines harbouring 
pathogenic OPA1 mutations, associated with DOA, have been linked with increased 
mitophagy, but in this case, the mitochondrial network was fragmented and not 
elongated as in CISD2 fibroblasts (Carelli et al., 2015; Yu-Wai-Man et al., 2016). The 
links between ER dysfunction, mitochondrial dynamics and mitophagy in RGCs 
clearly deserve further attention. 
In summary, the results of this study support a model whereby altered cellular 
Ca2+ homeostasis and disturbed ER-mitochondria interactions caused by CISD2 
mutations (Figure 7.16) are likely to be important pathophysiological players that 
contribute to the progressive neurodegenerative process that underlies Wolfram 
syndrome.  
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Figure 7.16 Schematic model highlighting the proposed dysfunction in 
CISD2 fibroblasts. Mutation of the CISD2 gene was associated with disturbed 
Ca2+ homeostasis including enhanced ER-mitochondrial Ca2+ flux and increased 
cytosolic [Ca2+]. This was accompanied by increased ER-mitochondrial contact.  
There was no evidence of disturbed OXPHOS dysfunction.  
CISD2 fibroblasts 
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Chapter 8. Quantifying Mitochondrial Axonal Transport in a Zebrafish 
Model 
8.1 Introduction 
RGCs have a long axonal segment that extends from the inner retina to the lateral 
geniculate nucleus which imposes a number of physical and functional constraints. 
The lamina cribosa at the optic nerve head divides the prelaminar unmyelinated 
axonal region from the post-laminar myelinated axonal region. Mitochondria are 
unevenly distributed in RGC and are concentrated in the prelaminar unmyelinated 
region due to the higher energy requirements for signal conduction in the absence of 
myelin insulation and at synapses where ATP demand is high (Barron et al., 2004). 
Consequently, the transport and distribution of mitochondria along RGC axons is 
critical for normal function (Yu et al., 2013), and the loss of RGCs in inherited optic 
neuropathies could result from the disturbance of this fundamental process (Lopez 
Sanchez et al., 2016). 
Mitochondrial distribution in neurones is highly regulated by cellular Ca2+ 
signalling (Lin and Sheng, 2015). A direct consequence of the disturbed Ca2+ 
homeostasis observed in Wolfram syndrome models could therefore be the 
disruption of mitochondrial transport and distribution in neurones (Lin and Sheng, 
2015). Consistent with this hypothesis, it has recently been demonstrated that 
mitochondrial transport was disturbed in WFS1 shRNA-treated neurones and 
neurones from Wfs1 -/- mice comprising a lower density of mitochondria in axons and 
decreased velocity of both anterograde and retrograde mitochondrial transport 
(Cagalinec et al., 2016). 
Zebrafish (Danio rerio) are tropical freshwater fish from the Cyprinidae family 
and they are frequently used to study biological processes, especially in early 
development, and to model human disease (Steele et al., 2014). There are several 
advantageous features of zebrafish that make them a valuable tool for disease 
modelling. Genetic information and cellular processes are largely conserved between 
humans and zebrafish. Moreover, zebrafish embryos develop rapidly, high numbers 
can be obtained and they are readily amenable to experimental manipulation (Pickart 
and Klee, 2014). Zebrafish embryos are also transparent, a unique advantage, which 
enables live imaging of cellular processes by microscopy and zebrafish are 
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increasingly being utilized for the in vivo analysis of mitochondrial dynamics in 
disease (Bergamin et al., 2016; Dukes et al., 2016).  
An assay to investigate mitochondrial motility in the lateral line of live zebrafish 
embryos has recently been described (Marra et al., 2015). The lateral line system is a 
mechanosensory organ which extends along the whole length of the zebrafish and 
detects movement and vibration in the surrounding water (Chitnis et al., 2012). The 
zebrafish lateral line and mitochondria are labelled by a GFP and a mitochondrial 
targeted-RFP (mito-RFP) tag, respectively. These are injected into one cell stage 
zebrafish embryos in plasmid form under a neuroD promoter. NeuroD is a 
transcription factor expressed in differentiating neurones including the lateral line 
(Marra et al., 2015). Mitochondria in the lateral line can then be directly visualised in 
live zebrafish by microscopy and the motility patterns of axonal mitochondria can be 
quantified (Marra et al., 2015). 
The aim of this study was to optimise the assay described by Marra and 
colleagues to both visualize and quantify mitochondrial motility along the lateral line 
of zebrafish embryos. Once established in Dr Yu-Wai-Man’s laboratory, this assay 
could be applied to zebrafish models of Wolfram syndrome and other inherited optic 
neuropathies to investigate how disturbed mitochondrial axonal transport influences 
the underlying neuropathology and the extent to which it contributes to RGC loss and 
visual failure. 
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8.2 Methods  
8.2.1 Zebrafish strain, maintenance and husbandry 
The golden zebrafish strain was used and maintained in accordance with standard 
guidelines. Zebrafish were paired the evening prior to injection. A single male and 
female zebrafish were paired in a breeding tank with two mesh dividers; one 
separating the two zebrafish and one separating the two zebrafish from the tank floor. 
On the morning of injection, the mesh divider separating the zebrafish was removed 
and the zebrafish coupled. Embryos were collected, washed in ‘blue water’ (system 
water containing 0.1% methylene blue (Sigma-Aldrich)) and raised at 28.5 °C in blue 
water.  
8.2.2 Plasmids and zebrafish embryo microinjection  
The neuroD:GFP and neuroD:mito-RFP plasmids were a kind gift from Assistant 
Professor Tamily A. Weismann (Lewis & Clark, USA). To co-label the zebrafish 
lateral line system and mitochondria, the neuroD:GFP and neuroD:mito-RFP 
plasmids were microinjected into one cell stage zebrafish embryos. Embryos were 
injected with 1.5 ng/µl (~3 pg total) of each plasmid in Danieau buffer (58 mM NaCl, 
0.7 mM KCL, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, and 0.5 mM HEPES, pH 7.6 (All 
Sigma-Aldrich)) with 0.05 % phenol red (Sigma-Aldrich). Microinjection was 
performed using a FemtoJet Microinjector (Eppendorf, Hamburg, Germany) and a 
glass needle (made by pulling a filamented glass capillary (Hilgenberg, Malsfeld, 
Germany) on a P-97 Flaming/Brown Micropipette puller (Sutter Instrument Co, 
California, USA)). A micrometer was used to calibrate the injection droplet to 
approximately 2 nl by changing the injection pressure (140-160 psi) and time (1-4 
seconds) on the microinjector. Embryos were viewed down a Leica MZ9.5 
stereomicroscope (Leica, Milton Keynes, UK) defective embryos were removed and 
the injection was performed into the yolk.  
8.2.3 Nocodazole treatment 
Zebrafish embryos were transferred into nocodazole (200 nM; Sigma-Aldrich) 
dissolved in blue water containing DMSO (0.1 %; Sigma-Aldrich) at 24 hours post 
fertilization (hpf) and maintained in this solution until imaging at 48 hpf. Control 
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zebrafish were maintained in blue water containing DMSO (0.1 %) without 
nocodazole.    
8.2.4 Zebrafish imaging 
Following plasmid injection (Section 8.2.2), zebrafish were screened at 48hpf for GFP 
expression using a Leica MZ9.5 stereomicroscope with an attached fluorescence 
illuminator. Selected zebrafish were mounted in low melt agarose (1 % v/v; Sigma-
Aldrich) on glass bottom dishes and covered with E3 medium (5 mM NaCl, 0.17 mM 
KCl, 0.33 mM CaCl2, 0.33 mM MgSO4 (All Sigma-Aldrich)) to maintain an aqueous 
environment. Time-lapse images of the GFP and mito-RFP signal were acquired at 5 
second intervals for 5 minutes with a Nikon A1R inverted confocal microscope 
equipped with a x60, 1.40 NA oil objective. Imaging was performed at room 
temperature.  
8.2.5 Analysis of mitochondrial movement 
Time-lapse image series were analyzed using Fiji. A segmented line was drawn 
along the ROI and a kymograph was generated to quantify mitochondrial movement 
using the multiple kymograph plugin (Fiji). A kymograph displays the fluorescent 
intensity along the segmented line from each frame as a horizontal line. The total 
kymograph, with a horizontal line for each frame of the time series stacked along the 
y axis shows a dynamic process in single image. The x axis represents distance and 
the y axis represents time (Figure 8.2). Mitochondrial velocity is calculated by 
converting the change in x into µm and the change in y into seconds; mitochondrial 
velocity is expressed as µm/s.  
    
. 
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8.3 Results 
8.3.1 Measuring mitochondrial motility in the zebrafish lateral line 
The zebrafish lateral line and the mitochondria were labelled with a GFP and a 
mitochondrial targeted RFP tag, respectively. Zebrafish embryo transparency 
enabled direct imaging of the lateral line and mitochondria by confocal microscopy. 
Time-lapse imaging of mitochondrial motility was performed in live 48 hpf zebrafish 
embryos; both stationary and motile mitochondria were readily identifiable (Figure 
8.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 sec 
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10 sec 
15 sec 
20 sec 
Figure 8.1 Time-lapse images showing mitochondrial motility in the 
zebrafish lateral line. Sequential images of the neuroD:GFP labelled 
zebrafish lateral line (green) and neuroD:mito-RFP labelled mitochondria 
(red) at 5 second (sec) intervals. The white arrow tracks a motile 
mitochondrion. 
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 A kymograph was generated to quantify mitochondrial motility. Diagonal white 
lines depict anterograde and retrograde mitochondrial movement, and vertical white 
lines depict stationary mitochondria (Figure 8.2A). Mitochondrial velocity is 
calculated based on the slope of the white line. In the example provided, the yellow 
line equates to a mitochondrial velocity of 0.61 µm/s. Mitochondria with a velocity 
≥0.01 µm/s are considered motile and ~42 % of mitochondria in the present 
kymograph were motile (Figure 8.2B). The mean mitochondrial velocities for 
anterograde and retrograde mitochondrial movement in the example kymograph can 
also be derived (Figure 8.2C).    
    
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Analysis of mitochondrial motility in the zebrafish lateral line.          
(A) Representative kymograph, white lines represent the spatial location of 
mitochondria over time. The yellow line highlights the analysis of mitochondrial 
velocity; change in x and y are converted into µm and seconds, respectively. 
Mitochondrial velocity is expressed as µm/s. (B) Patterns of mitochondrial motility 
quantified from the kymograph. (C) Mean mitochondrial velocity for anterograde and 
retrograde mitochondrial transport quantified from the kymograph. 
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8.3.2 Nocodazole inhibits mitochondrial motility in the zebrafish lateral line 
To confirm that disturbances in mitochondrial motility could be measured, zebrafish 
were treated with nocodazole, which interferes with microtubule polymerization, and 
mitochondrial motility was analyzed. As expected, nocodazole treatment arrested 
mitochondrial movement in the zebrafish lateral line. Kymograph analysis showed no 
actively moving mitochondria as observed under basal conditions; the mitochondria 
present have been depicted as vertical lines, indicating that mitochondria were mostly 
stationary in the lateral line of nocodazole treated zebrafish (Figure 8.3).    
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Figure 8.3 Analysis of mitochondrial motility in nocodazole treated 
zebrafish. (A) Sequential images of the neuroD:GFP labelled lateral line 
(green) and neuroD:mito-RFP labelled mitochondria (red) at 20 second 
(sec) intervals in nocodazole treated zebrafish. (B) Kymograph analysis 
of mitochondria in the lateral line of nocodazole treated zebrafish. 
Vertical lines indicate that mitochondria were mostly stationary.        
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8.4 Discussion  
This chapter describes the setting up of an experimental assay to analyze 
mitochondrial motility in the zebrafish lateral line (Marra et al., 2015). The expected 
patterns of mitochondrial movement in neuronal axons were observed in the 
zebrafish lateral line, including bi-directional movement, stop-start movement, 
changes in direction and also stationary mitochondria (Lin and Sheng, 2015). 
Moreover, the mitochondrial velocities that were quantified were within physiological 
ranges. The velocity of mitochondrial movement in neurones is somewhat variable 
and velocities ranging from 0.2 to 1.5 µm/s have previously been reported (MacAskill 
and Kittler, 2010; Bergamin et al., 2016). To investigate whether disturbances in 
mitochondrial motility could be detected by the assay zebrafish were treated with 
nocodazole. Nocodazole binds to tubulin and prevents the formation of interchain 
linkages, thus inhibiting the dynamic assembly of microtubules. As mitochondria are 
dependent on microtubule based motors for long-range transport in neurones, 
nocodazole treatment is known to disturbed mitochondrial transport  (Friedman et al., 
2010). As expected, nocodazole treatment severely impaired mitochondrial 
movement in the zebrafish lateral line, thus confirming that the assay can detect 
changes in mitochondrial dynamics (Plucinska et al., 2012). 
Previous studies investigating mitochondrial dynamics in zebrafish have 
primarily used transgenic zebrafish expressing a mitochondrial targeted fluorescent 
protein. In zebrafish, mitochondrial transport has been studied in at least Rohon-
Beard sensory neurones, the lateral line system, motor neurones, dopaminergic 
neurones and RGCs (Plucinska et al., 2012; Auer et al., 2015; Bergamin et al., 2016; 
Dukes et al., 2016). An advantage of the present assay is the simplicity of labelling 
the mitochondria and neurones with injectable plasmids and the ease of imaging the 
zebrafish lateral line. The present assay is readily applicable to the study of 
mitochondrial dynamics in an antisense morpholino based or transgenic zebrafish 
model of Wolfram syndrome. Quantification of mitochondrial motility in an in vivo 
model would provide important insight into the disease mechanisms underlying 
Wolfram syndrome. Importantly, if mitochondrial dynamics are disturbed in a 
zebrafish model of not only Wolfram syndrome, but also other inherited optic 
neuropathies such as DOA (Cagalinec et al., 2016; Yu-Wai-Man et al., 2016), this 
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assay could also facilitate the screening of candidate drug molecules to rescue the 
pathological cellular phenotype.  
The fact remains that mitochondrial dynamics are not being assessed directly 
in zebrafish RGCs, which is the specific cell type that contributes to optic nerve 
neurodegeneration and visual failure. One study has investigated mitochondrial 
dynamics in zebrafish RGCs (Auer et al., 2015). This study showed that disruption of 
a kinesin motor that mediates anterograde transport of mitochondria was associated 
with depletion of mitochondria from RGC axon terminals and impaired RGC synaptic 
transmission (Auer et al., 2015). However, imaging deeply located RGCs in an intact 
zebrafish embryo is technically more challenging than imaging the superficially 
located lateral line system (Auer et al., 2015). Still, the neuroD transcription factor is 
likely expressed in the RGCs of zebrafish, suggesting that this assay could be 
extended to investigate mitochondrial dynamics in RGCs of zebrafish (Ochocinska 
and Hitchcock, 2009). 
In summary, a reliable method has been established for imaging and 
quantifying mitochondrial axonal transport in an in vivo zebrafish model. This assay 
will be applied in future work aimed at further dissecting the disease mechanisms in 
Wolfram syndrome caused by WFS1 mutations and in therapeutic drug screening. 
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Chapter 9. General Discussion 
 
The research described within this thesis was undertaken to further explore the 
genetic and molecular basis of inherited optic neuropathies. The principle focus was 
on the disease mechanisms that contribute to the progressive neurodegenerative 
process seen in patients with Wolfram syndrome harbouring pathogenic WFS1 
mutations (Inoue et al., 1998; Strom et al., 1998).   
9.1 Genetic screening for WFS1, RTN4IP1 and C12orf65 mutations in patients 
with suspected inherited optic neuropathies 
The most common inherited optic neuropathies seen in clinical practice are LHON 
and DOA secondary to pathogenic OPA1 mutations. However, with the advent of 
next-generation sequencing, the list of genes known to cause optic atrophy has 
increased significantly (Table 1.1) and this genetic heterogeneity can pose 
considerable diagnostic challenges. The underlying molecular defect still remains 
unknown in ~40-60 % of patients with a likely genetic basis for their optic atrophy 
(Ferre et al., 2009; Yu-Wai-Man et al., 2011b). Genetic screening of the WFS1, 
RTN4IP1 and C12orf65 genes in selected patients from a well-characterised cohort 
of 30 patients with suspected inherited optic neuropathy revealed no pathogenic 
mutations (Chapter 4). Reaching a confirmed genetic diagnosis has important 
implications for patients and their families, and further investigations are underway to 
determine the causative genes in this patient cohort with a combination of whole 
exome and whole genome sequencing. It is likely that the optic atrophy genes that 
still remain to be found are relatively rare and multicentre collaborations will be 
essential to identify a sufficient number of families and unequivocally confirm 
pathogenicity.  
9.2 Mitochondrial dysfunction and the pathophysiology of Wolfram syndrome 
Two clinical subtypes of Wolfram syndrome have been described that share 
overlapping clinical features. WFS1 and related disorders are secondary to recessive 
or dominant mutations in the WFS1 gene, whereas, WFS2 is caused by recessive 
mutations in the CISD2 gene (Moosajee et al., 2016). The proteins encoded by 
WFS1 and CISD2 both localise to the ER, and although they have been proposed to 
have different cellular functions, one common role appears to be the regulation of 
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cellular Ca2+ homeostasis (Osman et al., 2003; Chang et al., 2010; Cagalinec et al., 
2016). In addition, the function of both proteins is essential for ER homeostasis as 
demonstrated by the onset of ER stress upon their deficiency (Fonseca et al., 2005; 
Wiley et al., 2013). It is now well established that mitochondrial dysfunction 
contributes to RGC loss in inherited optic neuropathies such as LHON and DOA (Yu-
Wai-Man et al., 2016). In contrast, the role of mitochondrial dysfunction in the 
pathophysiology of Wolfram syndrome is controversial and following the discovery of 
the WFS1 gene, the literature has primarily focused on the concept of Wolfram 
syndrome being an ER-related disease (Ishihara et al., 2004; Fonseca et al., 2005; 
Yamada et al., 2006). There are currently no treatments available for patients with 
Wolfram syndrome and further studies are required to clarify the disease 
mechanisms and identify therapeutic targets. 
These studies were conducted in fibroblasts harbouring WFS1 and CISD2 
mutations as it is relatively straightforward to obtain a skin biopsy and establish 
primary cell cultures. However, there are inherent limitations to using fibroblasts 
when trying to extrapolate the results obtained to a complex neuronal cell such as a 
RGC, which have a long axonal segment that extend from the inner retina to the 
lateral geniculate nucleus. Notwithstanding these limitations, fibroblasts established 
from Wolfram syndrome patients harbouring confirmed pathogenic WFS1 and CISD2 
mutations are a valid in vitro model and they can help elucidate relevant disease 
mechanisms that deserve further study and that could be manipulated as therapeutic 
targets. 
In fibroblasts, WFS1 mutations decreased ER-mitochondrial Ca2+ flux, which 
was associated with a selective impairment of complex I-dependent respiration 
(Chapter 5 and 6). Interestingly, CISD2 fibroblasts showed a contrasting phenotype 
characterised by enhanced ER-mitochondrial Ca2+ flux, which is likely the result of 
increased ER-mitochondrial apposition at the MAM (Chapter 7). The reasons for 
these differences are unclear; the functions of the Wolframin and CISD2 proteins 
appear to converge on regulation of the IP3R (Chang et al., 2010; Cagalinec et al., 
2016), and it will therefore be very interesting to further investigate IP3R function and 
how this is modulated by pathogenic WFS1 and CISD2 mutations. Taken in the 
context of the wider literature, these studies clearly demonstrate that mutations in 
genes that encode ER proteins with putative roles at the MAM can affect 
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mitochondrial function by disturbing the structure and function of ER-mitochondrial 
interactions. The observation that primary ER dysfunction can cause secondary 
mitochondrial impairment is mechanistically highly relevant and it represents an 
obvious pathological pathway that could be targeted for the development of 
therapeutic strategies for patients with Wolfram syndrome. 
As mentioned previously, a limitation of these studies is the use of fibroblasts 
as an in vitro disease model, which will not entirely reflect the neuropathology of 
Wolfram syndrome (Philbrook et al., 2005; Auburger et al., 2012). To address the 
need to study a neuronal model and replicate the findings obtained in mutant 
fibroblasts, four of the fibroblast cell lines harbouring WFS1 mutations (W1-W4) have 
been reprogrammed to derive iPSCs. The differentiation of these patient-specific 
iPSCs into RGCs or neuronal cell types will provide an extremely valuable model to 
investigate the disease mechanisms of Wolfram syndrome in disease-relevant cells. 
In addition, these iPSC-derived neuronal cells can be used to address questions that 
cannot be answered using WFS1 fibroblasts. In particular, it will be fascinating to 
determine the extent to which WFS1 mutations disturb the transport and distribution 
of mitochondria from the soma and along the long axonal segment towards the 
terminal synapses. The physical constraints imposed by long neurones can also be 
dissected further in the context of cellular Ca2+ homeostasis, neuronal cell death and 
mitophagy.  
The conclusions concerning the deleterious consequences of CISD2 
mutations are based on one cell line from a patient harbouring a novel homozygous 
mutation (c.215 A>G, p.Asn72Ser). Acknowledging the fact that WFS2 is relatively 
rare compared with WFS1, the phenotype of this specific CISD2 cell line was in part 
comparable to that observed in one cell line carrying a dominant WFS1 mutation 
(W5), which exhibited an apparent compensatory response with preserved complex I 
activity and no major disturbance in Ca2+ flux between the ER and mitochondrial 
compartments. The observations of increased MAM activity and elongated 
mitochondrial network in the CISD2 fibroblasts could therefore represent a 
compensatory response to the CISD2 mutation, rather than the disease mechanisms 
of WFS2. Further investigations are required to clarify mitochondrial function in the 
CISD2 fibroblasts, including the assays applied to the WFS1 fibroblasts such as 
Oxygraph respirometer analysis of mitochondrial respiratory chain function.  Although 
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somewhat limited by the relatively rarity of WFS2 in the population, the 
characterisation of additional cell lines established from patients carrying different 
pathogenic CISD2 mutations are required to fully establish the pathological 
consequences of CISD2 mutations and whether there are common patterns across 
different genotypes and phenotypes. 
9.3 Quantifying mitochondrial motility in the zebrafish lateral line 
As described in Chapter 8, an assay to analyze mitochondrial motility in the zebrafish 
lateral line using targeted fluorescent proteins and confocal microscopy was 
optimized (Marra et al., 2015). The assay enabled the quantification of dynamic 
mitochondrial processes and provided parameters, such as the velocity and direction 
of mitochondrial transport. This in vivo assay will now be used for the study of two 
transgenic zebrafish lines carrying pathogenic nonsense Wfs1 mutations.   
As previously discussed, the alterations in cellular Ca2+ homeostasis observed 
in WFS1 and CISD2 fibroblasts suggest that disturbed mitochondrial dynamics could 
underlie RGC loss in Wolfram syndrome. This disease mechanism has recently been 
investigated in WFS1 deficient neurones and rather strikingly, WFS1 deficiency 
disturbed neuronal mitochondrial transport and decreased axonal mitochondrial 
density (Cagalinec et al., 2016). However, these observations could be strengthened 
further by the use of an in vivo animal model, which enables the study of 
mitochondrial dynamics in neurones that still retain their physiological connectivity 
and synaptic activity (Dukes et al., 2016). Application of the present assay to 
investigate mitochondrial motility therefore represents a powerful method to study 
mitochondrial dynamics in disease not only for Wolfram syndrome, but also for other 
inherited optic neuropathies such as OPA1-related DOA.  
The zebrafish is an attractive in vivo disease model for a number of practical 
reasons, including cost and ease of genetic manipulation. One advantage of 
assessing mitochondrial dynamics in the zebrafish lateral line is that other 
physiological processes are readily investigable in this system. The zebrafish lateral 
line is amenable to the investigation of cellular Ca2+ homeostasis with genetically-
encoded calcium indicator (GECI) proteins targeted to the cytosol, mitochondria and 
ER. Conveniently, ER-mitochondrial Ca2+ flux can be assessed using these probes 
following IP3R stimulation with adenophostin A (Esterberg et al., 2014). In addition, 
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mitochondrial function in the zebrafish lateral line can be determined by assessing 
mitochondrial membrane potential with TMRM followed by treatment with the ATP 
synthase inhibitor oligomycin and the uncoupler FCCP (Esterberg et al., 2014). 
Application of these methods to a zebrafish model of Wolfram syndrome, which is 
currently being developed, would determine whether the model resembles the 
phenotype observed in WFS1 fibroblasts. Importantly, assessment of mitochondrial 
dynamics and function could be put into the context of cellular Ca2+ homeostasis. 
One limitation of the mitochondrial motility assay is that due to constraints of 
confocal microscopy, imaging is limited to a single focal plane. Nevertheless, these 
images can be used to assess the density of mitochondria in axons by calculating 
mitochondrial volume under the assumption that mitochondria are cylindrical in shape 
(Plucinska et al., 2012). To circumvent these technical limitations, the assay could be 
significantly improved by using advanced imaging techniques such as light-sheet 
microscopy, where a plane or ‘sheet of light’ is used to illuminate the sample rather 
than the point-scanning approach of confocal microscopy (Ahrens et al., 2013). This 
technique would enable the high-speed acquisition of a time-series in three 
dimensions of mitochondrial dynamics in the zebrafish lateral line. Analysis of these 
images would provide a thorough assessment of mitochondrial transport and 
morphology in an in vivo zebrafish model (Ahrens et al., 2013).  
9.4 Therapeutic strategies 
There are currently limited treatment options for patients with inherited optic 
neuropathies and progressive blindness imposes a significant social, economic and 
psychological burden on affected patients. Hopefully the body of work presented in 
this thesis will contribute to a better understanding of mitochondrial dysfunction in the 
pathophysiology of Wolfram syndrome and highlight potential options for rescuing or 
halting neuronal loss in this disorder. Future work involving the use of neuronal cell 
types differentiated from mutation-specific iPSCs and a zebrafish model of Wolfram 
syndrome will provide validation of the disease mechanisms found in WFS1 mutant 
fibroblasts. These models also represent powerful tools for prospective drug 
screening.  
Some candidate drug molecules include idebenone and EPI-743, which are 
shorter-chain analogues of ubiquinone that can act as electron carriers in the ETC, in 
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addition to being potent antioxidants (Yu-Wai-Man et al., 2016). These two 
compounds have shown promise in the treatment of LHON and DOA (Klopstock et 
al., 2011; Sadun et al., 2012; Smith et al., 2016), and should be tested in these in 
vitro and in vivo models to gather preclinical data on their possible efficacy in the 
context of pathogenic WFS1 mutations. Other therapeutic strategies for optic 
neuropathies that could be assessed in Wolfram syndrome models include drugs that 
stimulate mitochondrial biogenesis and ATP synthesis such as bezafibrate,                          
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) and acetyl-L-carnitine 
(ALCAR) (Yu-Wai-Man et al., 2016).   
 Another important therapeutic strategy is to target ER dysfunction in patients 
with Wolfram syndrome. The proposed options include the chemical chaperones                    
4-phenylbutyric acid (PBA) and tauroursodeoxycholic acid (TUDCA), which function 
to enhance protein folding and processing in the ER, and have been shown to 
alleviate ER stress in WFS1 deficient β-cells (Shang et al., 2014; Urano, 2016). 
Sodium valproate is another potential therapeutic option; this drug is proposed to 
activate the WFS1 promoter and increase Wolframin expression, and to increase the 
production of the cell cycle regulator p21cip, expression of which correlated with 
protection against cell death in WFS1 depleted human neuroblastoma SK-N-AS cells 
(Kakiuchi et al., 2009; Gharanei et al., 2013).  
9.5 Concluding remarks 
In summary, the findings outlined in this thesis indicate that pathogenic WFS1 
and CISD2 mutations impact negatively on mitochondrial function, which is a 
common thread uniting all inherited optic neuropathies. Disturbed interactions 
between the ER and mitochondria are increasingly being recognised in the context of 
human disease and the complex interplay between these two dynamic cellular 
compartments is only beginning the be unravelled. Ultimately, the hope is that the 
mechanistic insights gained from the study of Wolfram syndrome will lead to the 
development of effective treatments for patients suffering from progressive blindness 
and neurological decline.    
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Chapter 10. Appendices 
10.1 Appendix A 
Appendix A contains the data from the assays described in Chapter 5. Tables are 
named for the corresponding figure. Statistical analysis was performed using 
GraphPad with a two-tailed unpaired t test.    
Cell line Wolframin/Tubulin SEM N P value         
vs. control 
Controls 0.7050 0.3000 3 - 
W1 - - 3 - 
W2 - - 3 - 
W3 - - 3 - 
W4 0.3656 0.0817 3 0.3364 
W5 0.3261 0.0250 3 0.2767 
Table 10.1 Western blot analysis of Wolframin in WFS1 fibroblasts   
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 GRP98/Tubulin BIP/Tubulin 
Cell line Mean SEM N P value                                
vs. control 
Mean SEM N P value                               
vs. control 
Controls 0.1209 0.0119 4 - 0.9033 0.1810 4 - 
W1 01426 0.0280 4 0.4945 1.2963 0.2355 4 0.2141 
W2 0.1370 0.0276 4 0.6029 0.9844 0.0433 4 0.6354 
W3 0.1264 0.0240 4 0.8385 0.9985 0.1378 4 0.6642 
WFS1 rec 0.1354 0.0005 3 0.2387 1.0931 0.1017 3 0.3317 
W4 0.2250 0.0712 4 0.1984 1.6109 0.3032 4 0.0835 
W5 0.2025 0.0580 4 0.2152 0.9851 0.1138 4 0.6873 
Table 10.2 Western blot analyses of ER stress markers in WFS1 fibroblasts
 145 
Cell line FRET/CFP SEM N P value         
vs. control 
Controls 1.3556 0.0340 45 - 
W1 1.4325 0.1028 15 0.3590 
W2 1.4620 0.0619 15 0.1277 
W3 1.3705 0.0882 15 0.8481 
WFS1 rec 1.4216 0.0488 45 0.1368 
W4 1.4460 0.0736 15 0.2173 
W5 1.4435 0.1180 15 0.2701 
Table 10.3 Analysis of ER Ca2+ levels in WFS1 fibroblasts. 
 
Cell line Cytosolic Ca2+ 
(nM) 
SEM N P value         
vs. control 
Controls 65.2402 5.4824 3 - 
W1 63.98511 0.5370 3 0.8940 
W2 66.05383 11.6062 3 0.8351 
W3 65.6816 10.3400 3 0.8427 
WFS1 rec 63.2033 0.6367 3 0.7308 
W4 73.1005 23.4728 3 0.7024 
W5 82.4458 12.01878 3 0.2189 
Table 10.4 Analysis of basal cytosolic [Ca2+] in WFS1 fibroblasts. 
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 Peak Cytosolic Ca
2+ (nM) Tg sensitive Ca2+ stores (nM) 
Cell line Mean SEM N P value                    
vs. control 
Mean SEM N P value                     
vs. control 
Controls 143.8811 15.9811 3 - 80.6778 10.5952 3 - 
W1 124.4730 32.0574 3 0.6167 60.4879 32.5927 3 0.2491 
W2 114.3270 3.4469 3 0.1449 48.2732 11.2282 3 0.1038 
W3 138.6637 28.6149 3 0.8812 72.9822 29.7147 3 0.8193 
WFS1 rec 125.8212 7.0577 3 0.3597 60.5811 7.1330 3 0.1907 
W4 146.5606 5.3848 3 0.8815 73.4600 18.2237 3 0.7493 
W5 209.0087 46.3315 3 0.2546 126.5629 57.6378 3 0.4774 
Table 10.5 Analysis of thapsigargin induced ER Ca2+ depletion in WFS1 fibroblasts.
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 Rhod-2-AM Intensity (ΔF/Fo) Fluo-4-AM Intensity (ΔF/Fo) 
Cell line Mean SEM N P value                    
vs. control 
Mean SEM N P value                     
vs. control 
Controls 7.2403 0.2582 36 - 4.609 0.1721 24 - 
W1 4.5534 0.2876 14 0.0003 *** 4.734 0.1935 10 0.6743 
W2 4.8517 0.4418 14 0.0018 ** 4.249 0.2376 10 0.2516 
W3 5.1061 0.6181 8 0.0268 * 4.157 0.2356 12 0.1355 
WFS1 rec 4.7922 0.4191 35 <0.0001*** 4.353 0.1231 32 0.8356 
W4 3.8855 0.6420 9 0.0005 *** 5.544 0.1259 8 0.0229 * 
W5 6.6667 0.4730 12 0.4604 3.850 0.2362 9 0.2361 
Table 10.6 Disturbed Ca2+ flux in WFS1 fibroblasts.
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 M1 ER/mito colocalisation M2 mito/ER colocalisation 
Cell line Mean SEM N P value                    
vs. control 
Mean SEM N P value                     
vs. control 
Controls 0.0411 0.0028 56 - 0.2056 0.1321 56 - 
W1 0.0443 0.0047 20 0.5514 0.2029 0.0178 20 0.9115 
W2 0.0408 0.0028 23 0.9528 0.2008 0.0157 23 0.8362 
W3 0.0532 0.0065 16 0.0568 0.2404 0.0295 16 0.2387 
WFS1 rec 0.0477 0.0027 59 0.0909 0.2122 0.0117 59 0.7067 
W4 0.0457 0.0033 21 0.3619 0.1969 0.0159 21 0.7151 
W5 0.0476 0.0031 19 0.2127 0.2941 0.0245 19 0.0015 ** 
Table 10.7 Analysis of ER-mitochondrial contact in WFS1 fibroblasts.             
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Cell line TMRM intensity 
(F/Fo) 
SEM N P value         
vs. control 
Controls 35.22 3.105 19 - 
W1 27.19 5.201 6 0.2125 
W2 60.20 6.6167 6 0.0008 *** 
W3 28.78 4.597 5 0.3353 
WFS1 rec 39.31 4.865 17 0.4737 
W4 33.23 4.800 5 0.7694 
W5 33.04 8.911 7 0.7694 
Table 10.8 Mitochondrial membrane potential assessed by TMRM in WFS1 and 
control fibroblasts. 
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 IP3R/Tubulin SERCA/Tubulin VDAC/Tubulin MCU/Tubulin 
Cell line Mean SEM N P value         
vs. 
control 
Mean SEM N P value         
vs. 
control 
Mean SEM N P value         
vs. 
control 
Mean SEM N P value         
vs. 
control 
Controls 0.4158 0.1187 3 - 0.1808 0.0217 3 - 0.5624 0.2684 2 - 0.5843 0.01928 3 - 
W1 0.4276 0.04753 3 0.9310 0.8650 0.0889 3 0.0017 
** 
1.438 0.5824 2 0.3053 0.5715 0.0530 3 0.8329 
W2 0.7407 0.1217 3 0.1286 0.7124 0.0944 3 0.0054 
** 
0.6966 0.0596 2 0.6737 0.5413 0.1639 3 0.8075 
W3 0.7365 0.3009 3 0.3776 0.3999 0.3999 3 0.2240 0.2353 0.0134 2 0.3477 0.5258 0.1918 3 0.7770 
WFS1 
rec 
0.6350 0.1037 3 0.2368 0.6591 0.1369 3 0.0260 
** 
0.7901 0.4292 2 0.9322 0.5462 0.0134 3 0.1809 
W4 0.5218 0.1515 3 0.6111 1.1670 0.2497 3 0.0170 * 0.5882 0.0107 2 0.9322 0.6674 0.2560 3 0.7623 
W5 0.5626 0.2057 3 0.5700 0.6147 0.1369 3 0.2534 0.4851 0.0468 2 0.8033 1.0350 0.0821 3 0.0059 
** 
Table 10.9 Western blot analyses of key Ca2+ channels and pumps in WFS1 fibroblasts.
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10.2 Appendix B  
Appendix B contains the data from the assays described in Chapter 6. Tables are 
named for the corresponding figure. Statistical analysis was performed using 
GraphPad with a two-tailed unpaired t test.    
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 Basal respiration                  
OCR (pmol/min/mg of 
protein) 
ATP-linked respiration      
OCR (pmol/min/mg of 
protein) 
Proton Leak                      
OCR (pmol/min/mg of 
protein) 
Maximal Respiration         
OCR (pmol/min/mg of 
protein) 
Cell line Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Controls 3209 675 3 - 2555 590 3 - 693 164 3 - 4869 974 3 - 
W1 2819 1088 3 0.7762 1867 723 3 0.5021 952 366 3 0.5584 5256 2165 3 0.8785 
W2 5799 1182 3 0.1299 4120 713 3 0.1664 1776 389 3 0.0626 9871 2624 3 0.1485 
W3 8390 3995 3 0.2701 5702 1872 3 0.1842 2708 2119 3 0.3970 10511 2810 3 0.1307 
WFS1 
rec 
5669 1610 3 0.2314 3897 1113 3 0.3470 1812 507 3 0.1040 8546 1655 3 0.1281 
W4 3511 1285 3 0.8454 2740 762 3 0.8573 1228 181 3 0.0944 6729 2568 3 0.5355 
W5 8884 686 3 0.0041 ** 6228 119 3 0.0037 ** 2645 642 3 0.0423 * 12921 877 3 0.0036 ** 
Table 10.10 Parameters of mitochondrial respiratory function in WFS1 fibroblasts determined by Seahorse analysis. 
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 CI/(CI+CII) CII/(CI+CII) 
Cell line Mean SEM N P value                                
vs. control 
Mean SEM N P value                               
vs. control 
Controls 0.4416 0.0282 3 - 0.7451 0.0449 3 - 
W1 0.2372 0.0226 5 0.0014 ** 0.9337 0.0134 5 0.0023 ** 
W2 0.3098 0.0306 5 0.0279 * 0.8273 0.0022 5 0.1084 
W3 0.3596 0.0153 5 0.0301 * 0.7698 0.0221 5 0.5954 
WFS1 rec 0.3022 0.0296 3 0.0271 * 0.8436 0.0480 3 0.2083 
W4 0.4246 0.0378 5 0.6662 0.8434 0.0196 5 0.0573 
W5 0.4246 0.0235 5 0.6662 0.7721 0.0248 5 0.5825 
Table 10.11 Complex I-dependent respiration is reduced in WFS1 fibroblasts.
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Cell line pPDH/Total PDH  SEM N P value         
vs. control 
Controls 2.094 0.0667 3 - 
W1 1.882 0.1110 3 0.1755 
W2 1.572 0.1708 3 0.0464 * 
W3 2.336 0.3256 3 0.5077 
WFS1 rec 1.930 0.2219 3 0.5165 
W4 1.750 0.2294 3 0.2232 
W5 1.769 0.3437 3 0.4057 
Table 10.12 PDH regulation in WFS1 fibroblast.  
 
 
 155 
 Glucose            
Luminescence/mg of protein 
2-DG                   
Luminescence/mg of protein 
Oligomycin                 
Luminescence/mg of protein 
2-DG+Oligomycin 
Luminescence/mg of protein 
Cell line Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Controls 31930 4332 3 - 12054 1577 3 - 24630 2095 3 - 1924 646 3 - 
W1 19976 3325 4 0.0735 14527 2252 4 0.4434 27293 2659 4 0.4928 7442 2914 4 0.1747 
W2 27857 2609 4 0.4256 14988 2519 4 0.4093 23562 2058 4 0.7365 4594 1223 4 0.1445 
W3 28181 2096 4 0.4255 15707 2456 4 0.3043 26041 3133 4 0.7449 4167 1030 4 0.1533 
WFS1 
rec 
25338 2683 3 0.2587 15074 343 3 0.1347 25632 1096 3 0.6936 5401 1028 3 0.0458 * 
W4 31146 5864 4 0.9237 15233 4236 4 0.5664 26596 4889 4 0.7582 3268 798 4 0.2720 
W5 45805 8184 4 0.2587 41493 8419 4 0.0326 * 29346 7291 4 0.6151 8575 2568 4 0.0837 
Table 10.13 ATP content in WFS1 and control fibroblasts.
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 Basal                                                                                    
RFU/mg of protein 
H2O2                                                                                            
RFU/mg of protein 
Cell line Mean SEM N P value                                
vs. control 
Mean SEM N P value                               
vs. control 
Controls 92.30 12.68 3 - 181.4 42.01 3 - 
W1 67.67 17.36 3 0.3159 83.98 19.05 3 0.1021 
W2 84.34 28.74 3 0.8125 145.3 52.08 3 0.6174 
W3 94.41 39.38 3 0.9618 231.7 47.52 3 0.4728 
WFS1 rec 82.14 8.53 3 0.8052 153.6 13.86 3 0.4669 
W4 100.70 29.40 3 0.7682 208.7 43.23 3 0.6741 
W5 83.33 25.46 3 0.5143 127.7 22.17 3 0.3209 
Table 10.14 Assessment of ROS levels in WFS1 fibroblasts using H2DCFDA.
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Cell line mtDNA Copy 
Number  
SEM N P value         
vs. control 
Controls 125.6 11.11 3 - 
W1 142.7 6.007 3 0.2462 
W2 122.8 12.28 3 0.8753 
W3 158.2 12.28 3 0.1206 
WFS1 rec 141.2 10.22 3 0.3901 
W4 137 4.121 3 0.8241 
W5 121.5 13.18 3 0.3585 
Table 10.15 mtDNA Copy Number in WFS1 and control fibroblasts. 
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 STS 2 hours                                               
Cell viability (%)                           
STS 5 hours                                               
Cell viability (%)                           
STS 8 hours                                               
Cell viability (%)                           
Cell line Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Controls 82.48 3.929 3 - 67.90 3.80 3 - 46.15 13.29 3 - 
W1 68.45 5.743 4 0.0903 66.18 2.420 4 0.7155 50.03 7.000 4 0.8048 
W2 76.13 3.371 4 0.2659 72.50 2.399 4 0.3459 68.49 7.500 4 0.1937 
W3 79.67 3.737 4 0.6229 68.94 1.353 4 0.8061 52.96 7.547 4 0.6714 
WFS1 rec 77.46 5.625 3 0.4820 72.80 3.911 3 0.4188 62.35 61.61 3 0.3726 
W4 79.48 4.156 4 0.6185 72.84 2.405 4 0.3145 65.28 4.500 4 0.2218 
W5 82.20 2.782 4 0.9544 71.69 2.120 4 0.4181 72.03 9.000 4 0.1581 
Table 10.16 Viability of WFS1 and control fibroblasts following treatment with cell stressors 
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 t-BH 2 hours                                               
Cell viability (%)                           
t-BH 5 hours                                               
Cell viability (%)                           
t-BH 8 hours                                               
Cell viability (%)                           
Cell line Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Controls 101.6 1.1862 3 - 53.91 9.265 3 - 16.92 4.395 3 - 
W1 84.24 6.082 4 0.0341 * 60.11 3.058 4 0.5482 34.11 7.363 4 0.0919 
W2 97.92 4.511 4 0.4788 67.36 3.644 4 0.2254 17.95 5.902 4 0.8942 
W3 99.66 3.816 4 0.6631 57.47 14.15 4 0.8402 4.933 0.4571 4 0.0350 * 
WFS1 rec 93.94 4.878 3 0.1592 61.65 2.956 3 0.5217 19.00 8.438 3 0.8226 
W4 98.03 1.511 4 0.1859 79.92 3.650 4 0.0400  28.25 9.085 4 03046 
W5 99.19 5.430 4 0.6886 70.42 4.981 4 0.1676 13.89 9.001 4 0.7723 
Table 10.17 Viability of WFS1 and control fibroblasts following treatment with cell stressors 
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 Tg 2 hours                                               
Cell viability (%)                           
Tg 5 hours                                               
Cell viability (%)                           
Tg 8 hours                                               
Cell viability (%)                           
Cell line Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Controls 90.38 2.037 3 - 49.92 4.387 3 - 21.59 5.311 3 - 
W1 103.5 4.838 4 0.0462 * 76.00 3.768 4 0.0041 ** 50.20 4.408 4 0.0060 ** 
W2 111.2 5.201 4 0.0098 ** 75.69 3.366 4 0.0035 ** 40.92 2.074 4 0.0147 * 
W3 112.1 6.029 4 0.0144 * 82.75 3.142 4 0.0009 *** 43.34 6.802 4 0.0453 * 
WFS1 rec 108.9 2.709 3 0.0025 ** 78.15 2.303 3 0.0038 ** 44.82 2.780 3 0.0179 * 
W4 102.5 3.618 4 0.0268 ** 79.77 5.163 4 0.0045 ** 46.68 4.964 4 0.0136 * 
W5 86.91 4.023 4 0.4709 34.70 4.611 4 0.0539 9.486 2.780 4 0.0935 
Table 10.18 Viability of WFS1 and control fibroblasts following treatment with cell stressors 
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  Basal                                  
Specific Activity  
 
STS                              
Specific Activity  
 
t-BH                                 
Specific Activity  
 
Thapsigargin                          
Specific Activity  
 
Cell line Mean SEM N P value         
vs. 
control 
Mean SEM N P value         
vs. 
control 
Mean SEM N P value         
vs. 
control 
Mean SEM N P value         
vs. 
control 
Controls 1.163 0.06979 3 - 15.29 6.553 3 - 0.6502 0.05773 3 - 1.026 0.1020 3 - 
W1 1.062 0.4452 3 0.8337 9.557 3.005 3 0.4714 0.5372 0.1691 3 0.5618 0.9905 0.1001 3 0.8181 
W2 1.094 0.01992 3 0.3908 11.63 4.377 3 0.6673 0.5873 0.1796 3 0.7558 1.045 0.0312 3 0.8655 
W3 0.9608 0.1145 3 0.2053 4.162 1.292 3 0.1712 0.5422 0.1507 3 0.5403 1.005 0.0355 3 0.8591 
WFS1 
rec 
1.039 0.0401 3 0.1970 8.451 2.227 3 0.3794 0.5556 0.0160 3 0.1895 1.013 0.0121 3 0.9124 
W4 1.175 0.0859 3 0.9247 8.477 2.410 3 0.3847 0.6211 0.1812 3 0.8861 1.208 0.2484 3 0.5340 
W5 1.223 0.2893 3 0.8503 15.37 3.562 3 0.9918 0.6557 0.5556 3 0.9842 1.291 0.4383 3 0.5866 
Table 10.19 Caspase 3 activities in WFS1 and control fibroblasts following treatment with cell stressors. 
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10.3 Appendix C  
Appendix C contains the data from the assays described in Chapter 7. Tables are 
named for the corresponding figure. Statistical analysis was performed using 
GraphPad with a two-tailed unpaired t test.    
Cell line FRET/CFP SEM N P value         
vs. control 
Controls 1.356 0.0340 45 - 
CISD2 1.444 0.1180 15 0.3293 
Table 10.20 Evaluation of ER Ca2+ levels with the D1ER probe. 
Cell line Cytosolic Ca2+ 
(nM) 
SEM N P value         
vs. control 
Controls 63.20 5.485 3 - 
CISD2 103.7 5.415 3 0.0063 ** 
Table 10.21 Increased cytosolic [Ca2+] in CISD2 fibroblasts. 
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 Peak Cytosolic Ca
2+ (nM) Tg sensitive Ca2+ stores (nM) 
Cell line Mean SEM N P value                    
vs. control 
Mean SEM N P value                     
vs. control 
Controls 143.9 15.98 3 - 80.68 10.59 3 - 
CISD2 152.3 4.492 3 0.6383 48.60 9.751 3 0.0898 
Table 10.22 Analysis of thapsigargin induced ER Ca2+ depletion in CISD2 fibroblasts 
 Rhod-2-AM Intensity (ΔF/Fo) Fluo-4-AM Intensity (ΔF/Fo) 
Cell line Mean SEM N P value                    
vs. control 
Mean SEM N P value                     
vs. control 
Controls 7.515 0.3878 35 - 4.624 0.1612 25 - 
CISD2 9.304 0.7504 15 0.0240 * 3.929 0.1990 14 0.0117 * 
Table 10.23 Disturbed Ca2+ flux in CISD2 fibroblasts. 
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 M1 ER/mito colocalisation M2 mito/ER colocalisation 
Cell line Mean SEM N P value                    
vs. control 
Mean SEM N P value                     
vs. control 
Controls 0.0411 0.0028 56 - 0.2056 0.0132 56 - 
CISD2 0.0734 0.0060 26 <0.0001 *** 0.2616 0.0197 26 0.0199 * 
Table 10.24 Increased ER-mitochondrial contacts in CISD2 fibroblasts. 
 Average length (µm) Average volume (µm3) Average number of fragments 
Cell line Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Controls 3.130 0.08419 56 - 2.030 0.1911 56 - 90.34 6.961 56 - 
CISD2 3.970 0.2380 25 <0.0001 *** 4.380 0.6600 25 <0.0001 *** 53.88 4.466 25 0.0012 ** 
Table 10.25 Altered mitochondrial fragment morphology in CISD2 fibroblasts. 
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 Control (Relative frequency %) CISD2 (Relative frequency %) 
Mitochondrial length 
(µm) 
Mean SEM N Mean SEM N P value                               
vs. control 
<2 0.4500 0.0147 56 0.3800 0.0240 25 0.0120 * 
2 to 5 0.3600 0.0106 56 0.4500 0.0220 25 <0.0001 *** 
5 to 10 0.0900 0.0900 56 0.1100 0.0100 25 0.0284 * 
>10 0.0400 0.0040 56 0.0600 0.0008 25 0.0148 * 
Table 10.26 Distribution of the length of mitochondrial fragments in CISD2 fibroblasts. 
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 Control (Relative frequency %) CISD2 (Relative frequency %) 
Mitochondrial 
volume (µm3) 
Mean SEM N Mean SEM N P value                               
vs. control 
<0.5 0.5510 0.0134 56 0.3930 0.0244 25 <0.0001 *** 
0.5 to 1 0.1940 0.0079 56 0.1560 0.0145 25 0.0149 * 
1 to 5 0.2050 0.0094 56 0.3310 0.0223 25 <0.0001 *** 
5 to 10  0.0260 0.0028 56 0.0480 0.0068 25 0.0006 *** 
>10 0.0350 0.0039 56 0.0720 0.0061 25 <0.0001 *** 
Table 10.27 Distribution of the volume of mitochondrial fragments in CISD2 fibroblasts. 
 Average total length (µm) Average total volume (µm
3) 
Cell line Mean SEM N P value                                
vs. control 
Mean SEM N P value                               
vs. control 
Controls 261.7 15.28 56 - 141.7 8.157 56 - 
CISD2 191.4 9.910 25 0.0042 ** 179.7 12.09 25 0.0113 * 
Table 10.28 Altered mitochondrial network morphology in CISD2 fibroblasts
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Cell line Average total 
volume (µm3) 
SEM N P value         
vs. control 
Controls 634.7 37.48 51 - 
CISD2 965.8 48.74 25 0.3353 
Table 10.29 The average total ER volume in CISD2 fibroblasts. 
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 Glucose            
Luminescence/mg of protein 
2-DG                   
Luminescence/mg of protein 
Oligomycin                 
Luminescence/mg of protein 
2-DG+Oligomycin 
Luminescence/mg of protein 
Cell line Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Mean SEM N P value         
vs. control 
Controls 47761 2203 3 - 21250 4747 3 - 21304 1321 3 - 3971 1238 3 - 
CISD2 37382 5883 3 0.2098 14750 2425 3 0.2896 13637 3128 3 0.0869 2633 1044 3 0.4549 
Table 10.30 ATP content in CISD2 fibroblasts.
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10.4 Appendix D 
Appendix D contains the data from the assays described in Chapter 8. Tables are 
named for the corresponding figure.  
Cell line Mitochondria (%) SEM N 
Anterograde 38.46 - 1 
Retrograde 19.23 - 1 
Stationary 42.31 - 1 
Table 10.31 Analysis of mitochondrial motility in the zebrafish lateral line.           
Cell line Mitochondria (%) SEM N 
Anterograde 0.753 0.048 10 
Retrograde 1.021 0.151 5 
Table 10.32 Analysis of mitochondrial motility in the zebrafish lateral line.           
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